Background  ||| S:24 E:43 ||| NNP
Transforming  ||| S:43 E:56 ||| NNP
growth  ||| S:56 E:63 ||| NN
factor  ||| S:63 E:70 ||| NN
beta  ||| S:70 E:75 ||| NN
( ||| S:75 E:76 ||| -LRB-
TGF-β ||| S:76 E:81 ||| NNP
)  ||| S:81 E:83 ||| -RRB-
family  ||| S:83 E:90 ||| NN
proteins  ||| S:90 E:107 ||| NNS
are  ||| S:107 E:111 ||| VBP
multifunctional  ||| S:111 E:127 ||| JJ
cytokines  ||| S:127 E:137 ||| JJ
capable  ||| S:137 E:145 ||| JJ
of  ||| S:145 E:148 ||| IN
regulating  ||| S:148 E:159 ||| VBG
cell  ||| S:159 E:172 ||| NN
growth ||| S:172 E:178 ||| NN
,  ||| S:178 E:180 ||| ,
extracellular  ||| S:180 E:194 ||| FW
matrix  ||| S:194 E:201 ||| FW
protein  ||| S:201 E:209 ||| FW
synthesis ||| S:209 E:218 ||| FW
,  ||| S:218 E:220 ||| ,
and  ||| S:220 E:224 ||| CC
immune  ||| S:224 E:239 ||| JJ
cell  ||| S:239 E:244 ||| NN
functions  ||| S:244 E:254 ||| NNS
[  ||| S:254 E:256 ||| -LRB-
1  ||| S:256 E:258 ||| CD
2  ||| S:258 E:260 ||| CD
]  ||| S:260 E:262 ||| -RRB-
.  ||| S:262 E:264 ||| .
Hyaluronidase  ||| S:264 E:278 ||| NNP
is  ||| S:278 E:281 ||| VBZ
an  ||| S:281 E:284 ||| DT
extracellular  ||| S:284 E:306 ||| JJ
matrix-degrading  ||| S:306 E:323 ||| JJ
enzyme ||| S:323 E:329 ||| NN
.  ||| S:329 E:331 ||| .
Interestingly ||| S:331 E:344 ||| RB
,  ||| S:344 E:346 ||| ,
malignant  ||| S:346 E:356 ||| JJ
and  ||| S:356 E:368 ||| CC
metastatic  ||| S:368 E:379 ||| JJ
breast  ||| S:379 E:386 ||| NN
and  ||| S:386 E:390 ||| CC
prostate  ||| S:390 E:399 ||| JJ
cancer  ||| S:399 E:406 ||| NN
cells  ||| S:406 E:412 ||| NNS
frequently  ||| S:412 E:431 ||| RB
overexpress  ||| S:431 E:443 ||| VB
both  ||| S:443 E:448 ||| DT
hyaluronidase  ||| S:448 E:462 ||| NN
and  ||| S:462 E:466 ||| CC
TGF-β  ||| S:466 E:472 ||| JJ
proteins  ||| S:472 E:481 ||| NNS
[  ||| S:481 E:483 ||| -LRB-
3  ||| S:483 E:485 ||| CD
4  ||| S:485 E:487 ||| CD
5  ||| S:487 E:489 ||| CD
6  ||| S:489 E:499 ||| CD
7  ||| S:499 E:501 ||| CD
]  ||| S:501 E:503 ||| -RRB-
.  ||| S:503 E:505 ||| .
Previously  ||| S:505 E:516 ||| RB
we  ||| S:516 E:519 ||| PRP
have  ||| S:519 E:524 ||| VBP
shown  ||| S:524 E:530 ||| VBN
that  ||| S:530 E:535 ||| IN
bovine  ||| S:535 E:542 ||| JJ
testicular  ||| S:542 E:561 ||| JJ
hyaluronidase ||| S:561 E:574 ||| NN
,  ||| S:574 E:576 ||| ,
also  ||| S:576 E:581 ||| RB
known  ||| S:581 E:587 ||| VBN
as  ||| S:587 E:590 ||| IN
PH-20 ||| S:590 E:595 ||| NNP
,  ||| S:595 E:597 ||| ,
increases  ||| S:597 E:607 ||| VBZ
the  ||| S:607 E:619 ||| DT
susceptibility  ||| S:619 E:634 ||| NN
of  ||| S:634 E:637 ||| IN
various  ||| S:637 E:645 ||| JJ
cancer  ||| S:645 E:652 ||| NN
cells  ||| S:652 E:658 ||| NNS
to  ||| S:658 E:661 ||| TO
tumor  ||| S:661 E:667 ||| VB
necrosis  ||| S:667 E:684 ||| JJ
factor  ||| S:684 E:691 ||| NN
( ||| S:691 E:692 ||| -LRB-
TNF  ||| S:692 E:696 ||| NNP
or  ||| S:696 E:699 ||| CC
TNF-α ||| S:699 E:704 ||| NNP
)  ||| S:704 E:706 ||| -RRB-
cytotoxicity  ||| S:706 E:719 ||| FW
[  ||| S:719 E:721 ||| FW
[  ||| S:721 E:723 ||| -LRB-
8  ||| S:723 E:725 ||| CD
]  ||| S:725 E:727 ||| -RRB-
,  ||| S:727 E:729 ||| ,
review ||| S:729 E:735 ||| NN
] ||| S:735 E:736 ||| -RRB-
.  ||| S:736 E:738 ||| .
PH-20  ||| S:738 E:752 ||| NNP
induces  ||| S:752 E:760 ||| VBZ
the  ||| S:760 E:764 ||| DT
expression  ||| S:764 E:775 ||| NN
of  ||| S:775 E:778 ||| IN
proapoptotic  ||| S:778 E:791 ||| JJ
p53  ||| S:791 E:795 ||| NN
[  ||| S:795 E:797 ||| -LRB-
9  ||| S:797 E:799 ||| CD
]  ||| S:799 E:801 ||| -RRB-
and  ||| S:801 E:805 ||| CC
WOX1  ||| S:805 E:818 ||| NNP
( ||| S:818 E:819 ||| -LRB-
WW  ||| S:819 E:822 ||| NNP
domain-containing  ||| S:822 E:840 ||| JJ
oxidoreductase ||| S:840 E:854 ||| NN
;  ||| S:854 E:856 ||| :
also  ||| S:856 E:861 ||| RB
known  ||| S:861 E:867 ||| VBN
as  ||| S:867 E:870 ||| IN
WWOX  ||| S:870 E:875 ||| NNP
or  ||| S:875 E:886 ||| CC
FOR ||| S:886 E:889 ||| NNP
)  ||| S:889 E:891 ||| -RRB-
[  ||| S:891 E:893 ||| -LRB-
10  ||| S:893 E:896 ||| CD
]  ||| S:896 E:898 ||| -RRB-
,  ||| S:898 E:900 ||| ,
which  ||| S:900 E:906 ||| WDT
contributes  ||| S:906 E:918 ||| VBZ
to  ||| S:918 E:921 ||| TO
the  ||| S:921 E:925 ||| DT
increased  ||| S:925 E:935 ||| JJ
TNF  ||| S:935 E:947 ||| NNP
cytotoxic  ||| S:947 E:957 ||| JJ
effect ||| S:957 E:963 ||| NN
.  ||| S:963 E:965 ||| .
PH-20-induced  ||| S:965 E:979 ||| NNP
downregulation  ||| S:979 E:994 ||| NN
of  ||| S:994 E:997 ||| IN
the  ||| S:997 E:1009 ||| DT
extracellular  ||| S:1009 E:1023 ||| JJ
matrix  ||| S:1023 E:1030 ||| JJ
inter-α-inhibitor  ||| S:1030 E:1048 ||| NN
is  ||| S:1048 E:1051 ||| VBZ
also  ||| S:1051 E:1056 ||| RB
associated  ||| S:1056 E:1075 ||| VBN
with  ||| S:1075 E:1080 ||| IN
the  ||| S:1080 E:1084 ||| DT
enhanced  ||| S:1084 E:1093 ||| FW
TNF  ||| S:1093 E:1097 ||| FW
cytotoxicity  ||| S:1097 E:1110 ||| FW
[  ||| S:1110 E:1112 ||| -LRB-
9  ||| S:1112 E:1114 ||| CD
]  ||| S:1114 E:1116 ||| -RRB-
.  ||| S:1116 E:1126 ||| .
TGF-β  ||| S:1126 E:1132 ||| JJ
family  ||| S:1132 E:1139 ||| NN
proteins ||| S:1139 E:1147 ||| NNS
,  ||| S:1147 E:1149 ||| ,
including  ||| S:1149 E:1159 ||| VBG
β1 ||| S:1159 E:1161 ||| NNP
, ||| S:1161 E:1162 ||| ,
β2  ||| S:1162 E:1165 ||| NNP
and  ||| S:1165 E:1169 ||| CC
β3 ||| S:1169 E:1171 ||| NNP
,  ||| S:1171 E:1173 ||| ,
induce  ||| S:1173 E:1188 ||| VB
TNF-resistance  ||| S:1188 E:1203 ||| JJ
and  ||| S:1203 E:1207 ||| CC
suppress  ||| S:1207 E:1216 ||| VB
the  ||| S:1216 E:1220 ||| DT
PH-20  ||| S:1220 E:1226 ||| JJ
effect  ||| S:1226 E:1233 ||| NN
of  ||| S:1233 E:1236 ||| IN
increasing  ||| S:1236 E:1255 ||| VBG
TNF  ||| S:1255 E:1259 ||| NNP
cytotoxicity  ||| S:1259 E:1272 ||| FW
in  ||| S:1272 E:1275 ||| FW
murine  ||| S:1275 E:1282 ||| FW
L929  ||| S:1282 E:1287 ||| FW
fibroblasts  ||| S:1287 E:1299 ||| FW
[  ||| S:1299 E:1301 ||| -LRB-
8  ||| S:1301 E:1303 ||| CD
11  ||| S:1303 E:1306 ||| CD
]  ||| S:1306 E:1308 ||| -RRB-
.  ||| S:1308 E:1318 ||| .
TGF-β1  ||| S:1318 E:1325 ||| NNP
induces  ||| S:1325 E:1333 ||| VBZ
a  ||| S:1333 E:1335 ||| DT
novel  ||| S:1335 E:1341 ||| NN
extracellular  ||| S:1341 E:1355 ||| VBZ
matrix  ||| S:1355 E:1362 ||| JJ
protein  ||| S:1362 E:1370 ||| NN
that  ||| S:1370 E:1383 ||| WDT
prevents  ||| S:1383 E:1392 ||| VBZ
TNF-mediated  ||| S:1392 E:1405 ||| JJ
cell  ||| S:1405 E:1410 ||| NN
death  ||| S:1410 E:1416 ||| NN
and  ||| S:1416 E:1420 ||| CC
blocks  ||| S:1420 E:1427 ||| NNS
the  ||| S:1427 E:1431 ||| DT
activation  ||| S:1431 E:1450 ||| NN
of  ||| S:1450 E:1453 ||| IN
extracellular  ||| S:1453 E:1467 ||| JJ
signal-regulated  ||| S:1467 E:1484 ||| JJ
kinase  ||| S:1484 E:1491 ||| NNS
( ||| S:1491 E:1492 ||| -LRB-
ERK ||| S:1492 E:1495 ||| NNP
;  ||| S:1495 E:1497 ||| :
also  ||| S:1497 E:1502 ||| RB
known  ||| S:1502 E:1516 ||| VBN
as  ||| S:1516 E:1519 ||| IN
p42 ||| S:1519 E:1522 ||| CD
/ ||| S:1522 E:1523 ||| CD
44  ||| S:1523 E:1526 ||| CD
mitogen-activated  ||| S:1526 E:1544 ||| JJ
protein  ||| S:1544 E:1552 ||| NN
kinase ||| S:1552 E:1558 ||| NN
,  ||| S:1558 E:1560 ||| ,
p42 ||| S:1560 E:1563 ||| CD
/ ||| S:1563 E:1564 ||| CD
44  ||| S:1564 E:1567 ||| CD
MAPK ||| S:1567 E:1571 ||| NNP
)  ||| S:1571 E:1573 ||| -RRB-
in  ||| S:1573 E:1584 ||| IN
L929  ||| S:1584 E:1589 ||| CD
cells  ||| S:1589 E:1595 ||| NNS
[  ||| S:1595 E:1597 ||| -LRB-
8  ||| S:1597 E:1599 ||| CD
12  ||| S:1599 E:1602 ||| CD
]  ||| S:1602 E:1604 ||| -RRB-
.  ||| S:1604 E:1606 ||| .
Additionally ||| S:1606 E:1618 ||| RB
,  ||| S:1618 E:1620 ||| ,
TGF-β1  ||| S:1620 E:1627 ||| NNP
induces  ||| S:1627 E:1635 ||| VBZ
the  ||| S:1635 E:1647 ||| DT
expression  ||| S:1647 E:1658 ||| NN
of  ||| S:1658 E:1661 ||| IN
TIAF1  ||| S:1661 E:1667 ||| NNP
( ||| S:1667 E:1668 ||| -LRB-
TGF-β-induced  ||| S:1668 E:1682 ||| JJ
antiapoptotic  ||| S:1682 E:1696 ||| JJ
factor ||| S:1696 E:1702 ||| NN
)  ||| S:1702 E:1704 ||| -RRB-
[  ||| S:1704 E:1714 ||| -LRB-
13  ||| S:1714 E:1717 ||| CD
]  ||| S:1717 E:1719 ||| -RRB-
and  ||| S:1719 E:1723 ||| CC
TIF2  ||| S:1723 E:1728 ||| NNP
( ||| S:1728 E:1729 ||| -LRB-
TGF-β-induced  ||| S:1729 E:1743 ||| JJ
factor  ||| S:1743 E:1750 ||| NN
2 ||| S:1750 E:1751 ||| CD
)  ||| S:1751 E:1753 ||| -RRB-
[  ||| S:1753 E:1755 ||| -LRB-
14  ||| S:1755 E:1758 ||| CD
]  ||| S:1758 E:1760 ||| -RRB-
that  ||| S:1760 E:1765 ||| WDT
inhibit  ||| S:1765 E:1781 ||| VBP
TNF  ||| S:1781 E:1785 ||| JJ
cytotoxicity ||| S:1785 E:1797 ||| NN
.  ||| S:1797 E:1799 ||| .
Whether  ||| S:1799 E:1807 ||| IN
these  ||| S:1807 E:1813 ||| DT
TGF-β1-induced  ||| S:1813 E:1828 ||| CD
proteins  ||| S:1828 E:1845 ||| NNS
restrict  ||| S:1845 E:1854 ||| VBP
the  ||| S:1854 E:1858 ||| DT
ability  ||| S:1858 E:1866 ||| NN
of  ||| S:1866 E:1869 ||| IN
PH-20  ||| S:1869 E:1875 ||| CD
to  ||| S:1875 E:1878 ||| TO
increase  ||| S:1878 E:1887 ||| VB
TNF  ||| S:1887 E:1891 ||| JJ
cytotoxicity  ||| S:1891 E:1912 ||| NN
is  ||| S:1912 E:1915 ||| VBZ
unknown ||| S:1915 E:1922 ||| JJ
.  ||| S:1922 E:1932 ||| .
PH-20  ||| S:1932 E:1938 ||| NNP
blocks  ||| S:1938 E:1945 ||| VBZ
TGF-β1-mediated  ||| S:1945 E:1961 ||| CD
growth  ||| S:1961 E:1968 ||| NN
suppression  ||| S:1968 E:1980 ||| NN
of  ||| S:1980 E:1991 ||| IN
epithelial  ||| S:1991 E:2002 ||| JJ
cells  ||| S:2002 E:2008 ||| NNS
[  ||| S:2008 E:2010 ||| -LRB-
8  ||| S:2010 E:2012 ||| CD
15  ||| S:2012 E:2015 ||| CD
]  ||| S:2015 E:2017 ||| -RRB-
.  ||| S:2017 E:2019 ||| .
Additionally ||| S:2019 E:2031 ||| RB
,  ||| S:2031 E:2033 ||| ,
PH-20  ||| S:2033 E:2039 ||| NNP
rapidly  ||| S:2039 E:2055 ||| RB
activates  ||| S:2055 E:2065 ||| JJ
ERK  ||| S:2065 E:2069 ||| NN
in  ||| S:2069 E:2072 ||| IN
L929  ||| S:2072 E:2077 ||| CD
cells  ||| S:2077 E:2083 ||| NNS
and  ||| S:2083 E:2087 ||| CC
TGF-β1  ||| S:2087 E:2094 ||| NNP
reduces  ||| S:2094 E:2102 ||| VBZ
the  ||| S:2102 E:2114 ||| DT
PH-20-induced  ||| S:2114 E:2128 ||| FW
ERK  ||| S:2128 E:2132 ||| FW
activation  ||| S:2132 E:2143 ||| FW
[  ||| S:2143 E:2145 ||| -LRB-
16  ||| S:2145 E:2148 ||| CD
]  ||| S:2148 E:2150 ||| -RRB-
.  ||| S:2150 E:2152 ||| .
In  ||| S:2152 E:2155 ||| IN
contrast ||| S:2155 E:2163 ||| NN
,  ||| S:2163 E:2165 ||| ,
TGF-β1  ||| S:2165 E:2180 ||| CD
synergistically  ||| S:2180 E:2196 ||| CD
increases  ||| S:2196 E:2206 ||| NNS
PH-20-mediated  ||| S:2206 E:2221 ||| VBP
inhibition  ||| S:2221 E:2232 ||| VBN
of  ||| S:2232 E:2243 ||| IN
staurosporine  ||| S:2243 E:2257 ||| JJ
apoptosis  ||| S:2257 E:2267 ||| NNS
[  ||| S:2267 E:2269 ||| -LRB-
16  ||| S:2269 E:2272 ||| CD
]  ||| S:2272 E:2274 ||| -RRB-
.  ||| S:2274 E:2276 ||| .
Thus ||| S:2276 E:2280 ||| RB
,  ||| S:2280 E:2282 ||| ,
PH-20  ||| S:2282 E:2288 ||| NNP
and  ||| S:2288 E:2292 ||| CC
TGF-β1  ||| S:2292 E:2299 ||| NNP
are  ||| S:2299 E:2311 ||| VBP
physiological  ||| S:2311 E:2325 ||| JJ
antagonists  ||| S:2325 E:2337 ||| NNS
for  ||| S:2337 E:2341 ||| IN
only  ||| S:2341 E:2346 ||| RB
certain  ||| S:2346 E:2354 ||| JJ
cellular  ||| S:2354 E:2371 ||| JJ
responses ||| S:2371 E:2380 ||| NNS
.  ||| S:2380 E:2390 ||| .
Hyaluronidases  ||| S:2390 E:2405 ||| NNP
Hyal-1  ||| S:2405 E:2412 ||| NNP
and  ||| S:2412 E:2416 ||| CC
Hyal-2  ||| S:2416 E:2423 ||| RB
play  ||| S:2423 E:2428 ||| VB
a  ||| S:2428 E:2430 ||| DT
critical  ||| S:2430 E:2439 ||| JJ
role  ||| S:2439 E:2444 ||| NN
in  ||| S:2444 E:2455 ||| IN
cancer  ||| S:2455 E:2462 ||| NN
invasion  ||| S:2462 E:2471 ||| NN
and  ||| S:2471 E:2475 ||| CC
metastasis  ||| S:2475 E:2486 ||| NNS
[  ||| S:2486 E:2488 ||| -LRB-
3  ||| S:2488 E:2490 ||| CD
4  ||| S:2490 E:2492 ||| CD
5  ||| S:2492 E:2494 ||| CD
]  ||| S:2494 E:2496 ||| -RRB-
,  ||| S:2496 E:2498 ||| ,
although  ||| S:2498 E:2515 ||| IN
inactivation  ||| S:2515 E:2528 ||| NN
of  ||| S:2528 E:2540 ||| IN
HYAL1  ||| S:2540 E:2546 ||| CD
gene  ||| S:2546 E:2551 ||| NN
has  ||| S:2551 E:2555 ||| VBZ
been  ||| S:2555 E:2560 ||| VBN
shown  ||| S:2560 E:2566 ||| VBN
in  ||| S:2566 E:2569 ||| IN
head  ||| S:2569 E:2574 ||| NN
and  ||| S:2574 E:2586 ||| CC
neck  ||| S:2586 E:2591 ||| NN
squamous  ||| S:2591 E:2600 ||| NN
cell  ||| S:2600 E:2605 ||| NN
carcinomas  ||| S:2605 E:2616 ||| NNS
[  ||| S:2616 E:2618 ||| -LRB-
17  ||| S:2618 E:2621 ||| CD
]  ||| S:2621 E:2623 ||| -RRB-
.  ||| S:2623 E:2625 ||| .
Hyal-1 ||| S:2625 E:2631 ||| NNP
,  ||| S:2631 E:2633 ||| ,
also  ||| S:2633 E:2638 ||| RB
known  ||| S:2638 E:2652 ||| VBN
as  ||| S:2652 E:2655 ||| IN
Luca-1 ||| S:2655 E:2661 ||| NNP
,  ||| S:2661 E:2663 ||| ,
is  ||| S:2663 E:2666 ||| VBZ
a  ||| S:2666 E:2668 ||| DT
lysosomal  ||| S:2668 E:2678 ||| JJ
enzyme  ||| S:2678 E:2685 ||| NN
that  ||| S:2685 E:2690 ||| WDT
is  ||| S:2690 E:2693 ||| VBZ
secreted  ||| S:2693 E:2702 ||| VBN
from  ||| S:2702 E:2715 ||| IN
cells ||| S:2715 E:2720 ||| NNS
.  ||| S:2720 E:2722 ||| .
Hyal-1  ||| S:2722 E:2729 ||| NNP
is  ||| S:2729 E:2732 ||| VBZ
a  ||| S:2732 E:2734 ||| DT
candidate  ||| S:2734 E:2744 ||| NN
tumor  ||| S:2744 E:2750 ||| NN
suppressor  ||| S:2750 E:2761 ||| NN
[  ||| S:2761 E:2763 ||| -LRB-
5  ||| S:2763 E:2765 ||| CD
18  ||| S:2765 E:2768 ||| CD
]  ||| S:2768 E:2770 ||| -RRB-
,  ||| S:2770 E:2780 ||| ,
although  ||| S:2780 E:2789 ||| IN
it  ||| S:2789 E:2792 ||| PRP
enhances  ||| S:2792 E:2801 ||| VBZ
extravasation  ||| S:2801 E:2815 ||| VBN
and  ||| S:2815 E:2819 ||| CC
metastasis  ||| S:2819 E:2830 ||| NN
of  ||| S:2830 E:2841 ||| IN
prostate  ||| S:2841 E:2850 ||| JJ
cancer  ||| S:2850 E:2857 ||| NN
cells  ||| S:2857 E:2863 ||| NNS
[  ||| S:2863 E:2865 ||| -LRB-
3  ||| S:2865 E:2867 ||| LS
]  ||| S:2867 E:2869 ||| -RRB-
.  ||| S:2869 E:2871 ||| .
Also ||| S:2871 E:2875 ||| RB
,  ||| S:2875 E:2877 ||| ,
mutations  ||| S:2877 E:2887 ||| NNS
in  ||| S:2887 E:2890 ||| IN
Hyal-1  ||| S:2890 E:2897 ||| NNP
may  ||| S:2897 E:2909 ||| MD
contribute  ||| S:2909 E:2920 ||| VB
to  ||| S:2920 E:2923 ||| TO
the  ||| S:2923 E:2927 ||| DT
pathogenesis  ||| S:2927 E:2940 ||| NN
of  ||| S:2940 E:2943 ||| IN
a  ||| S:2943 E:2945 ||| DT
lysosomal  ||| S:2945 E:2955 ||| JJ
disorder ||| S:2955 E:2963 ||| NN
,  ||| S:2963 E:2973 ||| ,
mucopolysaccharidosis  ||| S:2973 E:2995 ||| CD
IX  ||| S:2995 E:2998 ||| CD
[  ||| S:2998 E:3000 ||| -LRB-
19  ||| S:3000 E:3003 ||| CD
]  ||| S:3003 E:3005 ||| -RRB-
.  ||| S:3005 E:3007 ||| .
Hyal-2  ||| S:3007 E:3014 ||| NNP
is  ||| S:3014 E:3017 ||| VBZ
a  ||| S:3017 E:3019 ||| DT
lysosomal  ||| S:3019 E:3037 ||| JJ
protein ||| S:3037 E:3044 ||| NN
,  ||| S:3044 E:3046 ||| ,
which  ||| S:3046 E:3052 ||| WDT
is  ||| S:3052 E:3055 ||| VBZ
active  ||| S:3055 E:3062 ||| JJ
at  ||| S:3062 E:3065 ||| IN
low  ||| S:3065 E:3069 ||| JJ
pH  ||| S:3069 E:3072 ||| NN
[  ||| S:3072 E:3074 ||| -LRB-
20  ||| S:3074 E:3077 ||| CD
]  ||| S:3077 E:3079 ||| -RRB-
.  ||| S:3079 E:3081 ||| .
This  ||| S:3081 E:3086 ||| DT
protein  ||| S:3086 E:3094 ||| NN
is  ||| S:3094 E:3105 ||| VBZ
also  ||| S:3105 E:3110 ||| RB
known  ||| S:3110 E:3116 ||| VBN
to  ||| S:3116 E:3119 ||| TO
be  ||| S:3119 E:3122 ||| VB
a  ||| S:3122 E:3124 ||| DT
glycosylphosphatidylinositol  ||| S:3124 E:3161 ||| NN
( ||| S:3161 E:3162 ||| -LRB-
GPI ||| S:3162 E:3165 ||| NNP
) ||| S:3165 E:3166 ||| -RRB-
-anchored  ||| S:3166 E:3176 ||| JJ
cell-surface  ||| S:3176 E:3189 ||| JJ
receptor  ||| S:3189 E:3198 ||| NN
for  ||| S:3198 E:3202 ||| IN
jaagsiekte  ||| S:3202 E:3213 ||| FW
sheep  ||| S:3213 E:3227 ||| FW
retrovirus  ||| S:3227 E:3238 ||| FW
[  ||| S:3238 E:3240 ||| -LRB-
21  ||| S:3240 E:3243 ||| CD
]  ||| S:3243 E:3245 ||| -RRB-
.  ||| S:3245 E:3255 ||| .
Testicular  ||| S:3255 E:3266 ||| FW
hyaluronidase  ||| S:3266 E:3280 ||| FW
PH-20  ||| S:3280 E:3286 ||| FW
counteracts  ||| S:3286 E:3306 ||| FW
TGF-β1-induced  ||| S:3306 E:3321 ||| FW
TNF-resistance  ||| S:3321 E:3336 ||| FW
in  ||| S:3336 E:3339 ||| FW
L929  ||| S:3339 E:3344 ||| FW
cells  ||| S:3344 E:3350 ||| FW
[  ||| S:3350 E:3352 ||| -LRB-
8  ||| S:3352 E:3354 ||| CD
]  ||| S:3354 E:3356 ||| -RRB-
.  ||| S:3356 E:3358 ||| .
The  ||| S:3358 E:3370 ||| DT
goal  ||| S:3370 E:3375 ||| NN
of  ||| S:3375 E:3378 ||| IN
the  ||| S:3378 E:3382 ||| DT
present  ||| S:3382 E:3390 ||| JJ
study  ||| S:3390 E:3396 ||| NN
was  ||| S:3396 E:3400 ||| VBD
to  ||| S:3400 E:3403 ||| TO
examine  ||| S:3403 E:3411 ||| VB
whether  ||| S:3411 E:3419 ||| IN
lysosomal  ||| S:3419 E:3437 ||| JJ
Hyal-1  ||| S:3437 E:3444 ||| NN
and  ||| S:3444 E:3448 ||| CC
Hyal-2  ||| S:3448 E:3455 ||| RB
enhance  ||| S:3455 E:3463 ||| VB
TNF  ||| S:3463 E:3467 ||| JJ
cytotoxic  ||| S:3467 E:3477 ||| JJ
function  ||| S:3477 E:3486 ||| NN
and  ||| S:3486 E:3498 ||| CC
counteract  ||| S:3498 E:3509 ||| VB
TGF-β1-mediated  ||| S:3509 E:3525 ||| CD
TNF-resistance  ||| S:3525 E:3540 ||| NN
in  ||| S:3540 E:3543 ||| IN
L929  ||| S:3543 E:3548 ||| CD
cells ||| S:3548 E:3553 ||| NNS
.  ||| S:3553 E:3555 ||| .
It  ||| S:3555 E:3566 ||| PRP
was  ||| S:3566 E:3570 ||| VBD
determined  ||| S:3570 E:3581 ||| VBN
that  ||| S:3581 E:3586 ||| IN
stable  ||| S:3586 E:3593 ||| JJ
expression  ||| S:3593 E:3604 ||| NN
of  ||| S:3604 E:3607 ||| IN
murine  ||| S:3607 E:3614 ||| JJ
Hyal-2  ||| S:3614 E:3621 ||| NN
in  ||| S:3621 E:3632 ||| IN
L929  ||| S:3632 E:3637 ||| CD
cells  ||| S:3637 E:3643 ||| NNS
increased  ||| S:3643 E:3653 ||| VBD
their  ||| S:3653 E:3659 ||| PRP$
sensitivity  ||| S:3659 E:3671 ||| NN
to  ||| S:3671 E:3674 ||| TO
TNF-mediated  ||| S:3674 E:3695 ||| JJ
death ||| S:3695 E:3700 ||| NN
,  ||| S:3700 E:3702 ||| ,
whereas  ||| S:3702 E:3710 ||| IN
Hyal-1  ||| S:3710 E:3717 ||| NNP
was  ||| S:3717 E:3721 ||| VBD
somewhat  ||| S:3721 E:3730 ||| RB
less  ||| S:3730 E:3735 ||| RBR
effective ||| S:3735 E:3744 ||| JJ
.  ||| S:3744 E:3746 ||| .
TGF-β1  ||| S:3746 E:3761 ||| NNP
blocked  ||| S:3761 E:3769 ||| VBD
this  ||| S:3769 E:3774 ||| DT
increased  ||| S:3774 E:3784 ||| JJ
sensitivity ||| S:3784 E:3795 ||| NN
.  ||| S:3795 E:3797 ||| .
In  ||| S:3797 E:3800 ||| IN
contrast ||| S:3800 E:3808 ||| NN
,  ||| S:3808 E:3810 ||| ,
Hyal-1  ||| S:3810 E:3817 ||| NNP
and  ||| S:3817 E:3829 ||| CC
Hyal-2  ||| S:3829 E:3836 ||| NNP
did  ||| S:3836 E:3840 ||| VBD
not  ||| S:3840 E:3844 ||| RB
enhance  ||| S:3844 E:3852 ||| VB
L929  ||| S:3852 E:3857 ||| CD
cell  ||| S:3857 E:3862 ||| NN
death  ||| S:3862 E:3868 ||| NN
by  ||| S:3868 E:3871 ||| IN
anticancer  ||| S:3871 E:3882 ||| JJ
drugs  ||| S:3882 E:3896 ||| NNS
such  ||| S:3896 E:3901 ||| JJ
as  ||| S:3901 E:3904 ||| IN
daunorubicin ||| S:3904 E:3916 ||| NN
,  ||| S:3916 E:3918 ||| ,
actinomycin  ||| S:3918 E:3930 ||| VBG
D ||| S:3930 E:3931 ||| NNP
,  ||| S:3931 E:3933 ||| ,
staurosporine  ||| S:3933 E:3947 ||| NN
and  ||| S:3947 E:3959 ||| CC
camptothecin ||| S:3959 E:3971 ||| NN
.  ||| S:3971 E:3973 ||| .
Overexpressed  ||| S:3973 E:3987 ||| NNP
Hyal-1  ||| S:3987 E:3994 ||| NNP
and  ||| S:3994 E:3998 ||| CC
Hyal-2  ||| S:3998 E:4005 ||| NNP
induced  ||| S:4005 E:4013 ||| VBD
the  ||| S:4013 E:4025 ||| DT
expression  ||| S:4025 E:4036 ||| NN
of  ||| S:4036 E:4039 ||| IN
proapoptotic  ||| S:4039 E:4052 ||| CD
WOX1 ||| S:4052 E:4056 ||| CD
,  ||| S:4056 E:4058 ||| ,
but  ||| S:4058 E:4062 ||| CC
not  ||| S:4062 E:4066 ||| RB
p53 ||| S:4066 E:4069 ||| CD
,  ||| S:4069 E:4071 ||| ,
suggesting  ||| S:4071 E:4082 ||| VBG
a  ||| S:4082 E:4092 ||| DT
role  ||| S:4092 E:4097 ||| NN
of  ||| S:4097 E:4100 ||| IN
WOX1  ||| S:4100 E:4105 ||| CD
in  ||| S:4105 E:4108 ||| IN
the  ||| S:4108 E:4112 ||| DT
increased  ||| S:4112 E:4122 ||| JJ
cellular  ||| S:4122 E:4131 ||| JJ
susceptibility  ||| S:4131 E:4146 ||| NN
to  ||| S:4146 E:4157 ||| TO
TNF  ||| S:4157 E:4161 ||| NNP
cytotoxicity ||| S:4161 E:4173 ||| NN
.  ||| S:4173 E:4175 ||| .
Additional  ||| S:4175 E:4186 ||| JJ
mechanisms  ||| S:4186 E:4197 ||| NNS
that  ||| S:4197 E:4202 ||| WDT
are  ||| S:4202 E:4206 ||| VBP
associated  ||| S:4206 E:4225 ||| VBN
with  ||| S:4225 E:4230 ||| IN
the  ||| S:4230 E:4234 ||| DT
increased  ||| S:4234 E:4244 ||| JJ
TNF  ||| S:4244 E:4248 ||| NNP
cytotoxicity  ||| S:4248 E:4261 ||| NN
were  ||| S:4261 E:4266 ||| VBD
also  ||| S:4266 E:4279 ||| RB
investigated ||| S:4279 E:4291 ||| VBN
.  ||| S:4291 E:4315 ||| .
Results  ||| S:4315 E:4331 ||| NNS
As  ||| S:4331 E:4334 ||| IN
summarized  ||| S:4334 E:4345 ||| NN
in  ||| S:4345 E:4348 ||| IN
Figure  ||| S:4348 E:4355 ||| NNP
1 ||| S:4355 E:4356 ||| CD
,  ||| S:4356 E:4358 ||| ,
PH-20  ||| S:4358 E:4364 ||| NNP
induces  ||| S:4364 E:4372 ||| VBZ
the  ||| S:4372 E:4376 ||| DT
expression  ||| S:4376 E:4395 ||| NN
of  ||| S:4395 E:4398 ||| IN
proapoptotic  ||| S:4398 E:4411 ||| JJ
p53  ||| S:4411 E:4415 ||| NN
and  ||| S:4415 E:4419 ||| CC
WOX1  ||| S:4419 E:4424 ||| NNP
[  ||| S:4424 E:4426 ||| -LRB-
9  ||| S:4426 E:4428 ||| CD
10  ||| S:4428 E:4431 ||| CD
]  ||| S:4431 E:4433 ||| -RRB-
and  ||| S:4433 E:4437 ||| CC
downregulates  ||| S:4437 E:4459 ||| FW
antiapoptotic  ||| S:4459 E:4473 ||| FW
matrix  ||| S:4473 E:4480 ||| FW
inter-α-inhibitor  ||| S:4480 E:4498 ||| FW
[  ||| S:4498 E:4500 ||| -LRB-
9  ||| S:4500 E:4502 ||| CD
]  ||| S:4502 E:4504 ||| -RRB-
,  ||| S:4504 E:4506 ||| ,
thereby  ||| S:4506 E:4522 ||| RB
enhancing  ||| S:4522 E:4532 ||| VBG
TNF  ||| S:4532 E:4536 ||| NNP
susceptibility  ||| S:4536 E:4551 ||| NN
in  ||| S:4551 E:4554 ||| IN
L929  ||| S:4554 E:4559 ||| CD
cells ||| S:4559 E:4564 ||| NNS
.  ||| S:4564 E:4566 ||| .
Also ||| S:4566 E:4570 ||| RB
,  ||| S:4570 E:4572 ||| ,
PH-20  ||| S:4572 E:4586 ||| NNP
rapidly  ||| S:4586 E:4594 ||| RB
activates  ||| S:4594 E:4604 ||| JJ
ERK  ||| S:4604 E:4608 ||| NNP
and  ||| S:4608 E:4612 ||| CC
c-Jun  ||| S:4612 E:4627 ||| NNP
N  ||| S:4627 E:4629 ||| NNP
-terminal  ||| S:4629 E:4639 ||| JJ
kinase  ||| S:4639 E:4646 ||| NNS
( ||| S:4646 E:4647 ||| -LRB-
JNK1  ||| S:4647 E:4652 ||| NNP
and  ||| S:4652 E:4656 ||| CC
JNK2 ||| S:4656 E:4660 ||| CD
)  ||| S:4660 E:4662 ||| -RRB-
[  ||| S:4662 E:4672 ||| -LRB-
16  ||| S:4672 E:4675 ||| CD
]  ||| S:4675 E:4677 ||| -RRB-
.  ||| S:4677 E:4679 ||| .
Whether  ||| S:4679 E:4687 ||| IN
these  ||| S:4687 E:4693 ||| DT
signaling  ||| S:4693 E:4703 ||| JJ
events  ||| S:4703 E:4710 ||| NNS
lead  ||| S:4710 E:4715 ||| VBP
to  ||| S:4715 E:4718 ||| TO
induction  ||| S:4718 E:4728 ||| VB
of  ||| S:4728 E:4739 ||| IN
p53  ||| S:4739 E:4743 ||| NN
and  ||| S:4743 E:4747 ||| CC
WOX1  ||| S:4747 E:4752 ||| NNP
is  ||| S:4752 E:4755 ||| VBZ
unknown ||| S:4755 E:4762 ||| JJ
.  ||| S:4762 E:4772 ||| .
In  ||| S:4772 E:4775 ||| IN
contrast ||| S:4775 E:4783 ||| NN
,  ||| S:4783 E:4785 ||| ,
TGF-β1  ||| S:4785 E:4792 ||| NNP
protects  ||| S:4792 E:4801 ||| VBZ
L929  ||| S:4801 E:4806 ||| CD
cells  ||| S:4806 E:4812 ||| NNS
from  ||| S:4812 E:4817 ||| IN
TNF  ||| S:4817 E:4829 ||| NNP
cytotoxicity  ||| S:4829 E:4842 ||| NN
by  ||| S:4842 E:4845 ||| IN
upregulating  ||| S:4845 E:4858 ||| VBG
the  ||| S:4858 E:4862 ||| DT
expression  ||| S:4862 E:4873 ||| NN
of  ||| S:4873 E:4884 ||| IN
antiapoptotic  ||| S:4884 E:4898 ||| CD
TIAF1 ||| S:4898 E:4903 ||| CD
,  ||| S:4903 E:4905 ||| ,
TIF2  ||| S:4905 E:4910 ||| NNP
and  ||| S:4910 E:4914 ||| CC
a  ||| S:4914 E:4916 ||| DT
novel  ||| S:4916 E:4922 ||| NN
matrix  ||| S:4922 E:4929 ||| NN
protein  ||| S:4929 E:4937 ||| NN
[  ||| S:4937 E:4939 ||| -LRB-
11  ||| S:4939 E:4950 ||| CD
12  ||| S:4950 E:4953 ||| CD
13  ||| S:4953 E:4956 ||| CD
14  ||| S:4956 E:4959 ||| CD
]  ||| S:4959 E:4961 ||| -RRB-
.  ||| S:4961 E:4963 ||| .
TGF-β1  ||| S:4963 E:4970 ||| FW
blocks  ||| S:4970 E:4977 ||| FW
PH-20-increased  ||| S:4977 E:4993 ||| FW
TNF  ||| S:4993 E:5005 ||| FW
susceptibility  ||| S:5005 E:5020 ||| FW
[  ||| S:5020 E:5022 ||| -LRB-
15  ||| S:5022 E:5025 ||| CD
]  ||| S:5025 E:5027 ||| -RRB-
.  ||| S:5027 E:5029 ||| .
Likewise ||| S:5029 E:5037 ||| RB
,  ||| S:5037 E:5039 ||| ,
PH-20  ||| S:5039 E:5045 ||| FW
inhibits  ||| S:5045 E:5062 ||| FW
TGF-β1-induced  ||| S:5062 E:5077 ||| FW
TNF-resistance  ||| S:5077 E:5092 ||| FW
[  ||| S:5092 E:5094 ||| -LRB-
15  ||| S:5094 E:5097 ||| CD
]  ||| S:5097 E:5099 ||| -RRB-
.  ||| S:5099 E:5101 ||| .
TGF-β1  ||| S:5101 E:5108 ||| FW
suppresses  ||| S:5108 E:5127 ||| FW
PH-20-mediated  ||| S:5127 E:5142 ||| FW
ERK  ||| S:5142 E:5146 ||| FW
activation  ||| S:5146 E:5157 ||| FW
[  ||| S:5157 E:5159 ||| -LRB-
16  ||| S:5159 E:5162 ||| CD
]  ||| S:5162 E:5164 ||| -RRB-
;  ||| S:5164 E:5166 ||| :
however ||| S:5166 E:5173 ||| RB
,  ||| S:5173 E:5175 ||| ,
the  ||| S:5175 E:5179 ||| DT
ERK  ||| S:5179 E:5191 ||| NNP
activation  ||| S:5191 E:5202 ||| NN
is  ||| S:5202 E:5205 ||| VBZ
not  ||| S:5205 E:5209 ||| RB
related  ||| S:5209 E:5217 ||| VBN
with  ||| S:5217 E:5222 ||| IN
PH-20-increased  ||| S:5222 E:5238 ||| NNP
TNF  ||| S:5238 E:5250 ||| NNP
susceptibility  ||| S:5250 E:5265 ||| NN
in  ||| S:5265 E:5268 ||| IN
L929  ||| S:5268 E:5273 ||| CD
cells  ||| S:5273 E:5279 ||| NNS
[  ||| S:5279 E:5281 ||| -LRB-
15  ||| S:5281 E:5284 ||| CD
]  ||| S:5284 E:5286 ||| -RRB-
.  ||| S:5286 E:5288 ||| .
Whether  ||| S:5288 E:5296 ||| IN
the  ||| S:5296 E:5308 ||| DT
proapoptotic  ||| S:5308 E:5321 ||| JJ
p53  ||| S:5321 E:5325 ||| NN
and  ||| S:5325 E:5329 ||| CC
WOX1  ||| S:5329 E:5334 ||| RB
block  ||| S:5334 E:5340 ||| VB
the  ||| S:5340 E:5344 ||| DT
function  ||| S:5344 E:5353 ||| NN
of  ||| S:5353 E:5364 ||| IN
antiapoptotic  ||| S:5364 E:5378 ||| JJ
TIAF1  ||| S:5378 E:5384 ||| NN
and  ||| S:5384 E:5388 ||| CC
TIF2  ||| S:5388 E:5393 ||| NNP
is  ||| S:5393 E:5396 ||| VBZ
not  ||| S:5396 E:5400 ||| RB
known ||| S:5400 E:5405 ||| VBN
.  ||| S:5405 E:5407 ||| .
In  ||| S:5407 E:5410 ||| IN
this  ||| S:5410 E:5415 ||| DT
study ||| S:5415 E:5420 ||| NN
,  ||| S:5420 E:5430 ||| ,
experiments  ||| S:5430 E:5442 ||| NNS
were  ||| S:5442 E:5447 ||| VBD
designed  ||| S:5447 E:5456 ||| VBN
to  ||| S:5456 E:5459 ||| TO
determine  ||| S:5459 E:5469 ||| VB
whether  ||| S:5469 E:5477 ||| IN
lysosomal  ||| S:5477 E:5495 ||| JJ
Hyal-1  ||| S:5495 E:5502 ||| NN
and  ||| S:5502 E:5506 ||| CC
Hyal-2  ||| S:5506 E:5513 ||| RB
enhance  ||| S:5513 E:5521 ||| VB
TNF  ||| S:5521 E:5525 ||| JJ
cytotoxic  ||| S:5525 E:5535 ||| JJ
function  ||| S:5535 E:5544 ||| NN
and  ||| S:5544 E:5556 ||| CC
counteract  ||| S:5556 E:5567 ||| VB
TGF-β1-mediated  ||| S:5567 E:5583 ||| CD
TNF-resistance  ||| S:5583 E:5598 ||| NN
in  ||| S:5598 E:5601 ||| IN
L929  ||| S:5601 E:5614 ||| CD
cells ||| S:5614 E:5619 ||| NNS
.  ||| S:5619 E:5629 ||| .
The  ||| S:5629 E:5633 ||| DT
full-length  ||| S:5633 E:5645 ||| JJ
murine  ||| S:5645 E:5652 ||| JJ
hyaluronidase  ||| S:5652 E:5675 ||| JJ
Hyal1  ||| S:5675 E:5681 ||| NN
and  ||| S:5681 E:5694 ||| CC
Hyal2  ||| S:5694 E:5700 ||| NNP
cDNAs  ||| S:5700 E:5706 ||| NNP
were  ||| S:5706 E:5711 ||| VBD
found  ||| S:5711 E:5717 ||| VBN
in  ||| S:5717 E:5720 ||| IN
the  ||| S:5720 E:5724 ||| DT
EST  ||| S:5724 E:5736 ||| NNP
database  ||| S:5736 E:5745 ||| NN
( ||| S:5745 E:5746 ||| -LRB-
GenBank  ||| S:5746 E:5754 ||| FW
accession  ||| S:5754 E:5764 ||| FW
AA688635  ||| S:5764 E:5773 ||| FW
and  ||| S:5773 E:5777 ||| CC
BF139787 ||| S:5777 E:5785 ||| NNP
,  ||| S:5785 E:5795 ||| ,
respectively ||| S:5795 E:5807 ||| RB
)  ||| S:5807 E:5809 ||| -RRB-
and  ||| S:5809 E:5813 ||| CC
the  ||| S:5813 E:5817 ||| DT
determined  ||| S:5817 E:5828 ||| JJ
DNA  ||| S:5828 E:5832 ||| NN
sequences  ||| S:5832 E:5842 ||| NNS
have  ||| S:5842 E:5847 ||| VBP
been  ||| S:5847 E:5860 ||| VBN
deposited  ||| S:5860 E:5870 ||| VBN
in  ||| S:5870 E:5873 ||| IN
the  ||| S:5873 E:5877 ||| DT
GenBank  ||| S:5877 E:5885 ||| JJ
(  ||| S:5885 E:5896 ||| -LRB-
Hyal1  ||| S:5896 E:5902 ||| NNP
,  ||| S:5902 E:5904 ||| ,
AF422176 ||| S:5904 E:5912 ||| NNP
;  ||| S:5912 E:5923 ||| :
Hyal2  ||| S:5923 E:5929 ||| CD
,  ||| S:5929 E:5931 ||| ,
AF422177 ||| S:5931 E:5939 ||| CD
) ||| S:5939 E:5940 ||| -RRB-
.  ||| S:5940 E:5942 ||| .
The  ||| S:5942 E:5955 ||| DT
Hyal1  ||| S:5955 E:5961 ||| NNP
cDNA  ||| S:5961 E:5966 ||| NNP
encodes  ||| S:5966 E:5974 ||| VBD
a  ||| S:5974 E:5976 ||| DT
463-amino-acid  ||| S:5976 E:5999 ||| JJ
protein ||| S:5999 E:6006 ||| NN
,  ||| S:6006 E:6008 ||| ,
which  ||| S:6008 E:6014 ||| WDT
has  ||| S:6014 E:6018 ||| VBZ
99.1 ||| S:6018 E:6022 ||| CD
%  ||| S:6022 E:6024 ||| NN
identity  ||| S:6024 E:6033 ||| NN
to  ||| S:6033 E:6036 ||| TO
a  ||| S:6036 E:6038 ||| DT
reported  ||| S:6038 E:6047 ||| VBN
murine  ||| S:6047 E:6062 ||| JJ
sequence  ||| S:6062 E:6071 ||| NN
( ||| S:6071 E:6072 ||| -LRB-
AF011567 ||| S:6072 E:6080 ||| NNP
)  ||| S:6080 E:6082 ||| -RRB-
[  ||| S:6082 E:6084 ||| -LRB-
18  ||| S:6084 E:6087 ||| CD
]  ||| S:6087 E:6089 ||| -RRB-
.  ||| S:6089 E:6091 ||| .
Differences  ||| S:6091 E:6103 ||| NNS
in  ||| S:6103 E:6106 ||| IN
the  ||| S:6106 E:6110 ||| DT
protein  ||| S:6110 E:6126 ||| NN
sequences  ||| S:6126 E:6136 ||| NNS
are  ||| S:6136 E:6140 ||| VBP
Gly-247 ||| S:6140 E:6147 ||| RB
,  ||| S:6147 E:6149 ||| ,
Gly-284  ||| S:6149 E:6157 ||| NNP
and  ||| S:6157 E:6161 ||| CC
Cys-450  ||| S:6161 E:6169 ||| CD
in  ||| S:6169 E:6172 ||| IN
our  ||| S:6172 E:6176 ||| PRP$
Hyal-1  ||| S:6176 E:6191 ||| JJ
protein ||| S:6191 E:6198 ||| NN
,  ||| S:6198 E:6200 ||| ,
compared  ||| S:6200 E:6209 ||| VBN
to  ||| S:6209 E:6212 ||| TO
Arg-247 ||| S:6212 E:6219 ||| CD
,  ||| S:6219 E:6221 ||| ,
Glu-284  ||| S:6221 E:6229 ||| NNP
and  ||| S:6229 E:6233 ||| CC
Arg-450  ||| S:6233 E:6241 ||| CD
in  ||| S:6241 E:6252 ||| IN
AF011567 ||| S:6252 E:6260 ||| CD
.  ||| S:6260 E:6262 ||| .
Transitions  ||| S:6262 E:6274 ||| NNP
in  ||| S:6274 E:6277 ||| IN
these  ||| S:6277 E:6283 ||| DT
amino  ||| S:6283 E:6289 ||| JJ
acid  ||| S:6289 E:6294 ||| NN
residues  ||| S:6294 E:6303 ||| NNS
are  ||| S:6303 E:6315 ||| VBP
non-conservative ||| S:6315 E:6331 ||| JJ
.  ||| S:6331 E:6341 ||| .
The  ||| S:6341 E:6345 ||| DT
murine  ||| S:6345 E:6361 ||| JJ
Hyal2  ||| S:6361 E:6367 ||| NNP
cDNA  ||| S:6367 E:6372 ||| NNP
( ||| S:6372 E:6373 ||| -LRB-
AF422177 ||| S:6373 E:6381 ||| NNP
)  ||| S:6381 E:6383 ||| -RRB-
encodes  ||| S:6383 E:6391 ||| VBZ
a  ||| S:6391 E:6401 ||| DT
473-amino-acid  ||| S:6401 E:6416 ||| JJ
protein ||| S:6416 E:6423 ||| NN
.  ||| S:6423 E:6425 ||| .
The  ||| S:6425 E:6429 ||| DT
deduced  ||| S:6429 E:6437 ||| JJ
protein  ||| S:6437 E:6445 ||| NN
sequence  ||| S:6445 E:6454 ||| NN
is  ||| S:6454 E:6465 ||| VBZ
identical  ||| S:6465 E:6475 ||| JJ
to  ||| S:6475 E:6478 ||| TO
a  ||| S:6478 E:6480 ||| DT
reported  ||| S:6480 E:6489 ||| VBN
murine  ||| S:6489 E:6496 ||| JJ
sequence  ||| S:6496 E:6505 ||| NN
( ||| S:6505 E:6506 ||| -LRB-
AF302844 ||| S:6506 E:6514 ||| NNP
) ||| S:6514 E:6515 ||| -RRB-
,  ||| S:6515 E:6517 ||| ,
but  ||| S:6517 E:6521 ||| CC
has  ||| S:6521 E:6533 ||| VBZ
an  ||| S:6533 E:6536 ||| DT
Ile-355  ||| S:6536 E:6544 ||| NN
to  ||| S:6544 E:6547 ||| TO
Val-355  ||| S:6547 E:6555 ||| CD
transition  ||| S:6555 E:6566 ||| NN
compared  ||| S:6566 E:6575 ||| VBN
to  ||| S:6575 E:6578 ||| TO
another  ||| S:6578 E:6586 ||| DT
clone  ||| S:6586 E:6600 ||| NN
( ||| S:6600 E:6601 ||| -LRB-
AF302843 ||| S:6601 E:6609 ||| NNP
) ||| S:6609 E:6610 ||| -RRB-
.  ||| S:6610 E:6612 ||| .
Variation  ||| S:6612 E:6622 ||| NN
in  ||| S:6622 E:6625 ||| IN
the  ||| S:6625 E:6629 ||| DT
protein  ||| S:6629 E:6637 ||| NN
sequence  ||| S:6637 E:6646 ||| NN
is  ||| S:6646 E:6649 ||| VBZ
also  ||| S:6649 E:6654 ||| RB
found  ||| S:6654 E:6668 ||| VBN
in  ||| S:6668 E:6671 ||| IN
a  ||| S:6671 E:6673 ||| DT
murine  ||| S:6673 E:6680 ||| FW
Hyal-2  ||| S:6680 E:6687 ||| FW
homologue  ||| S:6687 E:6697 ||| FW
( ||| S:6697 E:6698 ||| -LRB-
NP_034619 ||| S:6698 E:6707 ||| NNP
)  ||| S:6707 E:6709 ||| -RRB-
[  ||| S:6709 E:6711 ||| -LRB-
22  ||| S:6711 E:6714 ||| CD
]  ||| S:6714 E:6716 ||| -RRB-
,  ||| S:6716 E:6718 ||| ,
which  ||| S:6718 E:6732 ||| WDT
possesses  ||| S:6732 E:6742 ||| VBZ
three  ||| S:6742 E:6748 ||| CD
unique  ||| S:6748 E:6755 ||| JJ
2- ||| S:6755 E:6757 ||| NN
,  ||| S:6757 E:6759 ||| ,
5-  ||| S:6759 E:6762 ||| NNP
and  ||| S:6762 E:6766 ||| CC
7-amino-acid  ||| S:6766 E:6779 ||| CD
segments ||| S:6779 E:6787 ||| NNS
,  ||| S:6787 E:6797 ||| ,
not  ||| S:6797 E:6801 ||| RB
identical  ||| S:6801 E:6811 ||| JJ
to  ||| S:6811 E:6814 ||| TO
the  ||| S:6814 E:6818 ||| DT
above  ||| S:6818 E:6824 ||| IN
Hyal-2  ||| S:6824 E:6831 ||| CD
proteins ||| S:6831 E:6839 ||| NNS
.  ||| S:6839 E:6849 ||| .
L929  ||| S:6849 E:6854 ||| NNP
cells  ||| S:6854 E:6860 ||| NNS
were  ||| S:6860 E:6865 ||| VBD
engineered  ||| S:6865 E:6876 ||| VBN
to  ||| S:6876 E:6879 ||| TO
stably  ||| S:6879 E:6886 ||| VB
express  ||| S:6886 E:6894 ||| JJ
GFP-Hyal-1  ||| S:6894 E:6913 ||| NN
or  ||| S:6913 E:6916 ||| CC
GFP-Hyal-2  ||| S:6916 E:6927 ||| CD
fusion  ||| S:6927 E:6934 ||| NN
proteins ||| S:6934 E:6942 ||| NNS
.  ||| S:6942 E:6944 ||| .
The  ||| S:6944 E:6948 ||| DT
presence  ||| S:6948 E:6957 ||| NN
of  ||| S:6957 E:6960 ||| IN
these  ||| S:6960 E:6974 ||| DT
proteins  ||| S:6974 E:6983 ||| NNS
in  ||| S:6983 E:6986 ||| IN
these  ||| S:6986 E:6992 ||| DT
cells  ||| S:6992 E:6998 ||| NNS
was  ||| S:6998 E:7002 ||| VBD
demonstrated  ||| S:7002 E:7015 ||| VBN
in  ||| S:7015 E:7018 ||| IN
Western  ||| S:7018 E:7034 ||| JJ
blotting  ||| S:7034 E:7043 ||| NNS
using  ||| S:7043 E:7049 ||| VBG
anti-GFP  ||| S:7049 E:7058 ||| JJ
antibody  ||| S:7058 E:7067 ||| NN
( ||| S:7067 E:7068 ||| -LRB-
data  ||| S:7068 E:7073 ||| NNS
not  ||| S:7073 E:7077 ||| RB
shown ||| S:7077 E:7082 ||| VBN
) ||| S:7082 E:7083 ||| -RRB-
.  ||| S:7083 E:7093 ||| .
Exogenous  ||| S:7093 E:7103 ||| FW
bovine  ||| S:7103 E:7110 ||| FW
testicular  ||| S:7110 E:7121 ||| FW
hyaluronidase  ||| S:7121 E:7135 ||| FW
PH-20  ||| S:7135 E:7141 ||| FW
stimulates  ||| S:7141 E:7160 ||| FW
rapid  ||| S:7160 E:7166 ||| JJ
activation  ||| S:7166 E:7177 ||| NN
of  ||| S:7177 E:7180 ||| IN
c-Jun  ||| S:7180 E:7195 ||| NNP
N  ||| S:7195 E:7197 ||| NNP
-terminal  ||| S:7197 E:7207 ||| JJ
kinases  ||| S:7207 E:7215 ||| NNS
( ||| S:7215 E:7216 ||| -LRB-
JNK1  ||| S:7216 E:7221 ||| NNP
and  ||| S:7221 E:7225 ||| CC
JNK2 ||| S:7225 E:7229 ||| CD
)  ||| S:7229 E:7239 ||| -RRB-
in  ||| S:7239 E:7242 ||| IN
L929  ||| S:7242 E:7247 ||| CD
cells  ||| S:7247 E:7253 ||| NNS
[  ||| S:7253 E:7255 ||| -LRB-
16  ||| S:7255 E:7258 ||| CD
]  ||| S:7258 E:7260 ||| -RRB-
.  ||| S:7260 E:7262 ||| .
In  ||| S:7262 E:7265 ||| IN
contrast ||| S:7265 E:7273 ||| NN
,  ||| S:7273 E:7275 ||| ,
the  ||| S:7275 E:7279 ||| DT
stably  ||| S:7279 E:7286 ||| NN
expressed  ||| S:7286 E:7304 ||| VBD
Hyal-1  ||| S:7304 E:7311 ||| CD
and  ||| S:7311 E:7315 ||| CC
Hyal-2  ||| S:7315 E:7322 ||| NNP
could  ||| S:7322 E:7328 ||| MD
not  ||| S:7328 E:7332 ||| RB
mediate  ||| S:7332 E:7340 ||| VB
constitutive  ||| S:7340 E:7353 ||| JJ
activation  ||| S:7353 E:7372 ||| NN
of  ||| S:7372 E:7375 ||| IN
JNK1  ||| S:7375 E:7380 ||| NNP
and  ||| S:7380 E:7384 ||| CC
JNK2  ||| S:7384 E:7389 ||| CD
in  ||| S:7389 E:7392 ||| IN
L929  ||| S:7392 E:7397 ||| CD
cells  ||| S:7397 E:7403 ||| NNS
( ||| S:7403 E:7404 ||| -LRB-
data  ||| S:7404 E:7409 ||| NNS
not  ||| S:7409 E:7413 ||| RB
shown ||| S:7413 E:7418 ||| VBN
) ||| S:7418 E:7419 ||| -RRB-
.  ||| S:7419 E:7429 ||| .
Exposure  ||| S:7429 E:7438 ||| NN
of  ||| S:7438 E:7441 ||| IN
the  ||| S:7441 E:7445 ||| DT
Hyal-2-expressing  ||| S:7445 E:7463 ||| CD
L929  ||| S:7463 E:7468 ||| CD
cells  ||| S:7468 E:7474 ||| NNS
to  ||| S:7474 E:7477 ||| TO
TNF  ||| S:7477 E:7481 ||| NNP
for  ||| S:7481 E:7493 ||| IN
16-24  ||| S:7493 E:7499 ||| CD
hr  ||| S:7499 E:7502 ||| NNS
resulted  ||| S:7502 E:7511 ||| VBD
in  ||| S:7511 E:7514 ||| IN
increased  ||| S:7514 E:7524 ||| JJ
cell  ||| S:7524 E:7529 ||| NN
death  ||| S:7529 E:7535 ||| NN
by  ||| S:7535 E:7538 ||| IN
~60-110 ||| S:7538 E:7545 ||| CD
% ||| S:7545 E:7546 ||| NN
,  ||| S:7546 E:7556 ||| ,
compared  ||| S:7556 E:7565 ||| VBN
to  ||| S:7565 E:7568 ||| TO
the  ||| S:7568 E:7572 ||| DT
control  ||| S:7572 E:7580 ||| NN
GFP-expressing  ||| S:7580 E:7595 ||| JJ
cells  ||| S:7595 E:7601 ||| NNS
( ||| S:7601 E:7602 ||| -LRB-
Fig.  ||| S:7602 E:7607 ||| CD
2 ||| S:7607 E:7608 ||| CD
) ||| S:7608 E:7609 ||| -RRB-
.  ||| S:7609 E:7619 ||| .
These  ||| S:7619 E:7625 ||| DT
results  ||| S:7625 E:7633 ||| NNS
are  ||| S:7633 E:7637 ||| VBP
similar  ||| S:7637 E:7645 ||| JJ
to  ||| S:7645 E:7648 ||| TO
the  ||| S:7648 E:7652 ||| DT
bovine  ||| S:7652 E:7659 ||| FW
testicular  ||| S:7659 E:7678 ||| FW
PH-20-increased  ||| S:7678 E:7694 ||| FW
TNF  ||| S:7694 E:7698 ||| FW
cytotoxicity  ||| S:7698 E:7711 ||| FW
of  ||| S:7711 E:7714 ||| IN
L929  ||| S:7714 E:7719 ||| CD
cells  ||| S:7719 E:7725 ||| NNS
[  ||| S:7725 E:7727 ||| -LRB-
15  ||| S:7727 E:7730 ||| CD
]  ||| S:7730 E:7732 ||| -RRB-
.  ||| S:7732 E:7734 ||| .
In  ||| S:7734 E:7745 ||| IN
contrast ||| S:7745 E:7753 ||| NN
,  ||| S:7753 E:7755 ||| ,
there  ||| S:7755 E:7761 ||| EX
were  ||| S:7761 E:7766 ||| VBD
no  ||| S:7766 E:7769 ||| DT
significant  ||| S:7769 E:7781 ||| JJ
differences  ||| S:7781 E:7793 ||| NNS
in  ||| S:7793 E:7796 ||| IN
the  ||| S:7796 E:7808 ||| DT
extent  ||| S:7808 E:7815 ||| NN
of  ||| S:7815 E:7818 ||| IN
cell  ||| S:7818 E:7823 ||| NN
death  ||| S:7823 E:7829 ||| NN
when  ||| S:7829 E:7834 ||| WRB
GFP-Hyal-2  ||| S:7834 E:7845 ||| NNP
and  ||| S:7845 E:7849 ||| CC
control  ||| S:7849 E:7865 ||| VB
GFP-expressing  ||| S:7865 E:7880 ||| JJ
cells  ||| S:7880 E:7886 ||| NNS
were  ||| S:7886 E:7891 ||| VBD
exposed  ||| S:7891 E:7899 ||| VBN
to  ||| S:7899 E:7902 ||| TO
staurosporine ||| S:7902 E:7915 ||| VB
,  ||| S:7915 E:7925 ||| ,
actinomycin  ||| S:7925 E:7937 ||| VBG
D ||| S:7937 E:7938 ||| NNP
,  ||| S:7938 E:7940 ||| ,
daunorubicin ||| S:7940 E:7952 ||| NN
,  ||| S:7952 E:7954 ||| ,
or  ||| S:7954 E:7957 ||| CC
camptothecin  ||| S:7957 E:7970 ||| NN
for  ||| S:7970 E:7974 ||| IN
16-24  ||| S:7974 E:7980 ||| CD
hr  ||| S:7980 E:7991 ||| NNS
( ||| S:7991 E:7992 ||| -LRB-
Fig.  ||| S:7992 E:7997 ||| CD
2 ||| S:7997 E:7998 ||| CD
) ||| S:7998 E:7999 ||| -RRB-
.  ||| S:7999 E:8009 ||| .
There  ||| S:8009 E:8015 ||| EX
was  ||| S:8015 E:8019 ||| VBD
also  ||| S:8019 E:8024 ||| RB
an  ||| S:8024 E:8027 ||| DT
increased  ||| S:8027 E:8037 ||| JJ
susceptibility  ||| S:8037 E:8052 ||| NN
to  ||| S:8052 E:8055 ||| TO
TNF  ||| S:8055 E:8067 ||| NNP
cytotoxicity  ||| S:8067 E:8080 ||| NN
in  ||| S:8080 E:8083 ||| IN
the  ||| S:8083 E:8087 ||| DT
Hyal-1-expressing  ||| S:8087 E:8105 ||| CD
L929  ||| S:8105 E:8110 ||| CD
cells  ||| S:8110 E:8124 ||| NNS
( ||| S:8124 E:8125 ||| -LRB-
approximately  ||| S:8125 E:8139 ||| RB
20-90 ||| S:8139 E:8144 ||| CD
%  ||| S:8144 E:8146 ||| NN
increase ||| S:8146 E:8154 ||| NN
;  ||| S:8154 E:8156 ||| :
also  ||| S:8156 E:8161 ||| RB
see  ||| S:8161 E:8165 ||| VB
Fig.  ||| S:8165 E:8170 ||| CD
7 ||| S:8170 E:8171 ||| CD
) ||| S:8171 E:8172 ||| -RRB-
,  ||| S:8172 E:8174 ||| ,
compared  ||| S:8174 E:8191 ||| VBN
to  ||| S:8191 E:8194 ||| TO
the  ||| S:8194 E:8198 ||| DT
GFP  ||| S:8198 E:8202 ||| NNP
control  ||| S:8202 E:8210 ||| NN
cells ||| S:8210 E:8215 ||| NNS
.  ||| S:8215 E:8217 ||| .
However ||| S:8217 E:8224 ||| RB
,  ||| S:8224 E:8226 ||| ,
there  ||| S:8226 E:8232 ||| EX
were  ||| S:8232 E:8237 ||| VBD
no  ||| S:8237 E:8248 ||| DT
significant  ||| S:8248 E:8260 ||| JJ
differences  ||| S:8260 E:8272 ||| NNS
among  ||| S:8272 E:8278 ||| IN
these  ||| S:8278 E:8284 ||| DT
cells  ||| S:8284 E:8290 ||| NNS
in  ||| S:8290 E:8293 ||| IN
the  ||| S:8293 E:8297 ||| DT
extent  ||| S:8297 E:8304 ||| NN
of  ||| S:8304 E:8315 ||| IN
death  ||| S:8315 E:8321 ||| NN
caused  ||| S:8321 E:8328 ||| VBN
by  ||| S:8328 E:8331 ||| IN
staurosporine ||| S:8331 E:8344 ||| NN
,  ||| S:8344 E:8346 ||| ,
actinomycin  ||| S:8346 E:8358 ||| VBG
D ||| S:8358 E:8359 ||| NNP
,  ||| S:8359 E:8361 ||| ,
daunorubicin  ||| S:8361 E:8382 ||| NN
and  ||| S:8382 E:8386 ||| CC
camptothecin  ||| S:8386 E:8399 ||| NNS
( ||| S:8399 E:8400 ||| -LRB-
data  ||| S:8400 E:8405 ||| NNS
not  ||| S:8405 E:8409 ||| RB
shown ||| S:8409 E:8414 ||| VBN
) ||| S:8414 E:8415 ||| -RRB-
.  ||| S:8415 E:8425 ||| .
In  ||| S:8425 E:8428 ||| IN
similar  ||| S:8428 E:8436 ||| JJ
experiments ||| S:8436 E:8447 ||| NNS
,  ||| S:8447 E:8449 ||| ,
the  ||| S:8449 E:8453 ||| DT
effect  ||| S:8453 E:8460 ||| NN
of  ||| S:8460 E:8463 ||| IN
transient  ||| S:8463 E:8481 ||| JJ
expression  ||| S:8481 E:8492 ||| NN
of  ||| S:8492 E:8495 ||| IN
Hyal-1  ||| S:8495 E:8502 ||| NNP
and  ||| S:8502 E:8506 ||| CC
Hyal-2  ||| S:8506 E:8513 ||| CD
on  ||| S:8513 E:8516 ||| IN
cellular  ||| S:8516 E:8525 ||| JJ
sensitivity  ||| S:8525 E:8537 ||| NN
to  ||| S:8537 E:8548 ||| TO
anticancer  ||| S:8548 E:8559 ||| VB
drugs  ||| S:8559 E:8565 ||| NNS
was  ||| S:8565 E:8569 ||| VBD
examined ||| S:8569 E:8577 ||| VBN
.  ||| S:8577 E:8579 ||| .
L929  ||| S:8579 E:8584 ||| NNP
cells  ||| S:8584 E:8590 ||| NNS
were  ||| S:8590 E:8603 ||| VBD
electroporated  ||| S:8603 E:8618 ||| VBN
with  ||| S:8618 E:8623 ||| IN
the  ||| S:8623 E:8627 ||| DT
GFP-Hyal-1  ||| S:8627 E:8638 ||| NNP
or  ||| S:8638 E:8641 ||| CC
GFP-Hyal-2  ||| S:8641 E:8652 ||| CD
construct ||| S:8652 E:8661 ||| NN
,  ||| S:8661 E:8671 ||| ,
cultured  ||| S:8671 E:8680 ||| VBG
for  ||| S:8680 E:8684 ||| IN
48  ||| S:8684 E:8687 ||| CD
hr  ||| S:8687 E:8690 ||| NNS
and  ||| S:8690 E:8694 ||| CC
then  ||| S:8694 E:8699 ||| RB
exposed  ||| S:8699 E:8707 ||| VBN
to  ||| S:8707 E:8710 ||| TO
actinomycin  ||| S:8710 E:8722 ||| VB
D ||| S:8722 E:8723 ||| NNP
,  ||| S:8723 E:8733 ||| ,
daunorubicin  ||| S:8733 E:8746 ||| NN
or  ||| S:8746 E:8749 ||| CC
camptothecin  ||| S:8749 E:8762 ||| NN
for  ||| S:8762 E:8766 ||| IN
24  ||| S:8766 E:8769 ||| CD
hr ||| S:8769 E:8771 ||| NNS
.  ||| S:8771 E:8773 ||| .
There  ||| S:8773 E:8779 ||| EX
were  ||| S:8779 E:8784 ||| VBD
no  ||| S:8784 E:8795 ||| DT
differences  ||| S:8795 E:8807 ||| NNS
in  ||| S:8807 E:8810 ||| IN
cell  ||| S:8810 E:8815 ||| NN
death  ||| S:8815 E:8821 ||| NN
in  ||| S:8821 E:8824 ||| IN
these  ||| S:8824 E:8830 ||| DT
Hyal-1  ||| S:8830 E:8837 ||| NNP
and  ||| S:8837 E:8849 ||| CC
Hyal-2-expressing  ||| S:8849 E:8867 ||| CD
cells ||| S:8867 E:8872 ||| NNS
,  ||| S:8872 E:8874 ||| ,
compared  ||| S:8874 E:8883 ||| VBN
to  ||| S:8883 E:8886 ||| TO
control  ||| S:8886 E:8894 ||| VB
cells  ||| S:8894 E:8900 ||| NNS
( ||| S:8900 E:8901 ||| -LRB-
data  ||| S:8901 E:8914 ||| NNS
not  ||| S:8914 E:8918 ||| RB
shown ||| S:8918 E:8923 ||| VBN
) ||| S:8923 E:8924 ||| -RRB-
.  ||| S:8924 E:8926 ||| .
These  ||| S:8926 E:8932 ||| DT
findings  ||| S:8932 E:8941 ||| NNS
are  ||| S:8941 E:8945 ||| VBP
consistent  ||| S:8945 E:8956 ||| JJ
with  ||| S:8956 E:8961 ||| IN
the  ||| S:8961 E:8965 ||| DT
results  ||| S:8965 E:8981 ||| NNS
for  ||| S:8981 E:8985 ||| IN
stable  ||| S:8985 E:8992 ||| JJ
transfectants  ||| S:8992 E:9006 ||| NNS
presented  ||| S:9006 E:9016 ||| VBN
above  ||| S:9016 E:9022 ||| IN
( ||| S:9022 E:9023 ||| -LRB-
Fig.  ||| S:9023 E:9028 ||| CD
2 ||| S:9028 E:9029 ||| CD
) ||| S:9029 E:9030 ||| -RRB-
.  ||| S:9030 E:9040 ||| .
Bovine  ||| S:9040 E:9047 ||| FW
testicular  ||| S:9047 E:9058 ||| FW
PH-20  ||| S:9058 E:9064 ||| FW
enhances  ||| S:9064 E:9073 ||| FW
TNF  ||| S:9073 E:9077 ||| FW
sensitivity  ||| S:9077 E:9089 ||| FW
in  ||| S:9089 E:9092 ||| IN
L929  ||| S:9092 E:9105 ||| CD
cells  ||| S:9105 E:9111 ||| NNS
by  ||| S:9111 E:9114 ||| IN
increasing  ||| S:9114 E:9125 ||| VBG
the  ||| S:9125 E:9129 ||| DT
expression  ||| S:9129 E:9140 ||| NN
of  ||| S:9140 E:9143 ||| IN
proapoptotic  ||| S:9143 E:9156 ||| JJ
p53  ||| S:9156 E:9160 ||| NN
and  ||| S:9160 E:9172 ||| CC
WOX1  ||| S:9172 E:9177 ||| NNP
[  ||| S:9177 E:9179 ||| -LRB-
9  ||| S:9179 E:9181 ||| CD
10  ||| S:9181 E:9184 ||| CD
]  ||| S:9184 E:9186 ||| -RRB-
.  ||| S:9186 E:9188 ||| .
The  ||| S:9188 E:9192 ||| DT
ability  ||| S:9192 E:9200 ||| NN
of  ||| S:9200 E:9203 ||| IN
Hyal-1  ||| S:9203 E:9210 ||| NNP
and  ||| S:9210 E:9214 ||| CC
Hyal-2  ||| S:9214 E:9221 ||| CD
to  ||| S:9221 E:9224 ||| TO
induce  ||| S:9224 E:9239 ||| VB
the  ||| S:9239 E:9243 ||| DT
expression  ||| S:9243 E:9254 ||| NN
of  ||| S:9254 E:9257 ||| IN
p53  ||| S:9257 E:9261 ||| NN
and  ||| S:9261 E:9265 ||| CC
WOX1  ||| S:9265 E:9270 ||| CD
in  ||| S:9270 E:9273 ||| IN
L929  ||| S:9273 E:9278 ||| CD
cells  ||| S:9278 E:9284 ||| NNS
was  ||| S:9284 E:9288 ||| VBD
examined ||| S:9288 E:9296 ||| VBN
.  ||| S:9296 E:9306 ||| .
L929  ||| S:9306 E:9311 ||| NNP
cells  ||| S:9311 E:9317 ||| NNS
were  ||| S:9317 E:9322 ||| VBD
electroporated  ||| S:9322 E:9337 ||| VBN
with  ||| S:9337 E:9342 ||| IN
nothing  ||| S:9342 E:9350 ||| NN
( ||| S:9350 E:9351 ||| -LRB-
null ||| S:9351 E:9355 ||| LS
) ||| S:9355 E:9356 ||| -RRB-
,  ||| S:9356 E:9358 ||| ,
GFP ||| S:9358 E:9361 ||| NNP
,  ||| S:9361 E:9371 ||| ,
GFP-Hyal-1  ||| S:9371 E:9382 ||| NNP
or  ||| S:9382 E:9385 ||| CC
GFP-Hyal-2  ||| S:9385 E:9396 ||| CD
constructs  ||| S:9396 E:9407 ||| NNS
and  ||| S:9407 E:9411 ||| CC
cultured  ||| S:9411 E:9420 ||| NN
for  ||| S:9420 E:9424 ||| IN
48  ||| S:9424 E:9427 ||| CD
hr ||| S:9427 E:9429 ||| NNS
.  ||| S:9429 E:9439 ||| .
Transient  ||| S:9439 E:9449 ||| JJ
expression  ||| S:9449 E:9460 ||| NN
of  ||| S:9460 E:9463 ||| IN
GFP-Hyal-1  ||| S:9463 E:9474 ||| NNP
or  ||| S:9474 E:9477 ||| CC
GFP-Hyal-2  ||| S:9477 E:9488 ||| CD
in  ||| S:9488 E:9491 ||| IN
L929  ||| S:9491 E:9504 ||| CD
cells  ||| S:9504 E:9510 ||| NNS
induced  ||| S:9510 E:9518 ||| VBD
WOX1  ||| S:9518 E:9523 ||| CD
expression ||| S:9523 E:9533 ||| NN
,  ||| S:9533 E:9535 ||| ,
whereas  ||| S:9535 E:9543 ||| IN
no  ||| S:9543 E:9546 ||| DT
WOX1  ||| S:9546 E:9551 ||| JJ
expression  ||| S:9551 E:9570 ||| NN
was  ||| S:9570 E:9574 ||| VBD
observed  ||| S:9574 E:9583 ||| VBN
in  ||| S:9583 E:9586 ||| IN
non-transfected  ||| S:9586 E:9602 ||| JJ
cells  ||| S:9602 E:9608 ||| NNS
or  ||| S:9608 E:9611 ||| CC
control  ||| S:9611 E:9627 ||| VB
GFP-expressing  ||| S:9627 E:9642 ||| JJ
cells  ||| S:9642 E:9648 ||| NNS
( ||| S:9648 E:9649 ||| -LRB-
Fig.  ||| S:9649 E:9654 ||| NNP
3A ||| S:9654 E:9656 ||| NNP
) ||| S:9656 E:9657 ||| -RRB-
.  ||| S:9657 E:9659 ||| .
The  ||| S:9659 E:9663 ||| DT
46-kDa  ||| S:9663 E:9670 ||| JJ
band  ||| S:9670 E:9675 ||| NN
is  ||| S:9675 E:9686 ||| VBZ
full-length  ||| S:9686 E:9698 ||| JJ
WOX1 ||| S:9698 E:9702 ||| NN
,  ||| S:9702 E:9704 ||| ,
while  ||| S:9704 E:9710 ||| IN
the  ||| S:9710 E:9714 ||| DT
31-kDa  ||| S:9714 E:9721 ||| JJ
band  ||| S:9721 E:9726 ||| NN
is  ||| S:9726 E:9729 ||| VBZ
a  ||| S:9729 E:9731 ||| DT
degraded  ||| S:9731 E:9740 ||| JJ
WOX1  ||| S:9740 E:9753 ||| NNP
[  ||| S:9753 E:9755 ||| -LRB-
10  ||| S:9755 E:9758 ||| CD
]  ||| S:9758 E:9760 ||| -RRB-
.  ||| S:9760 E:9762 ||| .
No  ||| S:9762 E:9765 ||| DT
detectable  ||| S:9765 E:9776 ||| JJ
p53  ||| S:9776 E:9780 ||| NN
expression  ||| S:9780 E:9791 ||| NN
was  ||| S:9791 E:9795 ||| VBD
observed  ||| S:9795 E:9804 ||| VBN
in  ||| S:9804 E:9807 ||| IN
these  ||| S:9807 E:9821 ||| DT
cells  ||| S:9821 E:9827 ||| NNS
( ||| S:9827 E:9828 ||| -LRB-
Fig.  ||| S:9828 E:9833 ||| NNP
3A ||| S:9833 E:9835 ||| NNP
) ||| S:9835 E:9836 ||| -RRB-
.  ||| S:9836 E:9846 ||| .
In  ||| S:9846 E:9849 ||| IN
comparison ||| S:9849 E:9859 ||| NN
,  ||| S:9859 E:9861 ||| ,
the  ||| S:9861 E:9865 ||| DT
cytosolic  ||| S:9865 E:9875 ||| JJ
WOX1  ||| S:9875 E:9880 ||| NNP
( ||| S:9880 E:9881 ||| -LRB-
46  ||| S:9881 E:9884 ||| CD
kDa ||| S:9884 E:9887 ||| NN
)  ||| S:9887 E:9889 ||| -RRB-
was  ||| S:9889 E:9901 ||| VBD
constitutively  ||| S:9901 E:9916 ||| VBN
expressed  ||| S:9916 E:9926 ||| VBN
in  ||| S:9926 E:9929 ||| IN
the  ||| S:9929 E:9933 ||| DT
L929  ||| S:9933 E:9938 ||| CD
cells  ||| S:9938 E:9944 ||| NNS
stably  ||| S:9944 E:9959 ||| VBP
transfected  ||| S:9959 E:9971 ||| VBN
with  ||| S:9971 E:9976 ||| IN
the  ||| S:9976 E:9980 ||| DT
GFP-Hyal-2  ||| S:9980 E:9991 ||| JJ
construct ||| S:9991 E:10000 ||| NN
,  ||| S:10000 E:10002 ||| ,
while  ||| S:10002 E:10008 ||| IN
TNF  ||| S:10008 E:10020 ||| NNP
reduced  ||| S:10020 E:10028 ||| VBD
WOX1  ||| S:10028 E:10033 ||| CD
expression  ||| S:10033 E:10044 ||| NN
in  ||| S:10044 E:10047 ||| IN
a  ||| S:10047 E:10049 ||| DT
time-dependent  ||| S:10049 E:10064 ||| JJ
manner  ||| S:10064 E:10071 ||| NN
( ||| S:10071 E:10072 ||| -LRB-
Fig.  ||| S:10072 E:10085 ||| NNP
3B ||| S:10085 E:10087 ||| NNP
) ||| S:10087 E:10088 ||| -RRB-
.  ||| S:10088 E:10090 ||| .
This  ||| S:10090 E:10095 ||| DT
reduction  ||| S:10095 E:10105 ||| NN
is  ||| S:10105 E:10108 ||| VBZ
probably  ||| S:10108 E:10117 ||| RB
due  ||| S:10117 E:10121 ||| JJ
to  ||| S:10121 E:10124 ||| TO
TNF-mediated  ||| S:10124 E:10137 ||| JJ
WOX1  ||| S:10137 E:10150 ||| CD
nuclear  ||| S:10150 E:10158 ||| JJ
translocation  ||| S:10158 E:10172 ||| NN
from  ||| S:10172 E:10177 ||| IN
the  ||| S:10177 E:10181 ||| DT
mitochondria  ||| S:10181 E:10194 ||| NN
[  ||| S:10194 E:10196 ||| -LRB-
10  ||| S:10196 E:10199 ||| CD
]  ||| S:10199 E:10201 ||| -RRB-
.  ||| S:10201 E:10203 ||| .
In  ||| S:10203 E:10214 ||| IN
contrast ||| S:10214 E:10222 ||| NN
,  ||| S:10222 E:10224 ||| ,
WOX1  ||| S:10224 E:10229 ||| NNP
was  ||| S:10229 E:10233 ||| VBD
not  ||| S:10233 E:10237 ||| RB
expressed  ||| S:10237 E:10247 ||| VBN
in  ||| S:10247 E:10250 ||| IN
L929  ||| S:10250 E:10255 ||| CD
cells  ||| S:10255 E:10261 ||| NNS
stably  ||| S:10261 E:10276 ||| VBP
transfected  ||| S:10276 E:10288 ||| VBN
with  ||| S:10288 E:10293 ||| IN
the  ||| S:10293 E:10297 ||| DT
GFP-Hyal-1  ||| S:10297 E:10308 ||| JJ
construct ||| S:10308 E:10317 ||| NN
,  ||| S:10317 E:10319 ||| ,
and  ||| S:10319 E:10323 ||| CC
TNF  ||| S:10323 E:10327 ||| NNP
induced  ||| S:10327 E:10343 ||| VBD
WOX1  ||| S:10343 E:10348 ||| CD
expression  ||| S:10348 E:10359 ||| NN
in  ||| S:10359 E:10362 ||| IN
40  ||| S:10362 E:10365 ||| CD
min  ||| S:10365 E:10369 ||| NNS
( ||| S:10369 E:10370 ||| -LRB-
Fig.  ||| S:10370 E:10375 ||| NNP
3B ||| S:10375 E:10377 ||| NNP
) ||| S:10377 E:10378 ||| -RRB-
.  ||| S:10378 E:10380 ||| .
TNF  ||| S:10380 E:10384 ||| NNP
did  ||| S:10384 E:10388 ||| VBD
not  ||| S:10388 E:10392 ||| RB
induce  ||| S:10392 E:10407 ||| VB
WOX1  ||| S:10407 E:10412 ||| CD
expression  ||| S:10412 E:10423 ||| NN
in  ||| S:10423 E:10426 ||| IN
the  ||| S:10426 E:10430 ||| DT
control  ||| S:10430 E:10438 ||| NN
GFP-expressing  ||| S:10438 E:10453 ||| JJ
cells  ||| S:10453 E:10459 ||| NNS
( ||| S:10459 E:10460 ||| -LRB-
Fig.  ||| S:10460 E:10473 ||| NNP
3B ||| S:10473 E:10475 ||| NNP
) ||| S:10475 E:10476 ||| -RRB-
.  ||| S:10476 E:10486 ||| .
Whether  ||| S:10486 E:10494 ||| IN
Hyal-2  ||| S:10494 E:10501 ||| NNP
enhances  ||| S:10501 E:10510 ||| VBZ
the  ||| S:10510 E:10514 ||| DT
apoptosis-inducing  ||| S:10514 E:10533 ||| JJ
function  ||| S:10533 E:10550 ||| NN
of  ||| S:10550 E:10553 ||| IN
WOX1  ||| S:10553 E:10558 ||| NNP
was  ||| S:10558 E:10562 ||| VBD
determined ||| S:10562 E:10572 ||| VBN
.  ||| S:10572 E:10574 ||| .
In  ||| S:10574 E:10577 ||| IN
transient  ||| S:10577 E:10587 ||| JJ
transfection  ||| S:10587 E:10608 ||| JJ
experiments ||| S:10608 E:10619 ||| NNS
,  ||| S:10619 E:10621 ||| ,
L929  ||| S:10621 E:10626 ||| CD
cells  ||| S:10626 E:10632 ||| NNS
were  ||| S:10632 E:10637 ||| VBD
electroporated  ||| S:10637 E:10652 ||| VBN
with  ||| S:10652 E:10657 ||| IN
GFP-Hyal-2  ||| S:10657 E:10676 ||| NNP
and ||| S:10676 E:10679 ||| CC
/ ||| S:10679 E:10680 ||| NNP
or  ||| S:10680 E:10683 ||| CC
WOX1  ||| S:10683 E:10688 ||| CD
constructs ||| S:10688 E:10698 ||| NNS
.  ||| S:10698 E:10700 ||| .
GFP-Hyal-2  ||| S:10700 E:10711 ||| NNP
enhanced  ||| S:10711 E:10720 ||| VBD
WOX1-mediated  ||| S:10720 E:10742 ||| CD
L929  ||| S:10742 E:10747 ||| CD
cell  ||| S:10747 E:10752 ||| NN
death ||| S:10752 E:10757 ||| NN
,  ||| S:10757 E:10759 ||| ,
as  ||| S:10759 E:10762 ||| RB
determined  ||| S:10762 E:10773 ||| VBN
48  ||| S:10773 E:10776 ||| CD
hr  ||| S:10776 E:10779 ||| FW
post-transfection  ||| S:10779 E:10805 ||| FW
using  ||| S:10805 E:10811 ||| FW
crystal  ||| S:10811 E:10819 ||| FW
violet  ||| S:10819 E:10826 ||| FW
staining  ||| S:10826 E:10835 ||| FW
( ||| S:10835 E:10836 ||| -LRB-
Fig.  ||| S:10836 E:10841 ||| NNP
3C ||| S:10841 E:10843 ||| NNP
) ||| S:10843 E:10844 ||| -RRB-
.  ||| S:10844 E:10846 ||| .
In  ||| S:10846 E:10849 ||| IN
contrast ||| S:10849 E:10857 ||| NN
,  ||| S:10857 E:10867 ||| ,
GFP-Hyal-1  ||| S:10867 E:10878 ||| NNP
did  ||| S:10878 E:10882 ||| VBD
not  ||| S:10882 E:10886 ||| RB
enhance  ||| S:10886 E:10894 ||| VB
WOX1-mediated  ||| S:10894 E:10908 ||| CD
cell  ||| S:10908 E:10913 ||| NN
death  ||| S:10913 E:10919 ||| NN
( ||| S:10919 E:10920 ||| -LRB-
Fig.  ||| S:10920 E:10933 ||| NNP
3C ||| S:10933 E:10935 ||| NNP
) ||| S:10935 E:10936 ||| -RRB-
.  ||| S:10936 E:10938 ||| .
GFP-Hyal-1  ||| S:10938 E:10949 ||| NNP
and  ||| S:10949 E:10953 ||| CC
GFP-Hyal-2  ||| S:10953 E:10964 ||| NNP
alone  ||| S:10964 E:10970 ||| RB
did  ||| S:10970 E:10974 ||| VBD
not  ||| S:10974 E:10978 ||| RB
mediate  ||| S:10978 E:10986 ||| JJ
cell  ||| S:10986 E:10999 ||| NN
death  ||| S:10999 E:11005 ||| NN
( ||| S:11005 E:11006 ||| -LRB-
Fig.  ||| S:11006 E:11011 ||| NNP
3C ||| S:11011 E:11013 ||| NNP
) ||| S:11013 E:11014 ||| -RRB-
.  ||| S:11014 E:11024 ||| .
Next ||| S:11024 E:11028 ||| JJ
,  ||| S:11028 E:11030 ||| ,
the  ||| S:11030 E:11034 ||| DT
effect  ||| S:11034 E:11041 ||| NN
of  ||| S:11041 E:11044 ||| IN
TNF-mediated  ||| S:11044 E:11057 ||| JJ
IκBα  ||| S:11057 E:11062 ||| JJ
degradation  ||| S:11062 E:11074 ||| NN
and  ||| S:11074 E:11086 ||| CC
NF-κB  ||| S:11086 E:11092 ||| JJ
activation  ||| S:11092 E:11103 ||| NN
was  ||| S:11103 E:11107 ||| VBD
examined  ||| S:11107 E:11116 ||| VBN
in  ||| S:11116 E:11119 ||| IN
both  ||| S:11119 E:11124 ||| DT
Hyal-1  ||| S:11124 E:11131 ||| NNP
and  ||| S:11131 E:11135 ||| CC
Hyal-2  ||| S:11135 E:11150 ||| CD
cells ||| S:11150 E:11155 ||| NNS
.  ||| S:11155 E:11157 ||| .
The  ||| S:11157 E:11161 ||| DT
GFP-Hyal-1  ||| S:11161 E:11172 ||| NNP
and  ||| S:11172 E:11176 ||| CC
GFP-Hyal-2  ||| S:11176 E:11187 ||| CD
stable  ||| S:11187 E:11194 ||| JJ
transfectants  ||| S:11194 E:11216 ||| NN
and  ||| S:11216 E:11220 ||| CC
control  ||| S:11220 E:11228 ||| NN
cells  ||| S:11228 E:11234 ||| NNS
were  ||| S:11234 E:11239 ||| VBD
exposed  ||| S:11239 E:11247 ||| VBN
to  ||| S:11247 E:11250 ||| TO
TNF  ||| S:11250 E:11254 ||| NNP
for  ||| S:11254 E:11258 ||| IN
various  ||| S:11258 E:11266 ||| JJ
times ||| S:11266 E:11271 ||| NNS
.  ||| S:11271 E:11281 ||| .
IκBα  ||| S:11281 E:11286 ||| JJ
degradation  ||| S:11286 E:11298 ||| NN
and  ||| S:11298 E:11302 ||| CC
NF-κB  ||| S:11302 E:11308 ||| JJ
activation  ||| S:11308 E:11319 ||| NNS
( ||| S:11319 E:11320 ||| -LRB-
or  ||| S:11320 E:11323 ||| CC
NF-κB  ||| S:11323 E:11329 ||| JJ
nuclear  ||| S:11329 E:11345 ||| JJ
translocation ||| S:11345 E:11358 ||| NN
)  ||| S:11358 E:11360 ||| -RRB-
were  ||| S:11360 E:11365 ||| VBD
observed  ||| S:11365 E:11374 ||| VBN
at  ||| S:11374 E:11377 ||| IN
20  ||| S:11377 E:11380 ||| CD
to  ||| S:11380 E:11383 ||| TO
60  ||| S:11383 E:11386 ||| CD
min  ||| S:11386 E:11390 ||| NN
in  ||| S:11390 E:11393 ||| IN
Hyal-2  ||| S:11393 E:11408 ||| CD
cells  ||| S:11408 E:11414 ||| NNS
post  ||| S:11414 E:11419 ||| IN
TNF  ||| S:11419 E:11423 ||| NNP
stimulation ||| S:11423 E:11434 ||| NN
,  ||| S:11434 E:11436 ||| ,
but  ||| S:11436 E:11440 ||| CC
at  ||| S:11440 E:11443 ||| IN
the  ||| S:11443 E:11447 ||| DT
20  ||| S:11447 E:11450 ||| CD
min  ||| S:11450 E:11454 ||| JJ
time  ||| S:11454 E:11459 ||| NN
point  ||| S:11459 E:11465 ||| NN
in  ||| S:11465 E:11476 ||| IN
both  ||| S:11476 E:11481 ||| DT
control  ||| S:11481 E:11489 ||| NN
and  ||| S:11489 E:11493 ||| CC
Hyal-1  ||| S:11493 E:11500 ||| CD
cells  ||| S:11500 E:11506 ||| NNS
( ||| S:11506 E:11507 ||| -LRB-
Fig.  ||| S:11507 E:11512 ||| CD
4 ||| S:11512 E:11513 ||| CD
) ||| S:11513 E:11514 ||| -RRB-
.  ||| S:11514 E:11524 ||| .
To  ||| S:11524 E:11527 ||| TO
further  ||| S:11527 E:11535 ||| RB
understand  ||| S:11535 E:11546 ||| VB
how  ||| S:11546 E:11550 ||| WRB
Hyal-2  ||| S:11550 E:11557 ||| NNP
participates  ||| S:11557 E:11570 ||| VBZ
in  ||| S:11570 E:11573 ||| IN
the  ||| S:11573 E:11585 ||| DT
apoptosis  ||| S:11585 E:11595 ||| JJ
pathway ||| S:11595 E:11602 ||| NN
,  ||| S:11602 E:11604 ||| ,
the  ||| S:11604 E:11608 ||| DT
translocation  ||| S:11608 E:11622 ||| NN
of  ||| S:11622 E:11625 ||| IN
Hyal-2  ||| S:11625 E:11632 ||| CD
to  ||| S:11632 E:11635 ||| TO
the  ||| S:11635 E:11647 ||| DT
mitochondria  ||| S:11647 E:11660 ||| NN
was  ||| S:11660 E:11664 ||| VBD
examined  ||| S:11664 E:11673 ||| VBN
during  ||| S:11673 E:11680 ||| IN
cell  ||| S:11680 E:11685 ||| NN
death ||| S:11685 E:11690 ||| NN
.  ||| S:11690 E:11692 ||| .
Transient  ||| S:11692 E:11710 ||| JJ
expression  ||| S:11710 E:11721 ||| NN
of  ||| S:11721 E:11724 ||| IN
GFP-Hyal-2  ||| S:11724 E:11735 ||| CD
in  ||| S:11735 E:11738 ||| IN
COS7  ||| S:11738 E:11743 ||| CD
fibroblasts  ||| S:11743 E:11755 ||| NNS
showed  ||| S:11755 E:11762 ||| VBD
the  ||| S:11762 E:11774 ||| DT
localization  ||| S:11774 E:11787 ||| NN
of  ||| S:11787 E:11790 ||| IN
the  ||| S:11790 E:11794 ||| DT
expressed  ||| S:11794 E:11804 ||| JJ
protein  ||| S:11804 E:11812 ||| NN
in  ||| S:11812 E:11815 ||| IN
the  ||| S:11815 E:11819 ||| DT
lysosome  ||| S:11819 E:11828 ||| NN
but  ||| S:11828 E:11840 ||| CC
not  ||| S:11840 E:11844 ||| RB
in  ||| S:11844 E:11847 ||| IN
the  ||| S:11847 E:11851 ||| DT
mitochondria ||| S:11851 E:11863 ||| NN
,  ||| S:11863 E:11865 ||| ,
as  ||| S:11865 E:11868 ||| RB
determined  ||| S:11868 E:11879 ||| VBN
by  ||| S:11879 E:11882 ||| IN
staining  ||| S:11882 E:11891 ||| VBG
the  ||| S:11891 E:11903 ||| DT
cells  ||| S:11903 E:11909 ||| NNS
using  ||| S:11909 E:11915 ||| VBG
LysoTracker  ||| S:11915 E:11927 ||| JJ
and  ||| S:11927 E:11931 ||| CC
Mitotracker  ||| S:11931 E:11943 ||| NNP
Red  ||| S:11943 E:11947 ||| NNP
( ||| S:11947 E:11948 ||| -LRB-
data  ||| S:11948 E:11953 ||| NNS
not  ||| S:11953 E:11965 ||| RB
shown ||| S:11965 E:11970 ||| VBN
) ||| S:11970 E:11971 ||| -RRB-
.  ||| S:11971 E:11973 ||| .
These  ||| S:11973 E:11979 ||| DT
observations  ||| S:11979 E:11992 ||| NNS
are  ||| S:11992 E:11996 ||| VBP
consistent  ||| S:11996 E:12007 ||| JJ
with  ||| S:12007 E:12012 ||| IN
other  ||| S:12012 E:12026 ||| JJ
reports  ||| S:12026 E:12034 ||| NNS
[  ||| S:12034 E:12036 ||| -LRB-
5  ||| S:12036 E:12038 ||| CD
20  ||| S:12038 E:12041 ||| CD
]  ||| S:12041 E:12043 ||| -RRB-
.  ||| S:12043 E:12045 ||| .
COS7  ||| S:12045 E:12050 ||| NNP
cells  ||| S:12050 E:12056 ||| NNS
are  ||| S:12056 E:12060 ||| VBP
TNF-resistant ||| S:12060 E:12073 ||| JJ
.  ||| S:12073 E:12075 ||| .
The  ||| S:12075 E:12087 ||| DT
reasons  ||| S:12087 E:12095 ||| NNS
for  ||| S:12095 E:12099 ||| IN
using  ||| S:12099 E:12105 ||| VBG
this  ||| S:12105 E:12110 ||| DT
cell  ||| S:12110 E:12115 ||| NN
type  ||| S:12115 E:12120 ||| NN
are  ||| S:12120 E:12124 ||| VBP
its  ||| S:12124 E:12128 ||| PRP$
large  ||| S:12128 E:12134 ||| JJ
size  ||| S:12134 E:12139 ||| NN
( ||| S:12139 E:12140 ||| -LRB-
which  ||| S:12140 E:12154 ||| WDT
provides  ||| S:12154 E:12163 ||| VBZ
better  ||| S:12163 E:12170 ||| JJR
resolution  ||| S:12170 E:12181 ||| NN
under  ||| S:12181 E:12187 ||| IN
fluorescence  ||| S:12187 E:12200 ||| JJ
microscopy ||| S:12200 E:12210 ||| NN
)  ||| S:12210 E:12220 ||| -RRB-
and  ||| S:12220 E:12224 ||| CC
the  ||| S:12224 E:12228 ||| DT
ease  ||| S:12228 E:12233 ||| NN
of  ||| S:12233 E:12236 ||| IN
transfection  ||| S:12236 E:12249 ||| NN
and  ||| S:12249 E:12253 ||| CC
gene  ||| S:12253 E:12258 ||| NN
expression  ||| S:12258 E:12269 ||| NN
using  ||| S:12269 E:12283 ||| VBG
liposome-based  ||| S:12283 E:12298 ||| JJ
reagents  ||| S:12298 E:12307 ||| JJ
such  ||| S:12307 E:12312 ||| JJ
as  ||| S:12312 E:12315 ||| IN
FuGene  ||| S:12315 E:12322 ||| JJ
6  ||| S:12322 E:12324 ||| CD
and  ||| S:12324 E:12328 ||| CC
GeneFector ||| S:12328 E:12338 ||| JJ
.  ||| S:12338 E:12348 ||| .
Exposure  ||| S:12348 E:12357 ||| NN
of  ||| S:12357 E:12360 ||| IN
the  ||| S:12360 E:12364 ||| DT
GFP-Hyal-2-expressing  ||| S:12364 E:12386 ||| CD
COS7  ||| S:12386 E:12391 ||| CD
cells  ||| S:12391 E:12397 ||| NNS
to  ||| S:12397 E:12408 ||| TO
staurosporine  ||| S:12408 E:12422 ||| VB
( ||| S:12422 E:12423 ||| -LRB-
for  ||| S:12423 E:12427 ||| IN
inducing  ||| S:12427 E:12436 ||| JJ
apoptosis ||| S:12436 E:12445 ||| NN
)  ||| S:12445 E:12447 ||| -RRB-
resulted  ||| S:12447 E:12456 ||| VBD
in  ||| S:12456 E:12459 ||| IN
a  ||| S:12459 E:12469 ||| DT
time-related  ||| S:12469 E:12482 ||| JJ
increase  ||| S:12482 E:12491 ||| NN
in  ||| S:12491 E:12494 ||| IN
co-localization  ||| S:12494 E:12510 ||| JJ
of  ||| S:12510 E:12513 ||| IN
GFP-Hyal-2  ||| S:12513 E:12524 ||| CD
with  ||| S:12524 E:12537 ||| IN
the  ||| S:12537 E:12541 ||| DT
mitochondria  ||| S:12541 E:12554 ||| NN
( ||| S:12554 E:12555 ||| -LRB-
Fig.  ||| S:12555 E:12560 ||| CD
5 ||| S:12560 E:12561 ||| CD
) ||| S:12561 E:12562 ||| -RRB-
,  ||| S:12562 E:12564 ||| ,
suggesting  ||| S:12564 E:12575 ||| VBG
that  ||| S:12575 E:12580 ||| IN
a  ||| S:12580 E:12582 ||| DT
portion  ||| S:12582 E:12590 ||| NN
of  ||| S:12590 E:12601 ||| IN
GFP-Hyal-2  ||| S:12601 E:12612 ||| CD
migrates  ||| S:12612 E:12621 ||| NN
to  ||| S:12621 E:12624 ||| TO
the  ||| S:12624 E:12628 ||| DT
mitochondria  ||| S:12628 E:12641 ||| NN
during  ||| S:12641 E:12656 ||| IN
apoptosis ||| S:12656 E:12665 ||| NN
.  ||| S:12665 E:12675 ||| .
Next ||| S:12675 E:12679 ||| JJ
,  ||| S:12679 E:12681 ||| ,
whether  ||| S:12681 E:12689 ||| IN
TGF-β1  ||| S:12689 E:12696 ||| NNP
antagonizes  ||| S:12696 E:12708 ||| VBD
the  ||| S:12708 E:12712 ||| DT
function  ||| S:12712 E:12721 ||| NN
of  ||| S:12721 E:12724 ||| IN
Hyal-1  ||| S:12724 E:12739 ||| NNP
and  ||| S:12739 E:12743 ||| CC
Hyal-2  ||| S:12743 E:12750 ||| CD
in  ||| S:12750 E:12753 ||| IN
growth  ||| S:12753 E:12760 ||| NN
regulation  ||| S:12760 E:12771 ||| NN
was  ||| S:12771 E:12775 ||| VBD
examined ||| S:12775 E:12783 ||| VBN
.  ||| S:12783 E:12785 ||| .
TGF-β1  ||| S:12785 E:12800 ||| NNP
inhibits  ||| S:12800 E:12809 ||| VBD
epithelial  ||| S:12809 E:12820 ||| JJ
cell  ||| S:12820 E:12825 ||| NN
growth  ||| S:12825 E:12832 ||| NN
but  ||| S:12832 E:12836 ||| CC
promotes  ||| S:12836 E:12845 ||| VBZ
fibroblast  ||| S:12845 E:12864 ||| JJ
growth  ||| S:12864 E:12871 ||| NN
[  ||| S:12871 E:12873 ||| -LRB-
15  ||| S:12873 E:12876 ||| CD
]  ||| S:12876 E:12878 ||| -RRB-
.  ||| S:12878 E:12880 ||| .
TGF-β1  ||| S:12880 E:12887 ||| NNP
inhibition  ||| S:12887 E:12898 ||| NN
of  ||| S:12898 E:12901 ||| IN
epithelial  ||| S:12901 E:12912 ||| JJ
cell  ||| S:12912 E:12917 ||| NN
growth  ||| S:12917 E:12932 ||| NN
is  ||| S:12932 E:12935 ||| VBZ
blocked  ||| S:12935 E:12943 ||| VBN
by  ||| S:12943 E:12946 ||| IN
bovine  ||| S:12946 E:12953 ||| FW
testicular  ||| S:12953 E:12964 ||| FW
PH-20  ||| S:12964 E:12970 ||| FW
[  ||| S:12970 E:12972 ||| -LRB-
15  ||| S:12972 E:12975 ||| CD
]  ||| S:12975 E:12977 ||| -RRB-
.  ||| S:12977 E:12979 ||| .
In  ||| S:12979 E:12982 ||| IN
agreement  ||| S:12982 E:13000 ||| NN
with  ||| S:13000 E:13005 ||| IN
our  ||| S:13005 E:13009 ||| PRP$
previous  ||| S:13009 E:13018 ||| JJ
observations  ||| S:13018 E:13031 ||| NNS
[  ||| S:13031 E:13033 ||| -LRB-
11  ||| S:13033 E:13036 ||| CD
]  ||| S:13036 E:13038 ||| -RRB-
,  ||| S:13038 E:13040 ||| ,
TGF-β1  ||| S:13040 E:13047 ||| NNP
promoted  ||| S:13047 E:13064 ||| VBD
L929  ||| S:13064 E:13069 ||| CD
cell  ||| S:13069 E:13074 ||| NN
growth  ||| S:13074 E:13081 ||| NN
by  ||| S:13081 E:13084 ||| IN
approximately  ||| S:13084 E:13098 ||| RB
20 ||| S:13098 E:13100 ||| CD
%  ||| S:13100 E:13102 ||| NN
in  ||| S:13102 E:13105 ||| IN
24-48  ||| S:13105 E:13111 ||| CD
hr  ||| S:13111 E:13114 ||| NNS
( ||| S:13114 E:13115 ||| -LRB-
Fig.  ||| S:13115 E:13120 ||| CD
6 ||| S:13120 E:13121 ||| CD
) ||| S:13121 E:13122 ||| -RRB-
.  ||| S:13122 E:13132 ||| .
However ||| S:13132 E:13139 ||| RB
,  ||| S:13139 E:13141 ||| ,
TGF-β1  ||| S:13141 E:13148 ||| NNP
did  ||| S:13148 E:13152 ||| VBD
not  ||| S:13152 E:13156 ||| RB
promote  ||| S:13156 E:13164 ||| VB
the  ||| S:13164 E:13168 ||| DT
growth  ||| S:13168 E:13175 ||| NN
of  ||| S:13175 E:13178 ||| IN
L929  ||| S:13178 E:13183 ||| CD
cells  ||| S:13183 E:13197 ||| NNS
stably  ||| S:13197 E:13204 ||| VBP
expressing  ||| S:13204 E:13215 ||| VBG
Hyal-1  ||| S:13215 E:13222 ||| NNP
or  ||| S:13222 E:13225 ||| CC
Hyal-2  ||| S:13225 E:13232 ||| NNP
( ||| S:13232 E:13233 ||| -LRB-
Fig.  ||| S:13233 E:13238 ||| CD
6 ||| S:13238 E:13239 ||| CD
) ||| S:13239 E:13240 ||| -RRB-
.  ||| S:13240 E:13250 ||| .
Finally ||| S:13250 E:13257 ||| RB
,  ||| S:13257 E:13259 ||| ,
the  ||| S:13259 E:13263 ||| DT
functional  ||| S:13263 E:13274 ||| JJ
antagonism  ||| S:13274 E:13285 ||| NN
between  ||| S:13285 E:13293 ||| IN
TGF-β1  ||| S:13293 E:13300 ||| NNP
and  ||| S:13300 E:13312 ||| CC
Hyal-1  ||| S:13312 E:13319 ||| NNP
or  ||| S:13319 E:13322 ||| CC
Hyal-2  ||| S:13322 E:13329 ||| CD
in  ||| S:13329 E:13332 ||| IN
regulating  ||| S:13332 E:13343 ||| VBG
TNF  ||| S:13343 E:13347 ||| NNP
susceptibility  ||| S:13347 E:13362 ||| NN
in  ||| S:13362 E:13365 ||| IN
L929  ||| S:13365 E:13378 ||| CD
cells  ||| S:13378 E:13384 ||| NNS
was  ||| S:13384 E:13388 ||| VBD
examined ||| S:13388 E:13396 ||| VBN
.  ||| S:13396 E:13398 ||| .
The  ||| S:13398 E:13402 ||| DT
Hyal-1  ||| S:13402 E:13409 ||| NNP
and  ||| S:13409 E:13413 ||| CC
Hyal-2  ||| S:13413 E:13420 ||| CD
stable  ||| S:13420 E:13435 ||| JJ
transfectants  ||| S:13435 E:13449 ||| NN
were  ||| S:13449 E:13454 ||| VBD
pretreated  ||| S:13454 E:13465 ||| VBN
with  ||| S:13465 E:13470 ||| IN
TGF-β1  ||| S:13470 E:13477 ||| CD
for  ||| S:13477 E:13481 ||| IN
1  ||| S:13481 E:13483 ||| CD
hr  ||| S:13483 E:13486 ||| NNS
and  ||| S:13486 E:13490 ||| CC
then  ||| S:13490 E:13503 ||| RB
treated  ||| S:13503 E:13511 ||| VBN
with  ||| S:13511 E:13516 ||| IN
TNF  ||| S:13516 E:13520 ||| NNP
overnight ||| S:13520 E:13529 ||| JJ
.  ||| S:13529 E:13531 ||| .
Both  ||| S:13531 E:13536 ||| DT
Hyal-1-  ||| S:13536 E:13544 ||| NNP
and  ||| S:13544 E:13556 ||| CC
Hyal-2-increased  ||| S:13556 E:13573 ||| NNP
TNF  ||| S:13573 E:13577 ||| NNP
cytotoxicity  ||| S:13577 E:13590 ||| NN
were  ||| S:13590 E:13595 ||| VBD
suppressed  ||| S:13595 E:13606 ||| VBN
by  ||| S:13606 E:13609 ||| IN
TGF-β1  ||| S:13609 E:13624 ||| NNP
( ||| S:13624 E:13625 ||| -LRB-
30-50 ||| S:13625 E:13630 ||| NNP
% ||| S:13630 E:13631 ||| NN
)  ||| S:13631 E:13633 ||| -RRB-
( ||| S:13633 E:13634 ||| -LRB-
Fig.  ||| S:13634 E:13639 ||| CD
7 ||| S:13639 E:13640 ||| CD
) ||| S:13640 E:13641 ||| -RRB-
.  ||| S:13641 E:13643 ||| .
However ||| S:13643 E:13650 ||| RB
,  ||| S:13650 E:13652 ||| ,
TGF-β1  ||| S:13652 E:13659 ||| NNP
blocked  ||| S:13659 E:13667 ||| VBD
TNF  ||| S:13667 E:13671 ||| NNP
cytotoxicity  ||| S:13671 E:13692 ||| NN
of  ||| S:13692 E:13695 ||| IN
the  ||| S:13695 E:13699 ||| DT
GFP-expressing  ||| S:13699 E:13714 ||| JJ
control  ||| S:13714 E:13722 ||| NN
cells  ||| S:13722 E:13728 ||| NNS
to  ||| S:13728 E:13731 ||| TO
a  ||| S:13731 E:13733 ||| DT
greater  ||| S:13733 E:13741 ||| JJR
extent  ||| S:13741 E:13756 ||| NN
( ||| S:13756 E:13757 ||| -LRB-
50-70 ||| S:13757 E:13762 ||| NNP
% ||| S:13762 E:13763 ||| NN
)  ||| S:13763 E:13765 ||| -RRB-
( ||| S:13765 E:13766 ||| -LRB-
Fig.  ||| S:13766 E:13771 ||| CD
7 ||| S:13771 E:13772 ||| CD
) ||| S:13772 E:13773 ||| -RRB-
.  ||| S:13773 E:13797 ||| .
Discussion  ||| S:13797 E:13816 ||| NN
In  ||| S:13816 E:13819 ||| IN
this  ||| S:13819 E:13824 ||| DT
study ||| S:13824 E:13829 ||| NN
,  ||| S:13829 E:13831 ||| ,
the  ||| S:13831 E:13835 ||| DT
novel  ||| S:13835 E:13841 ||| NN
function  ||| S:13841 E:13850 ||| NN
of  ||| S:13850 E:13853 ||| IN
the  ||| S:13853 E:13857 ||| DT
lysosomal  ||| S:13857 E:13875 ||| JJ
hyaluronidases  ||| S:13875 E:13890 ||| JJ
Hyal-1  ||| S:13890 E:13897 ||| NN
and  ||| S:13897 E:13901 ||| CC
Hyal-2  ||| S:13901 E:13908 ||| CD
in  ||| S:13908 E:13911 ||| IN
increasing  ||| S:13911 E:13922 ||| VBG
cellular  ||| S:13922 E:13939 ||| JJ
sensitivity  ||| S:13939 E:13951 ||| NN
to  ||| S:13951 E:13954 ||| TO
TNF  ||| S:13954 E:13958 ||| NNP
cytotoxicity  ||| S:13958 E:13971 ||| NN
is  ||| S:13971 E:13974 ||| VBZ
reported ||| S:13974 E:13982 ||| VBN
.  ||| S:13982 E:13984 ||| .
TGF-β1  ||| S:13984 E:13999 ||| CD
counteracted  ||| S:13999 E:14012 ||| CD
Hyal-1-  ||| S:14012 E:14020 ||| CD
and  ||| S:14020 E:14024 ||| CC
Hyal-2-increased  ||| S:14024 E:14041 ||| NNP
TNF  ||| S:14041 E:14045 ||| NNP
killing  ||| S:14045 E:14053 ||| NN
of  ||| S:14053 E:14064 ||| IN
L929  ||| S:14064 E:14069 ||| CD
fibroblasts ||| S:14069 E:14080 ||| NNS
.  ||| S:14080 E:14082 ||| .
TGF-β1  ||| S:14082 E:14089 ||| NNP
increased  ||| S:14089 E:14099 ||| VBD
L929  ||| S:14099 E:14104 ||| CD
growth ||| S:14104 E:14110 ||| NN
,  ||| S:14110 E:14112 ||| ,
while  ||| S:14112 E:14126 ||| IN
Hyal-1  ||| S:14126 E:14133 ||| NNP
and  ||| S:14133 E:14137 ||| CC
Hyal-2  ||| S:14137 E:14144 ||| NNP
blocked  ||| S:14144 E:14152 ||| VBD
this  ||| S:14152 E:14157 ||| DT
enhancement  ||| S:14157 E:14169 ||| NN
of  ||| S:14169 E:14172 ||| IN
cell  ||| S:14172 E:14177 ||| NN
growth ||| S:14177 E:14183 ||| NN
.  ||| S:14183 E:14193 ||| .
These  ||| S:14193 E:14199 ||| DT
observations  ||| S:14199 E:14212 ||| NNS
are  ||| S:14212 E:14216 ||| VBP
consistent  ||| S:14216 E:14227 ||| JJ
with  ||| S:14227 E:14232 ||| IN
our  ||| S:14232 E:14236 ||| PRP$
previous  ||| S:14236 E:14245 ||| JJ
finding  ||| S:14245 E:14261 ||| NN
that  ||| S:14261 E:14266 ||| IN
exogenous  ||| S:14266 E:14276 ||| FW
bovine  ||| S:14276 E:14283 ||| FW
testicular  ||| S:14283 E:14294 ||| FW
hyaluronidase  ||| S:14294 E:14308 ||| FW
PH-20  ||| S:14308 E:14322 ||| FW
enhances  ||| S:14322 E:14331 ||| FW
TNF  ||| S:14331 E:14335 ||| FW
cytotoxicity  ||| S:14335 E:14348 ||| FW
in  ||| S:14348 E:14351 ||| IN
various  ||| S:14351 E:14359 ||| JJ
cancer  ||| S:14359 E:14366 ||| NN
cells ||| S:14366 E:14371 ||| NNS
,  ||| S:14371 E:14373 ||| ,
and  ||| S:14373 E:14377 ||| CC
that  ||| S:14377 E:14390 ||| IN
TGF-β1  ||| S:14390 E:14397 ||| CD
blocks  ||| S:14397 E:14404 ||| NNS
the  ||| S:14404 E:14408 ||| DT
increased  ||| S:14408 E:14418 ||| JJ
TNF  ||| S:14418 E:14422 ||| NN
cytotoxicity  ||| S:14422 E:14435 ||| NNS
[  ||| S:14435 E:14437 ||| -LRB-
8  ||| S:14437 E:14439 ||| CD
15  ||| S:14439 E:14442 ||| CD
]  ||| S:14442 E:14444 ||| -RRB-
.  ||| S:14444 E:14446 ||| .
As  ||| S:14446 E:14457 ||| IN
summarized  ||| S:14457 E:14468 ||| NN
in  ||| S:14468 E:14471 ||| IN
the  ||| S:14471 E:14475 ||| DT
Figure  ||| S:14475 E:14482 ||| NN
8 ||| S:14482 E:14483 ||| CD
,  ||| S:14483 E:14485 ||| ,
the  ||| S:14485 E:14489 ||| DT
underlying  ||| S:14489 E:14500 ||| JJ
mechanisms  ||| S:14500 E:14519 ||| NNS
whereby  ||| S:14519 E:14527 ||| WRB
Hyal-2  ||| S:14527 E:14534 ||| NNP
induces  ||| S:14534 E:14542 ||| VBZ
TNF  ||| S:14542 E:14546 ||| NNP
cytotoxicity  ||| S:14546 E:14559 ||| NNS
appear  ||| S:14559 E:14566 ||| VBP
to  ||| S:14566 E:14569 ||| TO
be  ||| S:14569 E:14580 ||| VB
associated  ||| S:14580 E:14591 ||| VBN
with  ||| S:14591 E:14596 ||| IN
1 ||| S:14596 E:14597 ||| CD
)  ||| S:14597 E:14599 ||| -RRB-
Hyal-2  ||| S:14599 E:14606 ||| CD
induction  ||| S:14606 E:14616 ||| NN
of  ||| S:14616 E:14619 ||| IN
the  ||| S:14619 E:14623 ||| DT
proapoptotic  ||| S:14623 E:14644 ||| JJ
WOX1 ||| S:14644 E:14648 ||| NN
,  ||| S:14648 E:14650 ||| ,
2 ||| S:14650 E:14651 ||| LS
)  ||| S:14651 E:14653 ||| -RRB-
Hyal-2  ||| S:14653 E:14660 ||| CD
migration  ||| S:14660 E:14670 ||| NN
to  ||| S:14670 E:14673 ||| TO
the  ||| S:14673 E:14677 ||| DT
mitochondria  ||| S:14677 E:14690 ||| NN
during  ||| S:14690 E:14705 ||| IN
apoptosis ||| S:14705 E:14714 ||| NN
,  ||| S:14714 E:14716 ||| ,
and  ||| S:14716 E:14720 ||| CC
3 ||| S:14720 E:14721 ||| LS
)  ||| S:14721 E:14723 ||| -RRB-
the  ||| S:14723 E:14727 ||| DT
prolonged  ||| S:14727 E:14737 ||| JJ
period  ||| S:14737 E:14744 ||| NN
of  ||| S:14744 E:14747 ||| IN
IκBα  ||| S:14747 E:14752 ||| JJ
degradation  ||| S:14752 E:14772 ||| NN
and  ||| S:14772 E:14776 ||| CC
NF-κB  ||| S:14776 E:14782 ||| JJ
activation  ||| S:14782 E:14793 ||| NN
in  ||| S:14793 E:14796 ||| IN
TNF-treated  ||| S:14796 E:14808 ||| JJ
Hyal-2-expressing  ||| S:14808 E:14834 ||| CD
cells ||| S:14834 E:14839 ||| NNS
.  ||| S:14839 E:14849 ||| .
Upregulation  ||| S:14849 E:14862 ||| NNP
of  ||| S:14862 E:14865 ||| IN
p53  ||| S:14865 E:14869 ||| NN
and  ||| S:14869 E:14873 ||| CC
WOX1  ||| S:14873 E:14878 ||| CD
contributes ||| S:14878 E:14889 ||| NN
,  ||| S:14889 E:14891 ||| ,
in  ||| S:14891 E:14894 ||| IN
part ||| S:14894 E:14898 ||| NN
,  ||| S:14898 E:14900 ||| ,
to  ||| S:14900 E:14911 ||| TO
the  ||| S:14911 E:14915 ||| DT
PH-20-enhanced  ||| S:14915 E:14930 ||| JJ
cytotoxic  ||| S:14930 E:14940 ||| JJ
function  ||| S:14940 E:14949 ||| NN
of  ||| S:14949 E:14952 ||| IN
TNF  ||| S:14952 E:14956 ||| NNP
[  ||| S:14956 E:14958 ||| -LRB-
9  ||| S:14958 E:14960 ||| CD
10  ||| S:14960 E:14963 ||| CD
23  ||| S:14963 E:14966 ||| CD
]  ||| S:14966 E:14968 ||| -RRB-
.  ||| S:14968 E:14978 ||| .
WOX1  ||| S:14978 E:14983 ||| NNP
is  ||| S:14983 E:14986 ||| VBZ
a  ||| S:14986 E:14988 ||| DT
p53-binding  ||| S:14988 E:15000 ||| JJ
protein ||| S:15000 E:15007 ||| NN
.  ||| S:15007 E:15009 ||| .
Ectopic  ||| S:15009 E:15017 ||| JJ
expression  ||| S:15017 E:15028 ||| NN
of  ||| S:15028 E:15031 ||| IN
both  ||| S:15031 E:15044 ||| DT
p53  ||| S:15044 E:15048 ||| NN
and  ||| S:15048 E:15052 ||| CC
WOX1  ||| S:15052 E:15057 ||| CD
cDNA  ||| S:15057 E:15062 ||| JJ
constructs  ||| S:15062 E:15073 ||| JJ
results  ||| S:15073 E:15081 ||| NNS
in  ||| S:15081 E:15084 ||| IN
colocalization  ||| S:15084 E:15099 ||| NN
of  ||| S:15099 E:15110 ||| IN
these  ||| S:15110 E:15116 ||| DT
proteins  ||| S:15116 E:15125 ||| NNS
in  ||| S:15125 E:15128 ||| IN
the  ||| S:15128 E:15132 ||| DT
mitochondria  ||| S:15132 E:15145 ||| NN
[  ||| S:15145 E:15147 ||| -LRB-
23  ||| S:15147 E:15150 ||| CD
]  ||| S:15150 E:15152 ||| -RRB-
.  ||| S:15152 E:15154 ||| .
Increased  ||| S:15154 E:15172 ||| JJ
synthesis  ||| S:15172 E:15182 ||| NN
and  ||| S:15182 E:15186 ||| CC
complex  ||| S:15186 E:15194 ||| JJ
formation  ||| S:15194 E:15204 ||| NN
between  ||| S:15204 E:15212 ||| IN
p53  ||| S:15212 E:15216 ||| NN
and  ||| S:15216 E:15220 ||| CC
WOX1  ||| S:15220 E:15225 ||| CD
in  ||| S:15225 E:15228 ||| IN
the  ||| S:15228 E:15240 ||| DT
cytoplasm  ||| S:15240 E:15250 ||| NNS
are  ||| S:15250 E:15254 ||| VBP
observed  ||| S:15254 E:15263 ||| VBN
during  ||| S:15263 E:15270 ||| IN
apoptosis  ||| S:15270 E:15280 ||| NNS
[  ||| S:15280 E:15282 ||| -LRB-
23  ||| S:15282 E:15285 ||| CD
]  ||| S:15285 E:15287 ||| -RRB-
.  ||| S:15287 E:15289 ||| .
Both  ||| S:15289 E:15294 ||| DT
p53  ||| S:15294 E:15306 ||| NN
and  ||| S:15306 E:15310 ||| CC
WOX1  ||| S:15310 E:15315 ||| FW
mediate  ||| S:15315 E:15323 ||| FW
apoptosis  ||| S:15323 E:15333 ||| FW
synergistically ||| S:15333 E:15348 ||| FW
.  ||| S:15348 E:15350 ||| .
Overexpressed  ||| S:15350 E:15372 ||| NNP
WOX1  ||| S:15372 E:15377 ||| NNP
alone  ||| S:15377 E:15383 ||| RB
mediates  ||| S:15383 E:15392 ||| JJ
apoptosis  ||| S:15392 E:15402 ||| NNS
independently  ||| S:15402 E:15416 ||| RB
of  ||| S:15416 E:15419 ||| IN
p53  ||| S:15419 E:15423 ||| NN
[  ||| S:15423 E:15425 ||| -LRB-
10  ||| S:15425 E:15428 ||| CD
]  ||| S:15428 E:15430 ||| -RRB-
.  ||| S:15430 E:15440 ||| .
However ||| S:15440 E:15447 ||| RB
,  ||| S:15447 E:15449 ||| ,
p53  ||| S:15449 E:15453 ||| NN
apoptosis  ||| S:15453 E:15463 ||| NN
requires  ||| S:15463 E:15472 ||| VBZ
the  ||| S:15472 E:15476 ||| DT
participation  ||| S:15476 E:15490 ||| NN
of  ||| S:15490 E:15493 ||| IN
WOX1 ||| S:15493 E:15497 ||| CD
.  ||| S:15497 E:15507 ||| .
Blocking  ||| S:15507 E:15516 ||| VBG
WOX1  ||| S:15516 E:15521 ||| CD
expression  ||| S:15521 E:15532 ||| NN
with  ||| S:15532 E:15537 ||| IN
antisense  ||| S:15537 E:15547 ||| JJ
mRNA  ||| S:15547 E:15552 ||| JJ
abolishes  ||| S:15552 E:15570 ||| NN
p53-mediated  ||| S:15570 E:15583 ||| CD
cell  ||| S:15583 E:15588 ||| NN
death ||| S:15588 E:15593 ||| NN
,  ||| S:15593 E:15595 ||| ,
suggesting  ||| S:15595 E:15606 ||| VBG
that  ||| S:15606 E:15611 ||| IN
WOX1  ||| S:15611 E:15616 ||| NNP
is  ||| S:15616 E:15619 ||| VBZ
a  ||| S:15619 E:15629 ||| DT
potential  ||| S:15629 E:15639 ||| JJ
partner  ||| S:15639 E:15647 ||| NN
of  ||| S:15647 E:15650 ||| IN
p53  ||| S:15650 E:15654 ||| NN
in  ||| S:15654 E:15657 ||| IN
apoptosis  ||| S:15657 E:15667 ||| NNS
[  ||| S:15667 E:15669 ||| -LRB-
10  ||| S:15669 E:15672 ||| CD
23  ||| S:15672 E:15675 ||| CD
]  ||| S:15675 E:15677 ||| -RRB-
.  ||| S:15677 E:15687 ||| .
Both  ||| S:15687 E:15692 ||| DT
Hyal-1  ||| S:15692 E:15699 ||| NNP
and  ||| S:15699 E:15703 ||| CC
Hyal-2  ||| S:15703 E:15710 ||| CD
induced  ||| S:15710 E:15718 ||| CD
WOX1  ||| S:15718 E:15723 ||| CD
expression  ||| S:15723 E:15734 ||| NN
when  ||| S:15734 E:15747 ||| WRB
transiently  ||| S:15747 E:15759 ||| NNS
expressed  ||| S:15759 E:15769 ||| VBD
in  ||| S:15769 E:15772 ||| IN
L929  ||| S:15772 E:15777 ||| CD
cells ||| S:15777 E:15782 ||| NNS
.  ||| S:15782 E:15784 ||| .
However ||| S:15784 E:15791 ||| RB
,  ||| S:15791 E:15793 ||| ,
only  ||| S:15793 E:15798 ||| RB
Hyal-2  ||| S:15798 E:15813 ||| CD
induced  ||| S:15813 E:15821 ||| CD
WOX1  ||| S:15821 E:15826 ||| CD
expression  ||| S:15826 E:15837 ||| NN
following  ||| S:15837 E:15847 ||| VBG
stable  ||| S:15847 E:15854 ||| JJ
transfection  ||| S:15854 E:15867 ||| NN
of  ||| S:15867 E:15878 ||| IN
L929  ||| S:15878 E:15883 ||| CD
cells ||| S:15883 E:15888 ||| NNS
.  ||| S:15888 E:15890 ||| .
This  ||| S:15890 E:15895 ||| DT
correlates  ||| S:15895 E:15906 ||| NN
with  ||| S:15906 E:15911 ||| IN
the  ||| S:15911 E:15915 ||| DT
greater  ||| S:15915 E:15923 ||| JJR
extent  ||| S:15923 E:15930 ||| NN
of  ||| S:15930 E:15941 ||| IN
Hyal-2  ||| S:15941 E:15948 ||| CD
enhancement  ||| S:15948 E:15960 ||| NN
of  ||| S:15960 E:15963 ||| IN
TNF  ||| S:15963 E:15967 ||| NNP
killing  ||| S:15967 E:15975 ||| VBG
compared  ||| S:15975 E:15984 ||| VBN
to  ||| S:15984 E:15987 ||| TO
Hyal-1 ||| S:15987 E:15993 ||| CD
.  ||| S:15993 E:15995 ||| .
WOX1  ||| S:15995 E:16008 ||| NNP
expression  ||| S:16008 E:16019 ||| NN
was  ||| S:16019 E:16023 ||| VBD
induced  ||| S:16023 E:16031 ||| VBN
by  ||| S:16031 E:16034 ||| IN
TNF  ||| S:16034 E:16038 ||| NNP
in  ||| S:16038 E:16041 ||| IN
the  ||| S:16041 E:16045 ||| DT
Hyal-1  ||| S:16045 E:16052 ||| JJ
stable  ||| S:16052 E:16067 ||| JJ
transfectant ||| S:16067 E:16079 ||| NN
.  ||| S:16079 E:16081 ||| .
In  ||| S:16081 E:16084 ||| IN
transient  ||| S:16084 E:16094 ||| JJ
transfection  ||| S:16094 E:16107 ||| JJ
experiments ||| S:16107 E:16118 ||| NNS
,  ||| S:16118 E:16120 ||| ,
Hyal-2  ||| S:16120 E:16135 ||| NNP
enhanced  ||| S:16135 E:16144 ||| VBD
WOX1-mediated  ||| S:16144 E:16158 ||| CD
L929  ||| S:16158 E:16163 ||| CD
cell  ||| S:16163 E:16168 ||| NN
death ||| S:16168 E:16173 ||| NN
,  ||| S:16173 E:16175 ||| ,
while  ||| S:16175 E:16181 ||| IN
Hyal-1  ||| S:16181 E:16188 ||| NNP
had  ||| S:16188 E:16192 ||| VBD
no  ||| S:16192 E:16203 ||| DT
effect ||| S:16203 E:16209 ||| NN
.  ||| S:16209 E:16211 ||| .
Both  ||| S:16211 E:16216 ||| DT
Hyal-1  ||| S:16216 E:16223 ||| NNP
and  ||| S:16223 E:16227 ||| CC
Hyal-2  ||| S:16227 E:16234 ||| NNP
alone  ||| S:16234 E:16240 ||| RB
failed  ||| S:16240 E:16247 ||| VBN
to  ||| S:16247 E:16250 ||| TO
induce  ||| S:16250 E:16257 ||| VB
cell  ||| S:16257 E:16270 ||| NN
death ||| S:16270 E:16275 ||| NN
.  ||| S:16275 E:16277 ||| .
Thus ||| S:16277 E:16281 ||| RB
,  ||| S:16281 E:16283 ||| ,
induction  ||| S:16283 E:16293 ||| VBG
of  ||| S:16293 E:16296 ||| IN
WOX1  ||| S:16296 E:16301 ||| CD
expression  ||| S:16301 E:16312 ||| NN
contributes ||| S:16312 E:16323 ||| VBZ
,  ||| S:16323 E:16325 ||| ,
in  ||| S:16325 E:16336 ||| IN
part ||| S:16336 E:16340 ||| NN
,  ||| S:16340 E:16342 ||| ,
to  ||| S:16342 E:16345 ||| TO
Hyal-1-  ||| S:16345 E:16353 ||| CD
and  ||| S:16353 E:16357 ||| CC
Hyal-2-increased  ||| S:16357 E:16374 ||| NNP
TNF  ||| S:16374 E:16378 ||| NNP
sensitivity  ||| S:16378 E:16390 ||| NN
in  ||| S:16390 E:16401 ||| IN
L929  ||| S:16401 E:16406 ||| CD
cells ||| S:16406 E:16411 ||| NNS
.  ||| S:16411 E:16421 ||| .
TNF  ||| S:16421 E:16425 ||| NNP
rapidly  ||| S:16425 E:16433 ||| RB
induces  ||| S:16433 E:16441 ||| VBZ
phosphorylation  ||| S:16441 E:16457 ||| VBN
of  ||| S:16457 E:16460 ||| IN
IκBα ||| S:16460 E:16464 ||| NNP
,  ||| S:16464 E:16466 ||| ,
which  ||| S:16466 E:16480 ||| WDT
normally  ||| S:16480 E:16489 ||| RB
peaks  ||| S:16489 E:16495 ||| VBN
at  ||| S:16495 E:16498 ||| IN
5-10  ||| S:16498 E:16503 ||| JJ
min ||| S:16503 E:16506 ||| NN
,  ||| S:16506 E:16508 ||| ,
followed  ||| S:16508 E:16517 ||| VBN
by  ||| S:16517 E:16528 ||| IN
proteasome-dependent  ||| S:16528 E:16549 ||| JJ
degradation  ||| S:16549 E:16561 ||| NNS
( ||| S:16561 E:16562 ||| -LRB-
10-20  ||| S:16562 E:16568 ||| FW
min ||| S:16568 E:16571 ||| FW
)  ||| S:16571 E:16573 ||| -RRB-
[  ||| S:16573 E:16575 ||| -LRB-
10  ||| S:16575 E:16578 ||| CD
24  ||| S:16578 E:16581 ||| CD
]  ||| S:16581 E:16583 ||| -RRB-
.  ||| S:16583 E:16593 ||| .
IκBα  ||| S:16593 E:16598 ||| JJ
degradation  ||| S:16598 E:16610 ||| NN
and  ||| S:16610 E:16614 ||| CC
NF-κB  ||| S:16614 E:16620 ||| JJ
activation  ||| S:16620 E:16631 ||| NN
occurred ||| S:16631 E:16639 ||| VBD
,  ||| S:16639 E:16641 ||| ,
as  ||| S:16641 E:16652 ||| RB
determined  ||| S:16652 E:16663 ||| VBN
20  ||| S:16663 E:16666 ||| CD
min  ||| S:16666 E:16670 ||| NN
after  ||| S:16670 E:16676 ||| IN
exposure  ||| S:16676 E:16685 ||| NN
of  ||| S:16685 E:16688 ||| IN
control  ||| S:16688 E:16696 ||| NN
and  ||| S:16696 E:16700 ||| CC
Hyal-1  ||| S:16700 E:16715 ||| CD
cells  ||| S:16715 E:16721 ||| NNS
to  ||| S:16721 E:16724 ||| TO
TNF ||| S:16724 E:16727 ||| NNP
.  ||| S:16727 E:16729 ||| .
However ||| S:16729 E:16736 ||| RB
,  ||| S:16736 E:16738 ||| ,
there  ||| S:16738 E:16744 ||| EX
was  ||| S:16744 E:16748 ||| VBD
an  ||| S:16748 E:16751 ||| DT
extended  ||| S:16751 E:16760 ||| JJ
period  ||| S:16760 E:16767 ||| NN
of  ||| S:16767 E:16778 ||| IN
TNF-mediated  ||| S:16778 E:16791 ||| JJ
IκBα  ||| S:16791 E:16796 ||| JJ
degradation  ||| S:16796 E:16808 ||| NN
and  ||| S:16808 E:16812 ||| CC
NF-κB  ||| S:16812 E:16818 ||| JJ
activation  ||| S:16818 E:16829 ||| NN
in  ||| S:16829 E:16840 ||| IN
Hyal-2  ||| S:16840 E:16847 ||| CD
cells ||| S:16847 E:16852 ||| NNS
,  ||| S:16852 E:16854 ||| ,
ranging  ||| S:16854 E:16862 ||| VBG
from  ||| S:16862 E:16867 ||| IN
20-60  ||| S:16867 E:16873 ||| CD
min ||| S:16873 E:16876 ||| NNS
.  ||| S:16876 E:16878 ||| .
It  ||| S:16878 E:16881 ||| PRP
is  ||| S:16881 E:16884 ||| VBZ
unclear  ||| S:16884 E:16892 ||| JJ
whether  ||| S:16892 E:16908 ||| IN
this  ||| S:16908 E:16913 ||| DT
extend  ||| S:16913 E:16920 ||| JJ
ed  ||| S:16920 E:16923 ||| JJ
period  ||| S:16923 E:16930 ||| NN
of  ||| S:16930 E:16933 ||| IN
IκBα  ||| S:16933 E:16938 ||| JJ
degradation  ||| S:16938 E:16950 ||| NN
and  ||| S:16950 E:16954 ||| CC
NF-κB  ||| S:16954 E:16968 ||| JJ
activation  ||| S:16968 E:16979 ||| NNS
directly  ||| S:16979 E:16988 ||| RB
contributes  ||| S:16988 E:17000 ||| VBZ
to  ||| S:17000 E:17003 ||| TO
the  ||| S:17003 E:17007 ||| DT
ability  ||| S:17007 E:17015 ||| NN
of  ||| S:17015 E:17018 ||| IN
Hyal-2  ||| S:17018 E:17025 ||| CD
to  ||| S:17025 E:17036 ||| TO
enhance  ||| S:17036 E:17044 ||| VB
TNF-mediated  ||| S:17044 E:17057 ||| JJ
apoptosis ||| S:17057 E:17066 ||| NN
.  ||| S:17066 E:17068 ||| .
IκBα  ||| S:17068 E:17073 ||| NNP
is  ||| S:17073 E:17076 ||| VBZ
a  ||| S:17076 E:17078 ||| DT
physiological  ||| S:17078 E:17100 ||| JJ
inhibitor  ||| S:17100 E:17110 ||| NN
of  ||| S:17110 E:17113 ||| IN
NF-κB  ||| S:17113 E:17119 ||| JJ
activation ||| S:17119 E:17129 ||| NN
;  ||| S:17129 E:17131 ||| :
IκBα  ||| S:17131 E:17136 ||| JJ
complexes  ||| S:17136 E:17146 ||| NNS
with  ||| S:17146 E:17151 ||| IN
NF-κB  ||| S:17151 E:17165 ||| JJ
and  ||| S:17165 E:17169 ||| CC
prevents  ||| S:17169 E:17178 ||| VBZ
its  ||| S:17178 E:17182 ||| PRP$
translocation  ||| S:17182 E:17196 ||| NN
to  ||| S:17196 E:17199 ||| TO
the  ||| S:17199 E:17203 ||| DT
nucleus  ||| S:17203 E:17211 ||| NN
[  ||| S:17211 E:17213 ||| -LRB-
10  ||| S:17213 E:17216 ||| CD
24  ||| S:17216 E:17219 ||| CD
]  ||| S:17219 E:17221 ||| -RRB-
.  ||| S:17221 E:17231 ||| .
NF-κB  ||| S:17231 E:17237 ||| JJ
activation  ||| S:17237 E:17248 ||| NN
is  ||| S:17248 E:17251 ||| VBZ
believed  ||| S:17251 E:17260 ||| VBN
to  ||| S:17260 E:17263 ||| TO
induce  ||| S:17263 E:17270 ||| VB
antiapoptotic  ||| S:17270 E:17292 ||| JJ
proteins  ||| S:17292 E:17301 ||| NNS
to  ||| S:17301 E:17304 ||| TO
block  ||| S:17304 E:17310 ||| VB
cell  ||| S:17310 E:17315 ||| NN
death  ||| S:17315 E:17321 ||| NN
[  ||| S:17321 E:17323 ||| -LRB-
8  ||| S:17323 E:17325 ||| CD
]  ||| S:17325 E:17327 ||| -RRB-
.  ||| S:17327 E:17329 ||| .
However ||| S:17329 E:17336 ||| RB
,  ||| S:17336 E:17338 ||| ,
in  ||| S:17338 E:17341 ||| IN
several  ||| S:17341 E:17357 ||| JJ
studies  ||| S:17357 E:17365 ||| NNS
activated  ||| S:17365 E:17375 ||| VBN
NF-κB  ||| S:17375 E:17381 ||| JJ
cannot  ||| S:17381 E:17388 ||| NNS
protect  ||| S:17388 E:17396 ||| VB
cells  ||| S:17396 E:17402 ||| NNS
from  ||| S:17402 E:17407 ||| IN
apoptosis  ||| S:17407 E:17425 ||| NNS
[  ||| S:17425 E:17427 ||| -LRB-
8  ||| S:17427 E:17429 ||| CD
]  ||| S:17429 E:17431 ||| -RRB-
.  ||| S:17431 E:17433 ||| .
Also ||| S:17433 E:17437 ||| RB
,  ||| S:17437 E:17439 ||| ,
NF-κB  ||| S:17439 E:17445 ||| NNP
appears  ||| S:17445 E:17453 ||| VBZ
to  ||| S:17453 E:17456 ||| TO
be  ||| S:17456 E:17459 ||| VB
essential  ||| S:17459 E:17469 ||| JJ
in  ||| S:17469 E:17472 ||| IN
the  ||| S:17472 E:17484 ||| DT
p53-mediated  ||| S:17484 E:17497 ||| JJ
apoptosis  ||| S:17497 E:17507 ||| NN
in  ||| S:17507 E:17510 ||| IN
tested  ||| S:17510 E:17517 ||| JJ
cell  ||| S:17517 E:17522 ||| NN
lines  ||| S:17522 E:17528 ||| NNS
[  ||| S:17528 E:17530 ||| -LRB-
25  ||| S:17530 E:17533 ||| CD
]  ||| S:17533 E:17535 ||| -RRB-
.  ||| S:17535 E:17545 ||| .
The  ||| S:17545 E:17549 ||| DT
mitochondrion  ||| S:17549 E:17563 ||| NN
is  ||| S:17563 E:17566 ||| VBZ
a  ||| S:17566 E:17568 ||| DT
reservoir  ||| S:17568 E:17578 ||| NN
of  ||| S:17578 E:17581 ||| IN
proapoptotic  ||| S:17581 E:17602 ||| JJ
proteins  ||| S:17602 E:17611 ||| NNS
and  ||| S:17611 E:17615 ||| CC
plays  ||| S:17615 E:17621 ||| VBZ
a  ||| S:17621 E:17623 ||| DT
key  ||| S:17623 E:17627 ||| JJ
role  ||| S:17627 E:17632 ||| NN
in  ||| S:17632 E:17635 ||| IN
apoptosis  ||| S:17635 E:17645 ||| NNS
[  ||| S:17645 E:17647 ||| -LRB-
[  ||| S:17647 E:17649 ||| CD
26  ||| S:17649 E:17652 ||| CD
27  ||| S:17652 E:17655 ||| CD
]  ||| S:17655 E:17657 ||| -RRB-
;  ||| S:17657 E:17667 ||| :
reviews ||| S:17667 E:17674 ||| NNS
] ||| S:17674 E:17675 ||| -RRB-
.  ||| S:17675 E:17677 ||| .
One  ||| S:17677 E:17681 ||| CD
of  ||| S:17681 E:17684 ||| IN
the  ||| S:17684 E:17688 ||| DT
pathways  ||| S:17688 E:17697 ||| NN
that  ||| S:17697 E:17702 ||| WDT
leads  ||| S:17702 E:17708 ||| VBZ
to  ||| S:17708 E:17711 ||| TO
the  ||| S:17711 E:17715 ||| DT
release  ||| S:17715 E:17723 ||| NN
of  ||| S:17723 E:17734 ||| IN
proapoptotic  ||| S:17734 E:17747 ||| JJ
proteins  ||| S:17747 E:17756 ||| NNS
in  ||| S:17756 E:17759 ||| IN
the  ||| S:17759 E:17763 ||| DT
mitochondria  ||| S:17763 E:17776 ||| NN
has  ||| S:17776 E:17780 ||| VBZ
been  ||| S:17780 E:17793 ||| VBN
determined ||| S:17793 E:17803 ||| VBN
.  ||| S:17803 E:17805 ||| .
For  ||| S:17805 E:17809 ||| IN
example ||| S:17809 E:17816 ||| NN
,  ||| S:17816 E:17818 ||| ,
the  ||| S:17818 E:17822 ||| DT
TNF ||| S:17822 E:17825 ||| NNP
/ ||| S:17825 E:17826 ||| NNP
TNF  ||| S:17826 E:17830 ||| NNP
receptor-signaling  ||| S:17830 E:17857 ||| JJ
complex  ||| S:17857 E:17865 ||| JJ
activates  ||| S:17865 E:17875 ||| NN
caspase  ||| S:17875 E:17883 ||| VBD
8 ||| S:17883 E:17884 ||| CD
,  ||| S:17884 E:17886 ||| ,
which  ||| S:17886 E:17892 ||| WDT
leads  ||| S:17892 E:17898 ||| VBZ
to  ||| S:17898 E:17901 ||| TO
the  ||| S:17901 E:17905 ||| DT
activation  ||| S:17905 E:17924 ||| NN
and  ||| S:17924 E:17928 ||| CC
cleavage  ||| S:17928 E:17937 ||| NN
of  ||| S:17937 E:17940 ||| IN
Bid ||| S:17940 E:17943 ||| NNP
,  ||| S:17943 E:17945 ||| ,
a  ||| S:17945 E:17947 ||| DT
proapoptotic  ||| S:17947 E:17960 ||| JJ
protein  ||| S:17960 E:17968 ||| NN
of  ||| S:17968 E:17971 ||| IN
the  ||| S:17971 E:17975 ||| DT
Bcl-2  ||| S:17975 E:17989 ||| JJ
family ||| S:17989 E:17995 ||| NN
.  ||| S:17995 E:17997 ||| .
Activated  ||| S:17997 E:18007 ||| NNP
or  ||| S:18007 E:18010 ||| CC
truncated  ||| S:18010 E:18020 ||| JJ
Bid  ||| S:18020 E:18024 ||| NNP
( ||| S:18024 E:18025 ||| -LRB-
tBid ||| S:18025 E:18029 ||| NNP
)  ||| S:18029 E:18031 ||| -RRB-
in  ||| S:18031 E:18034 ||| IN
turn  ||| S:18034 E:18039 ||| NN
activates  ||| S:18039 E:18057 ||| VBD
Bak  ||| S:18057 E:18061 ||| NNP
and  ||| S:18061 E:18065 ||| CC
Bax ||| S:18065 E:18068 ||| NNP
.  ||| S:18068 E:18070 ||| .
Bak  ||| S:18070 E:18074 ||| JJ
migrates  ||| S:18074 E:18083 ||| NN
to  ||| S:18083 E:18086 ||| TO
the  ||| S:18086 E:18090 ||| DT
mitochondrial  ||| S:18090 E:18104 ||| JJ
outer  ||| S:18104 E:18118 ||| JJ
membrane  ||| S:18118 E:18127 ||| NN
where  ||| S:18127 E:18133 ||| WRB
it  ||| S:18133 E:18136 ||| PRP
generates  ||| S:18136 E:18146 ||| VBZ
transmembrane  ||| S:18146 E:18160 ||| JJ
pores ||| S:18160 E:18165 ||| NN
;  ||| S:18165 E:18167 ||| :
Bax  ||| S:18167 E:18179 ||| NNP
induces  ||| S:18179 E:18187 ||| VBZ
the  ||| S:18187 E:18191 ||| DT
opening  ||| S:18191 E:18199 ||| NN
of  ||| S:18199 E:18202 ||| IN
the  ||| S:18202 E:18206 ||| DT
mitochondrial  ||| S:18206 E:18220 ||| JJ
permeability  ||| S:18220 E:18241 ||| JJ
transition  ||| S:18241 E:18252 ||| NN
pores ||| S:18252 E:18257 ||| VBZ
.  ||| S:18257 E:18259 ||| .
Cytochrome  ||| S:18259 E:18270 ||| NNP
c  ||| S:18270 E:18272 ||| SYM
is  ||| S:18272 E:18275 ||| VBZ
then  ||| S:18275 E:18280 ||| RB
released  ||| S:18280 E:18289 ||| VBN
from  ||| S:18289 E:18294 ||| IN
the  ||| S:18294 E:18306 ||| DT
mitochondria  ||| S:18306 E:18319 ||| NN
into  ||| S:18319 E:18324 ||| IN
the  ||| S:18324 E:18328 ||| DT
cytosol ||| S:18328 E:18335 ||| NN
,  ||| S:18335 E:18337 ||| ,
where  ||| S:18337 E:18343 ||| WRB
it  ||| S:18343 E:18346 ||| PRP
interacts  ||| S:18346 E:18356 ||| VBD
with  ||| S:18356 E:18369 ||| IN
downstream  ||| S:18369 E:18380 ||| JJ
proapoptotic  ||| S:18380 E:18393 ||| JJ
proteins  ||| S:18393 E:18402 ||| NNS
such  ||| S:18402 E:18407 ||| JJ
as  ||| S:18407 E:18410 ||| IN
Apaf-1  ||| S:18410 E:18417 ||| NNP
and  ||| S:18417 E:18421 ||| CC
caspase  ||| S:18421 E:18437 ||| CD
9 ||| S:18437 E:18438 ||| CD
.  ||| S:18438 E:18440 ||| .
Activation  ||| S:18440 E:18451 ||| NNP
of  ||| S:18451 E:18454 ||| IN
these  ||| S:18454 E:18460 ||| DT
proteins  ||| S:18460 E:18469 ||| NNS
further  ||| S:18469 E:18477 ||| RBR
activates  ||| S:18477 E:18495 ||| JJ
nucleases ||| S:18495 E:18504 ||| NN
,  ||| S:18504 E:18506 ||| ,
such  ||| S:18506 E:18511 ||| JJ
as  ||| S:18511 E:18514 ||| IN
caspase-activated  ||| S:18514 E:18532 ||| JJ
DNase  ||| S:18532 E:18538 ||| NN
( ||| S:18538 E:18539 ||| -LRB-
CAD ||| S:18539 E:18542 ||| NNP
) ||| S:18542 E:18543 ||| -RRB-
,  ||| S:18543 E:18545 ||| ,
which  ||| S:18545 E:18559 ||| WDT
cause  ||| S:18559 E:18565 ||| VBP
DNA  ||| S:18565 E:18569 ||| NN
fragmentation ||| S:18569 E:18582 ||| NN
.  ||| S:18582 E:18592 ||| .
During  ||| S:18592 E:18599 ||| IN
staurosporine-mediated  ||| S:18599 E:18622 ||| JJ
apoptosis ||| S:18622 E:18631 ||| NN
,  ||| S:18631 E:18633 ||| ,
a  ||| S:18633 E:18635 ||| DT
portion  ||| S:18635 E:18643 ||| NN
of  ||| S:18643 E:18654 ||| IN
the  ||| S:18654 E:18658 ||| DT
lysosomal  ||| S:18658 E:18668 ||| JJ
Hyal-2  ||| S:18668 E:18675 ||| CD
migrates  ||| S:18675 E:18684 ||| NN
to  ||| S:18684 E:18687 ||| TO
the  ||| S:18687 E:18691 ||| DT
mitochondria ||| S:18691 E:18703 ||| NN
.  ||| S:18703 E:18705 ||| .
Whether  ||| S:18705 E:18721 ||| IN
Hyal-2  ||| S:18721 E:18728 ||| CD
causes  ||| S:18728 E:18735 ||| NNS
mitochondrial  ||| S:18735 E:18749 ||| VBP
membrane  ||| S:18749 E:18758 ||| JJ
damage  ||| S:18758 E:18765 ||| NN
is  ||| S:18765 E:18768 ||| VBZ
unknown ||| S:18768 E:18775 ||| JJ
.  ||| S:18775 E:18785 ||| .
Presumably ||| S:18785 E:18795 ||| RB
,  ||| S:18795 E:18797 ||| ,
Hyal-2  ||| S:18797 E:18804 ||| CD
interacts  ||| S:18804 E:18814 ||| NN
with  ||| S:18814 E:18819 ||| IN
a  ||| S:18819 E:18821 ||| DT
specific  ||| S:18821 E:18830 ||| JJ
protein  ||| S:18830 E:18838 ||| NN
target  ||| S:18838 E:18853 ||| NN
on  ||| S:18853 E:18856 ||| IN
the  ||| S:18856 E:18860 ||| DT
mitochondrial  ||| S:18860 E:18874 ||| JJ
surface  ||| S:18874 E:18882 ||| NN
that  ||| S:18882 E:18887 ||| WDT
changes  ||| S:18887 E:18895 ||| VBZ
the  ||| S:18895 E:18899 ||| DT
membrane  ||| S:18899 E:18916 ||| JJ
permeability ||| S:18916 E:18928 ||| NN
.  ||| S:18928 E:18930 ||| .
This  ||| S:18930 E:18935 ||| DT
notion  ||| S:18935 E:18942 ||| NN
is  ||| S:18942 E:18945 ||| VBZ
supported  ||| S:18945 E:18955 ||| VBN
by  ||| S:18955 E:18958 ||| IN
our  ||| S:18958 E:18962 ||| PRP$
recent  ||| S:18962 E:18977 ||| JJ
screening  ||| S:18977 E:18987 ||| NN
of  ||| S:18987 E:18990 ||| IN
Hyal-1  ||| S:18990 E:18997 ||| NNP
and  ||| S:18997 E:19001 ||| CC
Hyal-2  ||| S:19001 E:19008 ||| CD
interacting  ||| S:19008 E:19020 ||| CD
proteins  ||| S:19020 E:19029 ||| NNS
in  ||| S:19029 E:19040 ||| IN
yeast  ||| S:19040 E:19046 ||| JJ
two-hybrid  ||| S:19046 E:19057 ||| JJ
interactions  ||| S:19057 E:19070 ||| NNS
( ||| S:19070 E:19071 ||| -LRB-
Chang  ||| S:19071 E:19086 ||| FW
et  ||| S:19086 E:19089 ||| FW
al  ||| S:19089 E:19092 ||| FW
,  ||| S:19092 E:19094 ||| ,
unpublished ||| S:19094 E:19105 ||| JJ
)  ||| S:19105 E:19115 ||| -RRB-
The  ||| S:19115 E:19119 ||| DT
functional  ||| S:19119 E:19130 ||| JJ
property  ||| S:19130 E:19139 ||| NN
of  ||| S:19139 E:19142 ||| IN
Hyal-2  ||| S:19142 E:19149 ||| CD
in  ||| S:19149 E:19152 ||| IN
degrading  ||| S:19152 E:19170 ||| JJ
hyaluronic  ||| S:19170 E:19181 ||| JJ
acid  ||| S:19181 E:19186 ||| NN
is  ||| S:19186 E:19189 ||| VBZ
controversial ||| S:19189 E:19202 ||| JJ
.  ||| S:19202 E:19204 ||| .
Hyal-2  ||| S:19204 E:19211 ||| NNP
is  ||| S:19211 E:19214 ||| VBZ
found  ||| S:19214 E:19220 ||| VBN
in  ||| S:19220 E:19223 ||| IN
the  ||| S:19223 E:19235 ||| DT
lysosome  ||| S:19235 E:19244 ||| NN
and  ||| S:19244 E:19248 ||| CC
is  ||| S:19248 E:19251 ||| VBZ
active  ||| S:19251 E:19258 ||| JJ
under  ||| S:19258 E:19264 ||| IN
conditions  ||| S:19264 E:19275 ||| NNS
of  ||| S:19275 E:19278 ||| IN
low  ||| S:19278 E:19282 ||| JJ
pH  ||| S:19282 E:19285 ||| NN
[  ||| S:19285 E:19287 ||| -LRB-
20  ||| S:19287 E:19290 ||| CD
]  ||| S:19290 E:19292 ||| -RRB-
.  ||| S:19292 E:19302 ||| .
Hyal-2  ||| S:19302 E:19309 ||| NNP
is  ||| S:19309 E:19312 ||| VBZ
also  ||| S:19312 E:19317 ||| RB
found  ||| S:19317 E:19323 ||| VBN
on  ||| S:19323 E:19326 ||| IN
the  ||| S:19326 E:19330 ||| DT
cell  ||| S:19330 E:19335 ||| NN
surface  ||| S:19335 E:19343 ||| NN
as  ||| S:19343 E:19346 ||| IN
a  ||| S:19346 E:19356 ||| DT
glycosylphosphatidylinositol  ||| S:19356 E:19385 ||| NN
( ||| S:19385 E:19386 ||| -LRB-
GPI ||| S:19386 E:19389 ||| NNP
) ||| S:19389 E:19390 ||| -RRB-
-anchored  ||| S:19390 E:19400 ||| JJ
receptor  ||| S:19400 E:19409 ||| NN
for  ||| S:19409 E:19421 ||| IN
jaagsiekte  ||| S:19421 E:19432 ||| FW
sheep  ||| S:19432 E:19438 ||| FW
retrovirus  ||| S:19438 E:19449 ||| FW
[  ||| S:19449 E:19451 ||| -LRB-
21  ||| S:19451 E:19454 ||| CD
]  ||| S:19454 E:19456 ||| -RRB-
.  ||| S:19456 E:19458 ||| .
Nonetheless ||| S:19458 E:19469 ||| RB
,  ||| S:19469 E:19471 ||| ,
the  ||| S:19471 E:19483 ||| DT
enzymatic  ||| S:19483 E:19493 ||| JJ
activity  ||| S:19493 E:19502 ||| NN
of  ||| S:19502 E:19505 ||| IN
Hyal-2  ||| S:19505 E:19512 ||| NNP
has  ||| S:19512 E:19516 ||| VBZ
not  ||| S:19516 E:19520 ||| RB
been  ||| S:19520 E:19525 ||| VBN
detected  ||| S:19525 E:19534 ||| VBN
[  ||| S:19534 E:19536 ||| -LRB-
21  ||| S:19536 E:19539 ||| CD
]  ||| S:19539 E:19541 ||| -RRB-
.  ||| S:19541 E:19551 ||| .
Whether  ||| S:19551 E:19559 ||| IN
the  ||| S:19559 E:19563 ||| DT
increased  ||| S:19563 E:19573 ||| JJ
TNF  ||| S:19573 E:19577 ||| NNP
cytotoxicity  ||| S:19577 E:19590 ||| NN
in  ||| S:19590 E:19593 ||| IN
L929  ||| S:19593 E:19598 ||| CD
cells  ||| S:19598 E:19604 ||| NNS
caused  ||| S:19604 E:19619 ||| VBN
by  ||| S:19619 E:19622 ||| IN
Hyal-1  ||| S:19622 E:19629 ||| NNP
and  ||| S:19629 E:19633 ||| CC
Hyal-2  ||| S:19633 E:19640 ||| NNP
is  ||| S:19640 E:19643 ||| VBZ
associated  ||| S:19643 E:19654 ||| VBN
with  ||| S:19654 E:19659 ||| IN
their  ||| S:19659 E:19665 ||| PRP$
enzymatic  ||| S:19665 E:19683 ||| JJ
activities  ||| S:19683 E:19694 ||| NNS
is  ||| S:19694 E:19697 ||| VBZ
being  ||| S:19697 E:19703 ||| VBG
studied  ||| S:19703 E:19711 ||| VBN
in  ||| S:19711 E:19714 ||| IN
this  ||| S:19714 E:19719 ||| DT
laboratory ||| S:19719 E:19729 ||| NN
.  ||| S:19729 E:19739 ||| .
The  ||| S:19739 E:19743 ||| DT
TGF-β1  ||| S:19743 E:19750 ||| JJ
inhibition  ||| S:19750 E:19761 ||| NN
of  ||| S:19761 E:19764 ||| IN
Hyal-1  ||| S:19764 E:19771 ||| NNP
and  ||| S:19771 E:19775 ||| CC
Hyal-2  ||| S:19775 E:19782 ||| CD
effects  ||| S:19782 E:19790 ||| NNS
could  ||| S:19790 E:19804 ||| MD
be  ||| S:19804 E:19807 ||| VB
abolished  ||| S:19807 E:19817 ||| VBN
by  ||| S:19817 E:19820 ||| IN
cycloheximide  ||| S:19820 E:19834 ||| NN
or  ||| S:19834 E:19837 ||| CC
actinomycin  ||| S:19837 E:19849 ||| JJ
D  ||| S:19849 E:19851 ||| NNP
( ||| S:19851 E:19852 ||| -LRB-
data  ||| S:19852 E:19857 ||| NNS
not  ||| S:19857 E:19869 ||| RB
shown ||| S:19869 E:19874 ||| VBN
) ||| S:19874 E:19875 ||| -RRB-
.  ||| S:19875 E:19877 ||| .
That  ||| S:19877 E:19882 ||| WDT
is ||| S:19882 E:19884 ||| VBZ
,  ||| S:19884 E:19886 ||| ,
inhibition  ||| S:19886 E:19897 ||| VBG
of  ||| S:19897 E:19900 ||| IN
protein  ||| S:19900 E:19908 ||| NN
synthesis  ||| S:19908 E:19918 ||| NN
or  ||| S:19918 E:19921 ||| CC
gene  ||| S:19921 E:19934 ||| NN
transcription  ||| S:19934 E:19948 ||| NNS
reduced  ||| S:19948 E:19956 ||| VBD
the  ||| S:19956 E:19960 ||| DT
inhibitory  ||| S:19960 E:19971 ||| JJ
effect  ||| S:19971 E:19978 ||| NN
of  ||| S:19978 E:19981 ||| IN
TGF-β1  ||| S:19981 E:19988 ||| CD
in  ||| S:19988 E:19999 ||| IN
the  ||| S:19999 E:20003 ||| DT
prevention  ||| S:20003 E:20014 ||| NN
of  ||| S:20014 E:20017 ||| IN
Hyal-1-  ||| S:20017 E:20025 ||| NNP
or  ||| S:20025 E:20028 ||| CC
Hyal-2-increased  ||| S:20028 E:20045 ||| NNP
TNF  ||| S:20045 E:20057 ||| NNP
cytotoxicity ||| S:20057 E:20069 ||| NN
.  ||| S:20069 E:20071 ||| .
Whether  ||| S:20071 E:20079 ||| IN
TGF-β1-induced  ||| S:20079 E:20094 ||| CD
antiapoptotic  ||| S:20094 E:20108 ||| CD
proteins  ||| S:20108 E:20125 ||| NNS
such  ||| S:20125 E:20130 ||| JJ
as  ||| S:20130 E:20133 ||| IN
TIAF1  ||| S:20133 E:20139 ||| NNP
and  ||| S:20139 E:20143 ||| CC
TIF2  ||| S:20143 E:20148 ||| RB
inhibit  ||| S:20148 E:20156 ||| VB
the  ||| S:20156 E:20160 ||| DT
function  ||| S:20160 E:20169 ||| NN
of  ||| S:20169 E:20172 ||| IN
Hyal-1  ||| S:20172 E:20179 ||| NNP
and  ||| S:20179 E:20191 ||| CC
Hyal-2  ||| S:20191 E:20198 ||| NNP
remains  ||| S:20198 E:20206 ||| VBZ
to  ||| S:20206 E:20209 ||| TO
be  ||| S:20209 E:20212 ||| VB
determined ||| S:20212 E:20222 ||| VBN
.  ||| S:20222 E:20246 ||| .
Conclusions  ||| S:20246 E:20266 ||| NNS
Like  ||| S:20266 E:20271 ||| IN
testicular  ||| S:20271 E:20282 ||| CD
PH-20 ||| S:20282 E:20287 ||| CD
,  ||| S:20287 E:20289 ||| ,
lysosomal  ||| S:20289 E:20299 ||| JJ
Hyal-1  ||| S:20299 E:20306 ||| NN
and  ||| S:20306 E:20310 ||| CC
Hyal-2  ||| S:20310 E:20325 ||| NNP
enhanced  ||| S:20325 E:20334 ||| VBD
TNF  ||| S:20334 E:20338 ||| NNP
susceptibility  ||| S:20338 E:20353 ||| NN
in  ||| S:20353 E:20356 ||| IN
L929  ||| S:20356 E:20361 ||| CD
cells ||| S:20361 E:20366 ||| NNS
.  ||| S:20366 E:20368 ||| .
TGF-β1  ||| S:20368 E:20383 ||| NNP
suppressed  ||| S:20383 E:20394 ||| VBD
the  ||| S:20394 E:20398 ||| DT
induced  ||| S:20398 E:20406 ||| JJ
TNF  ||| S:20406 E:20410 ||| NNP
sensitivity ||| S:20410 E:20421 ||| NN
.  ||| S:20421 E:20423 ||| .
Furthermore ||| S:20423 E:20434 ||| RB
,  ||| S:20434 E:20444 ||| ,
TGF-β1-mediated  ||| S:20444 E:20460 ||| CD
L929  ||| S:20460 E:20465 ||| CD
cell  ||| S:20465 E:20470 ||| NN
proliferation  ||| S:20470 E:20484 ||| NN
was  ||| S:20484 E:20488 ||| VBD
blocked  ||| S:20488 E:20496 ||| VBN
by  ||| S:20496 E:20507 ||| IN
Hyal-1  ||| S:20507 E:20514 ||| NNP
and  ||| S:20514 E:20518 ||| CC
Hyal-2 ||| S:20518 E:20524 ||| NNP
.  ||| S:20524 E:20526 ||| .
These  ||| S:20526 E:20532 ||| DT
data  ||| S:20532 E:20537 ||| NNS
indicate  ||| S:20537 E:20546 ||| VBP
that  ||| S:20546 E:20551 ||| IN
there  ||| S:20551 E:20557 ||| EX
is  ||| S:20557 E:20560 ||| VBZ
a  ||| S:20560 E:20570 ||| DT
functional  ||| S:20570 E:20581 ||| JJ
antagonism  ||| S:20581 E:20592 ||| NN
between  ||| S:20592 E:20600 ||| IN
TGF-β1  ||| S:20600 E:20607 ||| NNP
and  ||| S:20607 E:20611 ||| CC
Hyal-1  ||| S:20611 E:20618 ||| NNP
or  ||| S:20618 E:20621 ||| CC
Hyal-2 ||| S:20621 E:20627 ||| NNP
.  ||| S:20627 E:20637 ||| .
Hyal-2-increased  ||| S:20637 E:20654 ||| NNP
TNF  ||| S:20654 E:20658 ||| NNP
susceptibility  ||| S:20658 E:20673 ||| NN
in  ||| S:20673 E:20676 ||| IN
L929  ||| S:20676 E:20681 ||| CD
cells  ||| S:20681 E:20687 ||| NNS
appears  ||| S:20687 E:20703 ||| VBZ
to  ||| S:20703 E:20706 ||| TO
be  ||| S:20706 E:20709 ||| VB
associated  ||| S:20709 E:20720 ||| VBN
with  ||| S:20720 E:20725 ||| IN
1 ||| S:20725 E:20726 ||| CD
)  ||| S:20726 E:20728 ||| -RRB-
Hyal-2  ||| S:20728 E:20735 ||| CD
upregulation  ||| S:20735 E:20748 ||| NN
of  ||| S:20748 E:20751 ||| IN
the  ||| S:20751 E:20763 ||| DT
proapoptotic  ||| S:20763 E:20776 ||| JJ
WOX1 ||| S:20776 E:20780 ||| NN
,  ||| S:20780 E:20782 ||| ,
2 ||| S:20782 E:20783 ||| LS
)  ||| S:20783 E:20785 ||| -RRB-
Hyal-2  ||| S:20785 E:20792 ||| CD
migration  ||| S:20792 E:20802 ||| NN
to  ||| S:20802 E:20805 ||| TO
the  ||| S:20805 E:20809 ||| DT
mitochondria  ||| S:20809 E:20830 ||| NN
during  ||| S:20830 E:20837 ||| IN
apoptotic  ||| S:20837 E:20847 ||| JJ
cell  ||| S:20847 E:20852 ||| NN
death ||| S:20852 E:20857 ||| NN
,  ||| S:20857 E:20859 ||| ,
and  ||| S:20859 E:20863 ||| CC
3 ||| S:20863 E:20864 ||| LS
)  ||| S:20864 E:20866 ||| -RRB-
the  ||| S:20866 E:20870 ||| DT
prolonged  ||| S:20870 E:20880 ||| JJ
IκBα  ||| S:20880 E:20893 ||| JJ
degradation  ||| S:20893 E:20905 ||| NN
and  ||| S:20905 E:20909 ||| CC
NF-κB  ||| S:20909 E:20915 ||| JJ
activation  ||| S:20915 E:20926 ||| NN
in  ||| S:20926 E:20929 ||| IN
Hyal-2-expressing  ||| S:20929 E:20947 ||| CD
cells  ||| S:20947 E:20961 ||| NNS
stimulated  ||| S:20961 E:20972 ||| VBN
with  ||| S:20972 E:20977 ||| IN
TNF ||| S:20977 E:20980 ||| NNP
.  ||| S:20980 E:21004 ||| .
Materials  ||| S:21004 E:21014 ||| NNS
and  ||| S:21014 E:21018 ||| CC
Methods  ||| S:21018 E:21045 ||| NNP
cDNA  ||| S:21045 E:21050 ||| JJ
constructs ||| S:21050 E:21060 ||| NN
,  ||| S:21060 E:21062 ||| ,
transient  ||| S:21062 E:21072 ||| JJ
expression  ||| S:21072 E:21083 ||| NN
and  ||| S:21083 E:21087 ||| CC
stable  ||| S:21087 E:21104 ||| JJ
transfectants  ||| S:21104 E:21128 ||| NNS
The  ||| S:21128 E:21132 ||| DT
full-length  ||| S:21132 E:21144 ||| JJ
murine  ||| S:21144 E:21151 ||| JJ
hyaluronidase  ||| S:21151 E:21176 ||| JJ
Hyal1  ||| S:21176 E:21182 ||| NN
and  ||| S:21182 E:21197 ||| CC
Hyal2  ||| S:21197 E:21203 ||| NNP
cDNAs  ||| S:21203 E:21209 ||| NNP
were  ||| S:21209 E:21214 ||| VBD
found  ||| S:21214 E:21220 ||| VBN
in  ||| S:21220 E:21223 ||| IN
the  ||| S:21223 E:21227 ||| DT
EST  ||| S:21227 E:21241 ||| NNP
database  ||| S:21241 E:21250 ||| NN
( ||| S:21250 E:21251 ||| -LRB-
Genbank  ||| S:21251 E:21259 ||| FW
accession  ||| S:21259 E:21269 ||| FW
AA688635  ||| S:21269 E:21278 ||| FW
and  ||| S:21278 E:21282 ||| CC
BF139787 ||| S:21282 E:21290 ||| NNP
,  ||| S:21290 E:21302 ||| ,
respectively ||| S:21302 E:21314 ||| RB
)  ||| S:21314 E:21316 ||| -RRB-
and  ||| S:21316 E:21320 ||| CC
purchased  ||| S:21320 E:21330 ||| VBN
from  ||| S:21330 E:21335 ||| IN
Incyte  ||| S:21335 E:21342 ||| NNP
Genomics  ||| S:21342 E:21351 ||| NNP
( ||| S:21351 E:21352 ||| -LRB-
St.  ||| S:21352 E:21366 ||| NNP
Louis ||| S:21366 E:21371 ||| NNP
,  ||| S:21371 E:21373 ||| ,
MO ||| S:21373 E:21375 ||| NNP
) ||| S:21375 E:21376 ||| -RRB-
.  ||| S:21376 E:21378 ||| .
The  ||| S:21378 E:21382 ||| DT
determined  ||| S:21382 E:21393 ||| JJ
DNA  ||| S:21393 E:21397 ||| NN
sequences  ||| S:21397 E:21407 ||| NNS
have  ||| S:21407 E:21412 ||| VBP
been  ||| S:21412 E:21427 ||| VBN
deposited  ||| S:21427 E:21437 ||| VBN
in  ||| S:21437 E:21440 ||| IN
the  ||| S:21440 E:21444 ||| DT
GenBank  ||| S:21444 E:21452 ||| JJ
(  ||| S:21452 E:21465 ||| -LRB-
Hyal1  ||| S:21465 E:21471 ||| NNP
,  ||| S:21471 E:21473 ||| ,
AF422176 ||| S:21473 E:21481 ||| NNP
;  ||| S:21481 E:21494 ||| :
Hyal2  ||| S:21494 E:21500 ||| CD
,  ||| S:21500 E:21502 ||| ,
AF422177 ||| S:21502 E:21510 ||| CD
) ||| S:21510 E:21511 ||| -RRB-
.  ||| S:21511 E:21513 ||| .
The  ||| S:21513 E:21517 ||| DT
coding  ||| S:21517 E:21534 ||| JJ
regions  ||| S:21534 E:21542 ||| NNS
were  ||| S:21542 E:21547 ||| VBD
tagged  ||| S:21547 E:21554 ||| VBN
with  ||| S:21554 E:21559 ||| IN
a  ||| S:21559 E:21572 ||| DT
C  ||| S:21572 E:21574 ||| NNP
-terminal  ||| S:21574 E:21584 ||| JJ
green  ||| S:21584 E:21590 ||| JJ
fluorescent  ||| S:21590 E:21612 ||| JJ
protein  ||| S:21612 E:21620 ||| NN
( ||| S:21620 E:21621 ||| -LRB-
GFP ||| S:21621 E:21624 ||| NNP
)  ||| S:21624 E:21626 ||| -RRB-
sequence  ||| S:21626 E:21635 ||| NN
by  ||| S:21635 E:21638 ||| IN
subcloning  ||| S:21638 E:21649 ||| NN
into  ||| S:21649 E:21654 ||| IN
the  ||| S:21654 E:21669 ||| DT
EcoR  ||| S:21669 E:21674 ||| JJ
1  ||| S:21674 E:21676 ||| CD
site  ||| S:21676 E:21681 ||| NN
of  ||| S:21681 E:21684 ||| IN
the  ||| S:21684 E:21688 ||| DT
pEGFP-N1  ||| S:21688 E:21697 ||| JJ
vector  ||| S:21697 E:21714 ||| NN
( ||| S:21714 E:21715 ||| -LRB-
Clontech ||| S:21715 E:21723 ||| NNP
,  ||| S:21723 E:21725 ||| ,
Palo  ||| S:21725 E:21730 ||| NNP
Alto ||| S:21730 E:21734 ||| NNP
,  ||| S:21734 E:21736 ||| ,
CA ||| S:21736 E:21738 ||| NNP
) ||| S:21738 E:21739 ||| -RRB-
.  ||| S:21739 E:21741 ||| .
Murine  ||| S:21741 E:21748 ||| NNP
L929  ||| S:21748 E:21753 ||| NNP
cells  ||| S:21753 E:21759 ||| NNS
were  ||| S:21759 E:21774 ||| VBD
transfected  ||| S:21774 E:21786 ||| VBN
with  ||| S:21786 E:21791 ||| IN
the  ||| S:21791 E:21795 ||| DT
constructed  ||| S:21795 E:21807 ||| JJ
Hyal-1-pEGFP-N1  ||| S:21807 E:21823 ||| NN
or  ||| S:21823 E:21836 ||| CC
Hyal-2-pEGFP-N1  ||| S:21836 E:21852 ||| CD
vector ||| S:21852 E:21858 ||| NN
,  ||| S:21858 E:21860 ||| ,
or  ||| S:21860 E:21863 ||| CC
a  ||| S:21863 E:21865 ||| DT
control  ||| S:21865 E:21873 ||| NN
pEGFP-N1  ||| S:21873 E:21882 ||| CD
vector  ||| S:21882 E:21889 ||| NN
by  ||| S:21889 E:21902 ||| IN
electroporation  ||| S:21902 E:21918 ||| NNS
( ||| S:21918 E:21919 ||| -LRB-
40  ||| S:21919 E:21922 ||| CD
μg  ||| S:21922 E:21925 ||| JJ
DNA ||| S:21925 E:21928 ||| NN
/  ||| S:21928 E:21930 ||| CD
5  ||| S:21930 E:21932 ||| CD
×  ||| S:21932 E:21934 ||| CD
10  ||| S:21934 E:21937 ||| CD
6cells ||| S:21937 E:21943 ||| CD
;  ||| S:21943 E:21945 ||| :
250  ||| S:21945 E:21949 ||| CD
volt  ||| S:21949 E:21954 ||| NNS
and  ||| S:21954 E:21968 ||| CC
960  ||| S:21968 E:21972 ||| CD
Fd ||| S:21972 E:21974 ||| NNP
) ||| S:21974 E:21975 ||| -RRB-
,  ||| S:21975 E:21977 ||| ,
as  ||| S:21977 E:21980 ||| RB
previously  ||| S:21980 E:21991 ||| RB
described  ||| S:21991 E:22001 ||| VBN
[  ||| S:22001 E:22003 ||| -LRB-
10  ||| S:22003 E:22006 ||| CD
]  ||| S:22006 E:22008 ||| -RRB-
.  ||| S:22008 E:22010 ||| .
The  ||| S:22010 E:22014 ||| DT
cells  ||| S:22014 E:22020 ||| NNS
were  ||| S:22020 E:22035 ||| VBD
cultured  ||| S:22035 E:22044 ||| VBN
in  ||| S:22044 E:22047 ||| IN
the  ||| S:22047 E:22051 ||| DT
continuous  ||| S:22051 E:22062 ||| JJ
presence  ||| S:22062 E:22071 ||| NN
of  ||| S:22071 E:22074 ||| IN
G418  ||| S:22074 E:22079 ||| NNP
( ||| S:22079 E:22080 ||| -LRB-
200  ||| S:22080 E:22084 ||| CD
g ||| S:22084 E:22085 ||| CD
/ ||| S:22085 E:22086 ||| CD
ml ||| S:22086 E:22088 ||| CD
)  ||| S:22088 E:22100 ||| -RRB-
for  ||| S:22100 E:22104 ||| IN
approximately  ||| S:22104 E:22118 ||| RB
2  ||| S:22118 E:22120 ||| CD
weeks ||| S:22120 E:22125 ||| NNS
,  ||| S:22125 E:22127 ||| ,
and  ||| S:22127 E:22131 ||| CC
the  ||| S:22131 E:22135 ||| DT
resulting  ||| S:22135 E:22145 ||| VBG
total  ||| S:22145 E:22151 ||| JJ
cell  ||| S:22151 E:22166 ||| NN
colonies  ||| S:22166 E:22175 ||| NNS
were  ||| S:22175 E:22180 ||| VBD
harvested ||| S:22180 E:22189 ||| VBN
.  ||| S:22189 E:22191 ||| .
The  ||| S:22191 E:22195 ||| DT
presence  ||| S:22195 E:22204 ||| NN
of  ||| S:22204 E:22207 ||| IN
GFP-Hyal-1  ||| S:22207 E:22218 ||| NNP
and  ||| S:22218 E:22232 ||| CC
GFP-Hyal-2  ||| S:22232 E:22243 ||| CD
proteins  ||| S:22243 E:22252 ||| NNS
in  ||| S:22252 E:22255 ||| IN
these  ||| S:22255 E:22261 ||| DT
stable  ||| S:22261 E:22268 ||| JJ
transfectants  ||| S:22268 E:22282 ||| NN
was  ||| S:22282 E:22296 ||| VBD
examined  ||| S:22296 E:22305 ||| VBN
by  ||| S:22305 E:22308 ||| IN
Western  ||| S:22308 E:22316 ||| JJ
blotting  ||| S:22316 E:22325 ||| NNS
using  ||| S:22325 E:22331 ||| VBG
anti-GFP  ||| S:22331 E:22340 ||| JJ
antibodies  ||| S:22340 E:22361 ||| NNS
( ||| S:22361 E:22362 ||| -LRB-
Clontech ||| S:22362 E:22370 ||| NNP
) ||| S:22370 E:22371 ||| -RRB-
.  ||| S:22371 E:22373 ||| .
Where  ||| S:22373 E:22379 ||| WRB
indicated ||| S:22379 E:22388 ||| VBN
,  ||| S:22388 E:22390 ||| ,
COS7  ||| S:22390 E:22395 ||| CD
fibroblasts  ||| S:22395 E:22407 ||| NNS
were  ||| S:22407 E:22422 ||| VBD
transfected  ||| S:22422 E:22434 ||| VBN
with  ||| S:22434 E:22439 ||| IN
the  ||| S:22439 E:22443 ||| DT
above  ||| S:22443 E:22449 ||| JJ
constructs  ||| S:22449 E:22460 ||| NNS
using  ||| S:22460 E:22466 ||| VBG
a  ||| S:22466 E:22478 ||| DT
liposome-based  ||| S:22478 E:22493 ||| JJ
reagent  ||| S:22493 E:22501 ||| JJ
FuGene  ||| S:22501 E:22508 ||| JJ
6  ||| S:22508 E:22510 ||| CD
( ||| S:22510 E:22511 ||| -LRB-
Roche ||| S:22511 E:22516 ||| NNP
,  ||| S:22516 E:22518 ||| ,
Indianapolis ||| S:22518 E:22530 ||| NNP
,  ||| S:22530 E:22532 ||| ,
IN ||| S:22532 E:22534 ||| IN
)  ||| S:22534 E:22546 ||| -RRB-
or  ||| S:22546 E:22549 ||| CC
GeneFector  ||| S:22549 E:22560 ||| NNP
( ||| S:22560 E:22561 ||| -LRB-
Venn  ||| S:22561 E:22566 ||| NNP
Nova ||| S:22566 E:22570 ||| NNP
,  ||| S:22570 E:22572 ||| ,
Pompano  ||| S:22572 E:22580 ||| NNP
Beach ||| S:22580 E:22585 ||| NNP
,  ||| S:22585 E:22587 ||| ,
FL ||| S:22587 E:22589 ||| NNP
) ||| S:22589 E:22590 ||| -RRB-
.  ||| S:22590 E:22592 ||| .
Protein  ||| S:22592 E:22610 ||| NN
expression  ||| S:22610 E:22621 ||| NN
was  ||| S:22621 E:22625 ||| VBD
visualized  ||| S:22625 E:22636 ||| VBN
by  ||| S:22636 E:22639 ||| IN
fluorescence  ||| S:22639 E:22652 ||| JJ
microscopy ||| S:22652 E:22662 ||| NN
.  ||| S:22662 E:22674 ||| .
Also ||| S:22674 E:22678 ||| RB
,  ||| S:22678 E:22680 ||| ,
the  ||| S:22680 E:22684 ||| DT
cells  ||| S:22684 E:22690 ||| NNS
were  ||| S:22690 E:22695 ||| VBD
counterstained  ||| S:22695 E:22710 ||| VBN
with  ||| S:22710 E:22715 ||| IN
LysoTracker  ||| S:22715 E:22727 ||| JJ
or  ||| S:22727 E:22740 ||| CC
Mitotracker  ||| S:22740 E:22752 ||| NNP
Red  ||| S:22752 E:22756 ||| NNP
( ||| S:22756 E:22757 ||| -LRB-
Molecular  ||| S:22757 E:22767 ||| NNP
Probes ||| S:22767 E:22773 ||| NNP
,  ||| S:22773 E:22775 ||| ,
Eugene ||| S:22775 E:22781 ||| NNP
,  ||| S:22781 E:22783 ||| ,
OR ||| S:22783 E:22785 ||| NNP
)  ||| S:22785 E:22787 ||| -RRB-
to  ||| S:22787 E:22800 ||| TO
determine  ||| S:22800 E:22810 ||| VB
whether  ||| S:22810 E:22818 ||| IN
the  ||| S:22818 E:22822 ||| DT
expressed  ||| S:22822 E:22832 ||| JJ
protein  ||| S:22832 E:22840 ||| NN
was  ||| S:22840 E:22844 ||| VBD
located  ||| S:22844 E:22852 ||| VBN
in  ||| S:22852 E:22865 ||| IN
the  ||| S:22865 E:22869 ||| DT
lysosome  ||| S:22869 E:22878 ||| NN
or  ||| S:22878 E:22881 ||| CC
mitochondria ||| S:22881 E:22893 ||| NN
.  ||| S:22893 E:22923 ||| .
Cell  ||| S:22923 E:22928 ||| NN
lines  ||| S:22928 E:22934 ||| NNS
and  ||| S:22934 E:22938 ||| CC
chemicals  ||| S:22938 E:22958 ||| NNS
Murine  ||| S:22958 E:22965 ||| NNP
L929  ||| S:22965 E:22970 ||| NNP
fibroblasts  ||| S:22970 E:22982 ||| NN
and  ||| S:22982 E:22986 ||| CC
monkey  ||| S:22986 E:22993 ||| JJ
kidney  ||| S:22993 E:23000 ||| NN
COS7  ||| S:23000 E:23015 ||| CD
fibroblasts  ||| S:23015 E:23027 ||| NNS
were  ||| S:23027 E:23032 ||| VBD
cultured  ||| S:23032 E:23041 ||| VBN
as  ||| S:23041 E:23044 ||| IN
previously  ||| S:23044 E:23055 ||| RB
described  ||| S:23055 E:23065 ||| VBN
[  ||| S:23065 E:23067 ||| -LRB-
10  ||| S:23067 E:23070 ||| CD
]  ||| S:23070 E:23082 ||| -RRB-
.  ||| S:23082 E:23084 ||| .
Staurosporine ||| S:23084 E:23097 ||| NNP
,  ||| S:23097 E:23099 ||| ,
daunorubicin ||| S:23099 E:23111 ||| NN
,  ||| S:23111 E:23113 ||| ,
actinomycin  ||| S:23113 E:23125 ||| VBG
D ||| S:23125 E:23126 ||| NNP
,  ||| S:23126 E:23138 ||| ,
camptothecin  ||| S:23138 E:23151 ||| NN
and  ||| S:23151 E:23155 ||| CC
DAPI  ||| S:23155 E:23160 ||| NNP
were  ||| S:23160 E:23165 ||| VBD
from  ||| S:23165 E:23170 ||| IN
Calbiochem  ||| S:23170 E:23181 ||| NNP
( ||| S:23181 E:23182 ||| -LRB-
San  ||| S:23182 E:23186 ||| NNP
Diego ||| S:23186 E:23191 ||| NNP
,  ||| S:23191 E:23203 ||| ,
CA ||| S:23203 E:23205 ||| NNP
) ||| S:23205 E:23206 ||| -RRB-
,  ||| S:23206 E:23208 ||| ,
Sigma  ||| S:23208 E:23214 ||| NNP
( ||| S:23214 E:23215 ||| -LRB-
St.  ||| S:23215 E:23219 ||| NNP
Louis ||| S:23219 E:23224 ||| NNP
,  ||| S:23224 E:23226 ||| ,
MO ||| S:23226 E:23228 ||| NNP
)  ||| S:23228 E:23230 ||| -RRB-
and  ||| S:23230 E:23234 ||| CC
Biomol  ||| S:23234 E:23241 ||| NNP
( ||| S:23241 E:23242 ||| -LRB-
Plymouth  ||| S:23242 E:23251 ||| NNP
Meeting ||| S:23251 E:23258 ||| NNP
,  ||| S:23258 E:23270 ||| ,
PA ||| S:23270 E:23272 ||| NNP
) ||| S:23272 E:23273 ||| -RRB-
.  ||| S:23273 E:23275 ||| .
Purified  ||| S:23275 E:23284 ||| JJ
human  ||| S:23284 E:23290 ||| JJ
platelet  ||| S:23290 E:23299 ||| JJ
TGF-β1  ||| S:23299 E:23306 ||| NN
was  ||| S:23306 E:23310 ||| VBD
from  ||| S:23310 E:23315 ||| IN
R ||| S:23315 E:23316 ||| NNP
& ||| S:23316 E:23317 ||| CC
D  ||| S:23317 E:23329 ||| NNP
( ||| S:23329 E:23330 ||| -LRB-
Minneapolis ||| S:23330 E:23341 ||| NNP
,  ||| S:23341 E:23343 ||| ,
MN ||| S:23343 E:23345 ||| NNP
) ||| S:23345 E:23346 ||| -RRB-
.  ||| S:23346 E:23348 ||| .
Antisera  ||| S:23348 E:23357 ||| NNP
against  ||| S:23357 E:23365 ||| IN
WOX1  ||| S:23365 E:23370 ||| NNP
were  ||| S:23370 E:23375 ||| VBD
generated  ||| S:23375 E:23395 ||| VBN
in  ||| S:23395 E:23398 ||| IN
rabbits  ||| S:23398 E:23406 ||| NN
against  ||| S:23406 E:23414 ||| IN
a  ||| S:23414 E:23416 ||| DT
synthetic  ||| S:23416 E:23426 ||| JJ
peptide  ||| S:23426 E:23434 ||| NNS
[  ||| S:23434 E:23436 ||| -LRB-
10  ||| S:23436 E:23439 ||| CD
]  ||| S:23439 E:23441 ||| -RRB-
.  ||| S:23441 E:23453 ||| .
Antibodies  ||| S:23453 E:23464 ||| NNS
against  ||| S:23464 E:23472 ||| IN
p53 ||| S:23472 E:23475 ||| NN
,  ||| S:23475 E:23477 ||| ,
IκBα ||| S:23477 E:23481 ||| NNP
,  ||| S:23481 E:23483 ||| ,
NF-κB  ||| S:23483 E:23489 ||| NNP
p65  ||| S:23489 E:23493 ||| NNP
and  ||| S:23493 E:23497 ||| CC
α-tubulin  ||| S:23497 E:23517 ||| NNP
were  ||| S:23517 E:23522 ||| VBD
from  ||| S:23522 E:23527 ||| IN
Santa  ||| S:23527 E:23533 ||| NNP
Cruz  ||| S:23533 E:23538 ||| NNP
Biotechnology  ||| S:23538 E:23552 ||| NNP
( ||| S:23552 E:23553 ||| -LRB-
Santa  ||| S:23553 E:23559 ||| NNP
Cruz ||| S:23559 E:23563 ||| NNP
,  ||| S:23563 E:23565 ||| ,
CA ||| S:23565 E:23567 ||| NNP
)  ||| S:23567 E:23569 ||| -RRB-
and  ||| S:23569 E:23583 ||| CC
Accurate  ||| S:23583 E:23592 ||| NNP
Chemicals  ||| S:23592 E:23602 ||| NNPS
( ||| S:23602 E:23603 ||| -LRB-
Accurate  ||| S:23603 E:23612 ||| NNP
Chemical ||| S:23612 E:23620 ||| NNP
,  ||| S:23620 E:23622 ||| ,
Westbury ||| S:23622 E:23630 ||| NNP
,  ||| S:23630 E:23632 ||| ,
NY ||| S:23632 E:23634 ||| NNP
) ||| S:23634 E:23635 ||| -RRB-
.  ||| S:23635 E:23665 ||| .
TNF  ||| S:23665 E:23669 ||| NNP
cytotoxicity  ||| S:23669 E:23682 ||| NN
assay  ||| S:23682 E:23688 ||| NNS
and  ||| S:23688 E:23692 ||| CC
Western  ||| S:23692 E:23700 ||| JJ
blotting  ||| S:23700 E:23719 ||| VBG
The  ||| S:23719 E:23723 ||| DT
above  ||| S:23723 E:23729 ||| JJ
established  ||| S:23729 E:23741 ||| JJ
cell  ||| S:23741 E:23746 ||| NN
lines  ||| S:23746 E:23752 ||| NNS
were  ||| S:23752 E:23757 ||| VBD
treated  ||| S:23757 E:23765 ||| VBN
with  ||| S:23765 E:23780 ||| IN
TNF-α  ||| S:23780 E:23786 ||| NNP
( ||| S:23786 E:23787 ||| -LRB-
2.5-20  ||| S:23787 E:23794 ||| FW
ng ||| S:23794 E:23796 ||| FW
/ ||| S:23796 E:23797 ||| FW
ml ||| S:23797 E:23799 ||| FW
;  ||| S:23799 E:23801 ||| :
Pepro-Tech ||| S:23801 E:23811 ||| NNP
,  ||| S:23811 E:23813 ||| ,
Rocky  ||| S:23813 E:23819 ||| NNP
Hill ||| S:23819 E:23823 ||| NNP
,  ||| S:23823 E:23825 ||| ,
NJ ||| S:23825 E:23827 ||| NNP
)  ||| S:23827 E:23829 ||| -RRB-
for  ||| S:23829 E:23843 ||| IN
16-24  ||| S:23843 E:23849 ||| CD
hr ||| S:23849 E:23851 ||| NNS
.  ||| S:23851 E:23853 ||| .
The  ||| S:23853 E:23857 ||| DT
extent  ||| S:23857 E:23864 ||| NN
of  ||| S:23864 E:23867 ||| IN
cell  ||| S:23867 E:23872 ||| NN
death  ||| S:23872 E:23878 ||| NN
was  ||| S:23878 E:23882 ||| VBD
determined  ||| S:23882 E:23893 ||| VBN
by  ||| S:23893 E:23906 ||| IN
crystal  ||| S:23906 E:23914 ||| FW
violet  ||| S:23914 E:23921 ||| FW
staining  ||| S:23921 E:23930 ||| FW
[  ||| S:23930 E:23932 ||| -LRB-
10  ||| S:23932 E:23935 ||| CD
]  ||| S:23935 E:23937 ||| -RRB-
.  ||| S:23937 E:23939 ||| .
Where  ||| S:23939 E:23945 ||| WRB
indicated ||| S:23945 E:23954 ||| VBN
,  ||| S:23954 E:23956 ||| ,
the  ||| S:23956 E:23970 ||| DT
cells  ||| S:23970 E:23976 ||| NNS
were  ||| S:23976 E:23981 ||| VBD
also  ||| S:23981 E:23986 ||| RB
exposed  ||| S:23986 E:23994 ||| VBN
to  ||| S:23994 E:23997 ||| TO
staurosporine ||| S:23997 E:24010 ||| VB
,  ||| S:24010 E:24012 ||| ,
actinomycin  ||| S:24012 E:24024 ||| VBG
D ||| S:24024 E:24025 ||| NNP
,  ||| S:24025 E:24037 ||| ,
daunorubicin ||| S:24037 E:24049 ||| NN
,  ||| S:24049 E:24051 ||| ,
and  ||| S:24051 E:24055 ||| CC
camptothecin  ||| S:24055 E:24068 ||| NN
for  ||| S:24068 E:24072 ||| IN
16-24  ||| S:24072 E:24078 ||| CD
hr ||| S:24078 E:24080 ||| NN
,  ||| S:24080 E:24082 ||| ,
before  ||| S:24082 E:24099 ||| IN
determining  ||| S:24099 E:24111 ||| VBG
the  ||| S:24111 E:24115 ||| DT
extent  ||| S:24115 E:24122 ||| NN
of  ||| S:24122 E:24125 ||| IN
cell  ||| S:24125 E:24130 ||| NN
death ||| S:24130 E:24135 ||| NN
.  ||| S:24135 E:24137 ||| .
To  ||| S:24137 E:24140 ||| TO
determine  ||| S:24140 E:24160 ||| VB
whether  ||| S:24160 E:24168 ||| IN
TGF-β1  ||| S:24168 E:24175 ||| NNP
blocked  ||| S:24175 E:24183 ||| VBD
Hyal-1  ||| S:24183 E:24190 ||| CD
and  ||| S:24190 E:24194 ||| CC
Hyal-2-increased  ||| S:24194 E:24211 ||| NNP
TNF  ||| S:24211 E:24225 ||| NNP
killing ||| S:24225 E:24232 ||| NN
,  ||| S:24232 E:24234 ||| ,
the  ||| S:24234 E:24238 ||| DT
cells  ||| S:24238 E:24244 ||| NNS
were  ||| S:24244 E:24249 ||| VBD
pretreated  ||| S:24249 E:24260 ||| VBN
with  ||| S:24260 E:24265 ||| IN
TGF-β1  ||| S:24265 E:24272 ||| CD
for  ||| S:24272 E:24276 ||| IN
2  ||| S:24276 E:24278 ||| CD
hr  ||| S:24278 E:24291 ||| NNS
and  ||| S:24291 E:24295 ||| CC
then  ||| S:24295 E:24300 ||| RB
exposed  ||| S:24300 E:24308 ||| VBN
to  ||| S:24308 E:24311 ||| TO
TNF-α  ||| S:24311 E:24317 ||| JJ
in  ||| S:24317 E:24320 ||| IN
the  ||| S:24320 E:24324 ||| DT
continued  ||| S:24324 E:24334 ||| JJ
presence  ||| S:24334 E:24343 ||| NN
of  ||| S:24343 E:24356 ||| IN
TGF-β1  ||| S:24356 E:24363 ||| CD
for  ||| S:24363 E:24367 ||| IN
16-24  ||| S:24367 E:24373 ||| CD
hr ||| S:24373 E:24375 ||| NNS
.  ||| S:24375 E:24377 ||| .
The  ||| S:24377 E:24381 ||| DT
extent  ||| S:24381 E:24388 ||| NN
of  ||| S:24388 E:24391 ||| IN
cell  ||| S:24391 E:24396 ||| NN
death  ||| S:24396 E:24402 ||| NN
was  ||| S:24402 E:24406 ||| VBD
then  ||| S:24406 E:24421 ||| RB
determined ||| S:24421 E:24431 ||| VBN
.  ||| S:24431 E:24433 ||| .
Where  ||| S:24433 E:24439 ||| WRB
indicated ||| S:24439 E:24448 ||| VBN
,  ||| S:24448 E:24450 ||| ,
GFP-Hyal-1 ||| S:24450 E:24460 ||| NNP
,  ||| S:24460 E:24462 ||| ,
GFP-Hyal-2  ||| S:24462 E:24473 ||| NNP
and  ||| S:24473 E:24487 ||| CC
GFP  ||| S:24487 E:24491 ||| NNP
stable  ||| S:24491 E:24498 ||| JJ
transfectants  ||| S:24498 E:24512 ||| NN
were  ||| S:24512 E:24517 ||| VBD
treated  ||| S:24517 E:24525 ||| VBN
with  ||| S:24525 E:24530 ||| IN
TNF  ||| S:24530 E:24534 ||| NNP
( ||| S:24534 E:24535 ||| -LRB-
50  ||| S:24535 E:24538 ||| CD
ng ||| S:24538 E:24540 ||| CD
/ ||| S:24540 E:24541 ||| CD
ml ||| S:24541 E:24543 ||| CD
)  ||| S:24543 E:24555 ||| -RRB-
for  ||| S:24555 E:24559 ||| IN
0 ||| S:24559 E:24560 ||| CD
,  ||| S:24560 E:24562 ||| ,
20 ||| S:24562 E:24564 ||| CD
,  ||| S:24564 E:24566 ||| ,
40 ||| S:24566 E:24568 ||| CD
,  ||| S:24568 E:24570 ||| ,
60  ||| S:24570 E:24573 ||| CD
and  ||| S:24573 E:24577 ||| CC
120  ||| S:24577 E:24581 ||| CD
minutes ||| S:24581 E:24588 ||| NNS
.  ||| S:24588 E:24590 ||| .
The  ||| S:24590 E:24594 ||| DT
cells  ||| S:24594 E:24600 ||| NNS
were  ||| S:24600 E:24615 ||| VBD
extracted  ||| S:24615 E:24625 ||| VBN
using  ||| S:24625 E:24631 ||| VBG
NE-PER  ||| S:24631 E:24638 ||| JJ
Nuclear  ||| S:24638 E:24646 ||| NNP
and  ||| S:24646 E:24650 ||| CC
Cytoplasmic  ||| S:24650 E:24662 ||| NNP
Extraction  ||| S:24662 E:24683 ||| NNP
Reagents  ||| S:24683 E:24692 ||| NNP
( ||| S:24692 E:24693 ||| -LRB-
Pierce ||| S:24693 E:24699 ||| NNP
,  ||| S:24699 E:24701 ||| ,
Rockford ||| S:24701 E:24709 ||| NNP
,  ||| S:24709 E:24711 ||| ,
IL ||| S:24711 E:24713 ||| NNP
)  ||| S:24713 E:24715 ||| -RRB-
to  ||| S:24715 E:24718 ||| TO
separate  ||| S:24718 E:24727 ||| VB
the  ||| S:24727 E:24741 ||| DT
cytoplasmic  ||| S:24741 E:24753 ||| NN
and  ||| S:24753 E:24757 ||| CC
nuclear  ||| S:24757 E:24765 ||| JJ
fractions ||| S:24765 E:24774 ||| NNS
.  ||| S:24774 E:24776 ||| .
These  ||| S:24776 E:24782 ||| DT
preparations  ||| S:24782 E:24805 ||| NN
were  ||| S:24805 E:24810 ||| VBD
subjected  ||| S:24810 E:24820 ||| VBN
to  ||| S:24820 E:24823 ||| TO
SDS-PAGE  ||| S:24823 E:24832 ||| JJ
and  ||| S:24832 E:24836 ||| CC
Western  ||| S:24836 E:24844 ||| JJ
blotting  ||| S:24844 E:24853 ||| NNS
using  ||| S:24853 E:24869 ||| VBG
specific  ||| S:24869 E:24878 ||| JJ
antibodies  ||| S:24878 E:24889 ||| NNS
against  ||| S:24889 E:24897 ||| IN
IκBα ||| S:24897 E:24901 ||| NNP
,  ||| S:24901 E:24903 ||| ,
WOX1  ||| S:24903 E:24908 ||| NNP
and  ||| S:24908 E:24912 ||| CC
NF-κB ||| S:24912 E:24917 ||| JJ
.  ||| S:24917 E:24947 ||| .
Gene  ||| S:24947 E:24952 ||| NN
transfection  ||| S:24952 E:24965 ||| NNS
and  ||| S:24965 E:24969 ||| CC
fluorescent  ||| S:24969 E:24981 ||| CD
microscopy  ||| S:24981 E:25002 ||| CD
COS7  ||| S:25002 E:25007 ||| CD
cells  ||| S:25007 E:25013 ||| NNS
were  ||| S:25013 E:25018 ||| VBD
transfected  ||| S:25018 E:25030 ||| VBN
with  ||| S:25030 E:25035 ||| IN
the  ||| S:25035 E:25039 ||| DT
GFP-Hyal-2  ||| S:25039 E:25050 ||| JJ
vector  ||| S:25050 E:25067 ||| NN
using  ||| S:25067 E:25073 ||| VBG
the  ||| S:25073 E:25077 ||| DT
liposome-based  ||| S:25077 E:25092 ||| JJ
FuGene  ||| S:25092 E:25099 ||| JJ
6  ||| S:25099 E:25101 ||| CD
or  ||| S:25101 E:25104 ||| CC
GeneFector ||| S:25104 E:25114 ||| JJ
,  ||| S:25114 E:25116 ||| ,
cultured  ||| S:25116 E:25135 ||| VBG
for  ||| S:25135 E:25139 ||| IN
24-48  ||| S:25139 E:25145 ||| CD
hr ||| S:25145 E:25147 ||| NN
,  ||| S:25147 E:25149 ||| ,
and  ||| S:25149 E:25153 ||| CC
treated  ||| S:25153 E:25161 ||| VBN
with  ||| S:25161 E:25166 ||| IN
staurosporine  ||| S:25166 E:25180 ||| NNS
( ||| S:25180 E:25181 ||| -LRB-
1  ||| S:25181 E:25183 ||| CD
M ||| S:25183 E:25184 ||| NNP
)  ||| S:25184 E:25186 ||| -RRB-
for  ||| S:25186 E:25190 ||| IN
0 ||| S:25190 E:25191 ||| CD
,  ||| S:25191 E:25203 ||| ,
1 ||| S:25203 E:25204 ||| CD
,  ||| S:25204 E:25206 ||| ,
2  ||| S:25206 E:25208 ||| CD
and  ||| S:25208 E:25212 ||| CC
4  ||| S:25212 E:25214 ||| CD
hr ||| S:25214 E:25216 ||| NNS
.  ||| S:25216 E:25218 ||| .
Mitochondria  ||| S:25218 E:25231 ||| NNP
were  ||| S:25231 E:25236 ||| VBD
stained  ||| S:25236 E:25244 ||| VBN
with  ||| S:25244 E:25249 ||| IN
the  ||| S:25249 E:25263 ||| DT
membrane  ||| S:25263 E:25272 ||| JJ
potential  ||| S:25272 E:25282 ||| JJ
sensitive  ||| S:25282 E:25292 ||| JJ
Mitotracker  ||| S:25292 E:25304 ||| NNP
Red ||| S:25304 E:25307 ||| NNP
.  ||| S:25307 E:25309 ||| .
Nuclei  ||| S:25309 E:25316 ||| NNP
were  ||| S:25316 E:25331 ||| VBD
stained  ||| S:25331 E:25339 ||| VBN
by  ||| S:25339 E:25342 ||| IN
DAPI ||| S:25342 E:25346 ||| NNP
.  ||| S:25346 E:25348 ||| .
The  ||| S:25348 E:25352 ||| DT
cells  ||| S:25352 E:25358 ||| NNS
were  ||| S:25358 E:25363 ||| VBD
then  ||| S:25363 E:25368 ||| RB
examined  ||| S:25368 E:25377 ||| VBN
by  ||| S:25377 E:25390 ||| IN
fluorescence  ||| S:25390 E:25403 ||| JJ
microscopy ||| S:25403 E:25413 ||| NN
.  ||| S:25413 E:25439 ||| .
